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ABSTRACT 
Sondag, Gregory R., Ph.D., December 2015   Biomedical Sciences 
OSTEOACTIVIN AND CD44 : 
A NOVEL INTERACTION STIMULATING BONE FORMATION AND INHIBITING BONE 
RESORPTION 
 
Dissertation Advisor: Fayez F. Safadi, Ph.D. 
 
Osteoporosis is a growing problem for the elderly population. The 
bisphosphonate anti-resorptive class of drugs is the most commonly prescribed 
medication, however, the need for anabolic agents to stimulate bone formation is 
crucial. Osteoactivin was first discovered in bone using the op osteopetrotic mutant rat 
model. Our lab was the first to show that Osteoactivin stimulates bone formation in 
osteoblasts. Although several pieces of literature exist describing the role of 
Osteoactivin in both osteoblasts and osteoclasts, little is known about the signaling 
pathway involved in its function.  
In this study, we used the recombinant Osteoactivin in culture to determine its 
effects on osteoblast and osteoclast differentiation in vitro. First, we added recombinant 
Osteoactivin to osteoblast and mesenchymal stem cells in culture and found an 
enhancement in osteoblast differentiation and function by ALP staining, activity, 
mineralization and upregulation of gene expression. We found that Osteoactivin binds to 
 xviii 
 
and interacts with CD44 to stimulate osteoblast differentiation. Furthermore, we 
determined that CD44 deficient mice have a skeletal phenotype in vivo and ex vivo that 
results in less bone mass. Lastly, we found that Osteoactivin mediated enhancement of 
osteoblast differentiation is mediated through the CD44-ERK signaling pathway. 
In our next study, we wanted to determine if the lipid raft is important for 
Osteoactivin mediated signaling in osteoblast. Our results have shown that Osteoactivin 
co-localizes within caveolin rich lipid rafts. Furthermore, Osteoactivin stimulates 
clustering of CD44 with Caveolin-1 and disruption of lipid rafts prevents this process. 
Lastly, we show that disruption of lipid rafts results in an inhibition of Osteoactivin 
mediated ERK signaling in osteoblasts. 
In our last study, as opposed to the above role of Osteoactivin in osteoblast 
formation we wanted to determine the role of recombinant Osteoactivin during 
osteoclast differentiation and function. Our results reveal that recombinant Osteoactivin 
inhibits osteoclast differentiation and size in a dose dependent manner. Futhermore, we 
show that Osteoactivin reduces ERK and AKT phosphorylation in osteoclasts. The 
Osteoactivin mediated inhibition of osteoclasts was found to involve its interaction with 
CD44. Lastly, we show that recombinant Osteoactivin inhibits osteoclast migration and 
recruitment in wild type samples in vivo, and that this effect is abrogated in CD44 
deficient mice. Overall, we believe that Osteoactivin and its interaction with CD44 
results in the enhancement of osteoblast differentiation and an inhibition of osteoclast 
resorption. 
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Chapter 1 
Introduction 
The purpose of this proposed study was to observe the effects of recombinant 
Osteoactivin in both osteoblasts and osteoclasts using both in vitro and in vivo 
techniques. Furthermore, we wanted to determine a novel signaling pathway 
responsible for Osteoactivin-mediated function. Lastly, we wished to determine the 
effects of recombinant Osteoactivin in vivo using a calvaria osteolysis model. Our 
overall hypothesis is that Osteoactivin stimulates bone formation and inhibits bone 
resorption through the CD44 receptor. We believe that our results indicate that 
Osteoactivin may potentially be used as a therapeutic to treat bone loss and accelerate 
fracture healing. 
Bone is a dynamic tissue consisting of a variety of cell types. The osteoblasts are 
the cells that secrete organic matrix and minerals that form bone. Osteoclasts are 
multinucleated cells that secrete degradative enzymes that result in the resorption of 
bone matrix. Through the use of genetically manipulated animal models the discovery of 
new molecules important for the treatment of bone diseases has exceedingly increased. 
Osteoactivin (OA) is a type I transmembrane protein that was first discovered in a model 
of the op osteopetrotic rat [1]. Since its discovery in bone there have been several 
publications describing the role of Osteoactivin in osteoblasts and osteoclasts.  
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Our lab has shown that Osteoactivin is a positive regulator of bone formation in 
vitro and in vivo [2-5]. 
 Previously, we have shown that introduction of a nonsense mutation in the 
Osteoactivin gene resulting in a biologically inactive truncated protein of 150 amino 
acids at the N-terminal domain resulted in impaired bone formation both in vivo and ex 
vivo [6]. The mutation in Osteoactivin was shown to affect both cell types [6, 7]. For 
osteoblasts the mutation in Osteoactivin resulted in an inhibition of osteoblast 
differentiation and function [6]. For osteoclasts, mutation in Osteoactivin resulted in 
enhanced osteoclast differentiation but defective osteoclast resorption [7]. Therefore, 
we came to the conclusion that Osteoactivin acts as a positive regulator of osteoblast 
differentiation and function, a negative regulator of osteoclast differentiation, and a 
positive regulator of osteoclast function.  Although our studies indicate that Osteoactivin 
is a negative regulator of osteoclast differentiation but a positive regulator of osteoclast 
function, other groups have shown that Osteoactivin acts as a positive regulator for both 
osteoclast differentiation and function [8-10]. The role of Osteoactivin should be clearly 
defined in order for its potential use as a therapeutic option.  
As the aging population continues to increase, the prevalence of bone related 
pathologies will also continue to increase. According to the US Census Bureau, the 
number of people age 65 and older is expected to increase from 35 to 86 million, and 
people age 85 and older is expected to increase from 4 to 20 million between 2000 and 
2050 [11]. Fractures seem to be the largest problem as they are common, costly, and 
have a substantial impact on the quality of life for the elderly population. There is an 
estimated 1.5 million individuals that suffer fractures caused by bone disease each year 
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[12]. It is expected that women over the age of 50 have a 40% risk of fracture which 
continues to increase with age [13]. Osteoporosis is the most common cause of 
fractures with an estimated 33.6 million individuals over the age of 50 having osteopenia 
or low bone mass [11]. There are other bone diseases that are much less common but 
still have a detrimental impact on the U.S. population.  
 An estimated one million individuals are diagnosed with Paget’s disease, 
characterized by abnormal bone remodeling resulting in few or several sclerotic bone 
lesions within the body [14]. Furthermore, roughly 20-30 thousand individuals have 
Osteogenesis Imperfecta (OI), also known as brittle bone disease due to a mutation in 
the synthesis of type I collagen [13]. Patients with OI are at a higher risk for fracture due 
to decrease bone mass but also suffer several skeletal abnormalities including 
shortening of the limbs and severe kyphoscoliosis [15].   Osteopetrosis is a rare bone 
disease caused by a defect in bone resorption by the osteoclasts [16]. The resulting 
symptoms are abnormally dense bone, smaller medullary cavities affecting 
hematopoiesis, and nerve dysfunction. Experimental evidence gathered from animal 
models mimicking bone disease have been beneficial in the discovery of new 
therapeutics to help treat a variety of bone diseases. The search for new therapeutics is 
necessary to enhance the quality of life for those suffering from bone related 
pathologies.  
Although the role of Osteoactivin in both osteoblasts and osteoclasts is becoming 
more defined, the signaling pathway involved in Osteoactivin-mediated stimulation of 
osteoblast differentiation and inhibition of osteoclast differentiation has yet to be 
determined. Previous literature has shown that Osteoactivin extracellular domain (ECD) 
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can be shed from the membrane by ADAM10 resulting in the release of a 500 amino 
acid biologically active molecule [17]. In this study, we used the recombinant 
Osteoactivin (which mimics the extracellular domain) to determine its effect on 
osteoblast and osteoclast differentiation and signaling. This study consisted of three 
specific aims and that tested our overall hypotheses that recombinant Osteoactivin is a 
positive regulator of bone formation by stimulating osteoblast and inhibiting osteoclast 
differentiation, respectively. We investigated this hypothesis using three specific aims.  
 Aim 1: To determine the role of recombinant Osteoactivin on osteoblast 
differentiation in vitro and identify a novel signaling pathway involved in Osteoactivin-
mediated osteoblast differentiation and function. 
 Aim 2: To determine the role of recombinant Osteoactivin in the osteoblast lipid 
raft.  
 Aim 3: To determine the role of recombinant Osteoactivin on osteoclast 
differentiation in vivo and in vitro and identify a novel signaling pathway involved in 
Osteoactivin-mediated osteoclast differentiation and resorption. 
 This study was able to more clearly define the role of recombinant Osteoactivin in 
both osteoblasts and osteoclasts, and define a signaling pathway relating to its function. 
This study will be an important indicator for the use of Osteoactivin as a viable treatment 
option for osteoporosis and the acceleration of bone growth in cases of non-union 
fractures and spinal fusions. 
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Methodology 
 In this study several techniques were used to study the role of Osteoactivin in 
vitro and in vivo. 
 In Aim 1, the use of in vitro culture to assess osteoblast differentiation and 
function was determined. The two cell types used to assess osteoblast differentiation 
were the MC3T3-E1 osteoblast like cell line and bone marrow derived mesenchymal 
stem cells (MSCs) from mice. Other molecular techniques such as qPCR, Western blot, 
luciferase assay, immunofluorescence, and immunoprecipitation were used to 
determine the role of Osteoactivin in osteoblast signaling. Furthermore, several in vivo 
techniques were used to characterize the CD44 deficient (CD44KO) animals. These 
techniques include micro computed tomography (microCT; µCT), histology and 
histomorphometry, calcein labeling, and biochemical analysis of bone formation and 
resorption markers through the use of ELISA. Furthermore ex-vivo analysis using wild 
type (WT) and CD44 deficient cells was determined in order to observe the relationship 
between CD44 and Osteoactivin.  
 In Aim 2, the use of in vitro techniques such as immunofluorescence and 
Western blot were used in order to determine the role of Osteoactivin with the lipid raft. 
Futhermore, the use of sucrose-gradient ultracentrifugation was used in order to isolate 
lipid raft fractions.  
 In Aim 3, the use of in vitro techniques such as TRAP staining and activity, 
qPCR, Western blot, immunofluorescence, and ELISA were used to determine the role 
of Osteoactivin in osteoclast differentiation and signaling. Furthermore, we used an in 
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vivo osteolysis model to determine the role of Osteoactivin in osteoclast differentiation 
and recruitment.  
Limitations 
 In this study, we used the recombinant extracellular domain of the Osteoactivin 
protein. Therefore, the effects that we observed are strictly due to the extracellular 
domain, and may not mimic the same effects of the entire molecule. Furthermore, the 
osteolysis model used in Aim 3 only mimics what is occurring within the local 
environment. Systemic injections of either RANKL or Osteoactivin were not given due to 
cost, dosing and timing therefore, we cannot conclude that our model would show 
similar results if used systemically.  
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Chapter 2 
Literature Review 
2.1 The Skeleton 
 The mature adult human skeleton consists of 213 bones: 126 from the 
appendicular skeleton, 74 from the axial skeleton, and 6 auditory ossicle bones [18]. 
Throughout the course of life, bone undergoes constant remodeling which can be 
influenced by a variety of factors, including genetics, aging, sex, biomechanical forces, 
and dietary habits (Figure 2.1). The skeleton serves a variety of unique functions. These 
functions include movement and structural support, protection of vital organs, regulation 
of mineral homeostasis, a reservoir for certain growth factors and cytokines, and 
provides an environment for hematopoiesis within the bone marrow microenvironment 
[19]. There are four general categories of bone. These include long bones (i.e. femur, 
tibia, humerus, etc.), short bones (carpals, tarsals, patellae, and sesamoid bones), flat 
bones (craniofacial bones, sternum, and ribs), and irregular bones (vertebrae, coccyx, 
sacrum, and hyoid bones) [20]. 
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Figure 2.1: Schematic diagram indicating the effects of hormones, dietary intake, 
and mechanical strain on the regulation of bone mass. Several factors influence 
bone homeostasis and remodeling. The above diagram indicates the role of several 
important hormones and vitamins including estrogens, androgens, PTH and vitamin D 
and their effects on osteoblasts and osteoclasts. Furthermore, mechanical strain also 
plays a major role in the regulation of bone formation. 
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 The external anatomy of long bones consists of three parts. The longest portion 
consists of a hollow medial diaphysis, which houses the bone marrow; the cone-shaped 
metaphysis below the growth plate; and the epiphyses, which sits directly above the 
growth plates. Bone is generally categorized into two different types: cortical or compact 
bone and trabecular bone, also known as cancellous or spongy bone. In general, the 
human skeleton is comprised of 80% cortical and 20% trabecular bone; however, the 
ratio can change based on the bone observed [20]. Cortical bone is much denser than 
trabecular and surrounds the marrow space, whereas trabecular bone has a sponge or 
honeycomb-like network composed of interspersed bone (Figure 2.2). 
 Trabecular bone is much more porous than cortical bone.  Trabecular bone 
consists of roughly 50-95% porosity in which the spaces are primarily filled with marrow, 
and the remaining bone matrix has the form of plates referred to as the trabeculae [21]. 
Cortical bone porosity in general is roughly 5% and contains within it Haversian systems 
or Osteons. Haversian systems are formed of concentric lamellae along their walls and 
align with the long axis of the bone. Within the Haversian system are osteocytes which 
are housed within the lacunae and communicate with other cells by canaliculi [22]. 
Volkmann’s canals are also located within the cortical bone and function as transverse 
canals connecting other Haversian canals (Figure 2.4). Blood vessels and nerves are 
located in both the Haversian and Volkmann’s canals. 
 Cortical bone contains an outer periosteal layer and an inner bone marrow facing 
endosteal surface. The periosteum contains a fibrous connective tissue layer with an 
inner cambium layer in direct contact with the cortical bone [23]. The inner cambium 
layer is highly cellular, which contains osteoblasts, fibroblasts, mesenchymal progenitor 
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cells, as well as blood vessels and nerves [24]. The outer fibrous layer consists primarily 
of collagen and elastin fibers important for other connective tissue and muscle 
attachment. Both layers have been shown to be important for fracture healing and 
appositional growth. The endosteal surface, or endosteum, covers the inner surface of 
the cortical bone in direct contact with the marrow space. It consists of osteoblasts, 
osteoclasts, bone lining cells, nerves, and blood vessels.  
 
 
 
 
 
 
 
 
 
 
 11 
 
 
Figure 2.2: Bone histomorphology of the distal femur using Masson’s trichrome 
staining. Histological image depicting the distal femur of a C57Blk6 8 week old mouse. 
The collagen (blue) indicates areas of both trabecular and cortical bone. Furthermore, 
both outer periosteal and inner endosteal surfaces of cortical bone are shown along with 
the three primary regions of long bones (epiphysis, metaphysis, and diaphysis). 
Sections of the distal femur were imaged at 2X magnification. 
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Figure 2.3: Bone histomorphology of the osteoblast and osteoclast. (A) Von kossa 
staining of the distal femur from an 8 week old C57Blk6 male mouse. Notice the 
osteoblasts (OB, arrows) sit on the trabecular bone surface (black) where they deposit 
extracellular bone matrix and minerals. (B) Tartrate resistant acid phosphatase (TRAP) 
staining of the distal femur from an 8 week old C57Blk6 male mouse. Notice the 
osteoclasts (OC, red, arrow) also sit on the trabecular surface (green) where they 
secrete degradative enzymes that break down bone matrix. Sections of the distal femur 
(A and B) were imaged at 20X magnification. 
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Figure 2.4: Schematic diagram of the osteon, Haversian canals, and Volksmann 
canals in cortical bone. (A) Longitudinal section of cortical bone depicting the 
Haversian and Volkmanns canals along with osteocytes (below arrow, pink cells) and 
connecting canaliculi (above arrow, pink lines). Notice the Haversian canals run in 
parallel with the cortical bone whereas the Volkmanns canals run transverse. (B) Cross-
section of cortical bone depicting the osteons that contain the osteocytes housed within 
lacunae and communicate by canaliculi. Notice the Haversian canal in the center of the 
osteon. 
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2.2 The Composition of Bone 
 Bone is a composite material consisting of a variety of molecules that include 
minerals, organic matrix, water, and lipids [25]. The bone structure relies on several 
factors including sex, age, dietary status, and health. The structural differences seen in 
skeletal sexual dimorphism can be attributed to the opposing sex steroid actions that 
differ among men and women [26]. The changes in skeletal structure associated with 
aging can be attributed to the loss of the homeostatic mechanisms that regulate bone 
remodeling. These include changes in hormones, biochemical factors, and genetics 
[27]. Dietary intake of several vitamins and minerals such as vitamin D and calcium are 
critical for proper skeletal development [28]. Lastly, health status can have a crucial 
impact on skeletal maintenance. For example both diabetes [29] and cancer [30] can 
have negative impacts on bone homeostasis. All of these factors influence the structure 
and composite of bone. This aspect is important as proper maintenance of bone 
structure and composition allow it to carry out its several mechanical and metabolic 
functions.  
 The minerals of bone are a complex system composed primarily of calcium, 
phosphate, magnesium, and carbonate [31]. The most highly, naturally occurring 
mineral within the bone microenvironment is an analog of hydroxyapatite 
[Ca10(PO4)6(OH)2] [32]. The mineral phase of bone has several functions.  These 
functions include providing mechanical resistance to the tissue by strengthening the 
collagen matrix and serving as a reservoir for mineral homeostasis for ions including 
calcium, phosphate, and magnesium [33]. Bone hydroxyapatite, also referred to as 
bone apatite, contains crystals that can be found in a variety of sizes. During the 
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remodeling phase it is the smaller crystals that undergo physiochemical reactions that 
result in the release of ions due to the resorptive activity of the osteoclasts [32]. The 
size and nature of the apatite crystals can serve as a diagnostic indicator for bone 
diseases such as osteoporosis and osteopetrosis. In the case of osteoporosis, larger 
apatite crystals are present within the bone matrix in greater abundance, which 
contribute to the brittle bone phenotype [34]. In the case of osteopetrosis in which bone 
remodeling is impaired, the apatite crystals are relatively small compared to age- 
matched controls. 
 Type I collagen serves as the basic building block of the bone matrix network and 
consists of roughly 85-90% of the total bone protein content [35]. Type I collagen 
consists of three polypeptide chains that form a triple-helix structure [36]. The helix 
structure contains two identical α1 (I) chains and a structurally similar α2 chain [37]. 
Collagen provides strength and elasticity for the bone, and its structure directs 
organization of the bone matrix. The collagen fibers are oriented in one of two ways: in 
the case of periosteal bone, collagen fibers are organized in sheets, and in osteonal 
bone, they are organized circumferentially [25]. In the collagen-mineral interface, the 
long axes of apatite crystals are aligned parallel to the collagen fiber axis (Figure 2.5) 
[38]. This orientation allows the minerals to contribute strength to the collagen matrix. 
Collagen undergoes several post-translational modifications that determine its structural 
and mechanical components within the bone microenvironment. Two examples of these 
post-translational modifications include hydroxylation of lysine residues and 
glycosylation of hydroxylysine [39-41]. The proper modifications to collagen are 
important for its biomechanical properties such as toughness and ductility.  
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Abnormalities in the cross-linking of collagen fibers have been used as a diagnostic 
indicator for several bone diseases including Osteoporosis,  Osteogenesis Imperfecta, 
and Ehler’s-Danlos syndrome [35]. Collagen is rapidly and frequently degraded within 
the bone extracellular matrix. Cleaved products of collagen can also act as diagnostic 
indicators in such cases of rapid bone resorption or formation.  In the case of bone 
formation, Procollagen type 1 amino terminal propetide (P1NP), cleaved by procollagen 
peptidases, serves as specific byproducts of osteoblasts during collagen formation [42]. 
In the case of bone resorption, Carboxy-terminal cross-linked telopeptide of type I 
collagen (CTX-1), cleaved by enzymes such as Cathepsin K and matrix 
metalloproteinases (MMPs), serves as byproducts of osteoclast activity during bone 
resorption [43, 44]. The structure of collagen also allows for the interaction with non-
collagenous matrix proteins. Collagen along with other non-collagenous proteins have 
shown to serve to regulate the size and orientation of mineral deposits within the bone 
microenvironment [45]. 
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Figure 2.5: Schematic diagram depicting the orientation of collagen fibers and 
hydroxyapatite minerals in bone. Type I collagen found in bone consists of three 
polypeptide chains, two of which are identical, that form a triple helix. In the collagen-
mineral interface, hydroxyapatite crystals are oriented parallel along the collagen fibers. 
The orientation of the collagen-mineral interface is crucial for maintaining the proper 
biomechanical properties of bone. 
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 Noncollagenous proteins (NCPs) consist of a wide variety of proteins that 
comprise roughly 10-15% of the bone matrix. These proteins have a wide variety of 
functions, and their discovery has primarily arisen from the use of knockout or 
transgenic animals. The NCPs of bone matrix are categorized primarily based on their 
structural properties and their function to bone. 
 Serum-derived proteins comprise about 25% of the NCPs found in bone matrix 
and, due to their acidic nature, have high affinity for binding to hydroxyapatite [32]. 
These proteins are not endogenously synthesized within the cell; however, they have 
shown to play a role in both matrix mineralization and cell proliferation. An example of a 
serum derived protein that plays a role in bone is α2-HS-glycoprotein. The knockout 
animal of this serum derived protein exhibits ectopic calcification, indicating α2-HS-
glycoprotein plays a role in the regulation of matrix mineralization [46]. There are a 
variety of other NCPs present in smaller trace amounts that have shown to play a role in 
matrix development.  These NCPs include proteoglycans, glycosylated proteins, and γ-
carboxylated (gla) proteins. 
 Proteoglycans are large macromolecules with a central core protein and acidic 
polysaccharide side chains (glycosaminoglycans) [47]. There are several bone 
proteoglycans all with a variety of functions. During bone formation chondroitin sulfate 
and hyaluronan are highly expressed proteoglycans that make up the foundation for 
areas that will eventually become bone [48]. Several proteoglycans contain a leucine- 
rich repeat sequence that relates to their specific function in bone. Two examples of 
these proteoglycans are Decorin and Biglycan. Decorin has been shown to play a role 
in collagen regulation, whereas Biglycan has been shown to be a positive regulator of 
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bone formation as the knockout animal has shown to have decreased trabecular bone 
[49]. In addition there are also smaller proteoglycans that have a rich leucine repeat 
(SLRP) that play a role in bone.  These SLRPs include Osteoadherin, Osteoglycin, and 
Fibromodulin. The functions of these proteins in bone are still relatively unknown; 
however, it is thought they may play a role in maintaining the integrity of connective 
tissue matrices and modulate the activity of certain growth factors and cytokines in the 
extracellular space [50, 51]. 
 Glycoproteins play a very diverse, multifunctional role within the bone matrix. 
Alkaline Phosphatase (ALP) is an important bone glycoprotein that has been used as a 
marker to assess bone formation. Lack of ALP has been linked to the human disease 
hypophosphatasia, in which patients have significant decreases in mineralized bone 
(hypomineralization) [52]. Although the specific role of ALP has not been clearly 
defined, it is believed that ALP hydrolyzes mineral inhibitor pyrophosphates (PPi) which 
yields monophosphate ions important for bone mineralization [53]. Therefore, in the 
case of ALP deficiency, inhibitory pyrophosphates accumulate into matrix vesicles 
resulting in an inhibition of mineralization of bone. Osteonectin is also a very abundant 
glycoprotein found within the bone matrix. It is the most abundant non-collagenous 
protein in the bone matrix (~2%), and mice deficient in Osteonectin are severely 
osteopenic [54]. Osteonectin has been shown to play a role in the regulation of both 
osteoclasts and osteoblasts. A previous report has shown that osteonectin seems to 
play a large role in osteoblast proliferation and matrix mineralization [55].  
 Several glycoproteins within the matrix have several unique domains, which 
include sulfation sites, phosphorylation sites, large sugar moieties, and RGD domains. 
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These glycosylation sites have several roles within the matrix; however, one of the more 
important roles of these domains involves cell attachment through focal adhesions to 
other extracellular macromolecules within the matrix through integrin binding [56]. Many 
of these glycosylation sites occur on the N-terminal side of the protein and belong to a 
family of proteins known as the SIBLING (small integrin-binding ligand, N-glycosylated 
proteins) family which include Bone Sialoprotein, Osteopontin, and Dentin Matrix 
Protein [32]. Bone Sialoprotein (BSP) is a 34 kDa protein with an RGD domain that 
plays a role in matrix mineralization [57, 58]. In 16 week BSP knockout mice, it was 
found that the animals had higher trabecular bone density and lower bone turnover with 
shorter femurs, smaller body length, and thinner cortices [59]. BSP knockout mice also 
had dysfunctional osteoblast and osteoclast differentiation which indicates that BSP 
plays a role in both cell types [60, 61]. Osteopontin (OPN, SPP1) is a phosphorylated 
SIBLING family member that shows similar structure and function as BSP. Previous 
work has shown that both OPN and BSP bind to the αvβ3 integrin in osteoclasts and are 
important for osteoclast bone resorption in vitro [62]. OPN knockout mice have been 
shown to develop normally [63]; however, ovariectomized mice that resemble post-
menopausal osteoporosis are resistant to bone loss indicating OPN plays a major role 
in bone in post-menopausal women [64]. Dentin Matrix Protein-1 (DMP-1) is a cleaved 
SIBLING protein expressed predominantly in osteocytes and odontoblasts of the teeth 
[65]. DMP-1 knockout mice have shown to display the human condition autosomal 
recessive hypophosphatemic rickets with severe osteomalacia and hypocalcemia [66]. 
This indicates DMP-1 plays a large role in the mineralization process. DMP-1 has been 
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found to regulate skeletal mineralization through its regulation of fibroblast growth 
factor-23 (FGF-23).    
 There are several other RGD proteins that play a primary role in cell attachment. 
Fibronectin is a highly expressed protein in bone that has shown to have a dual role in 
the differentiation of both osteoblasts and osteoclasts. Fibronectin as an extracellular 
matrix protein has shown to play a positive role in osteoblasts [67, 68] by regulating 
mineralized nodule formation through integrin receptors α5β1 and α8β1. Fibronectin also 
plays a role in osteoclasts by inhibiting their differentiation, but stimulating their function 
through nitric oxide and IL-1β signaling [69]. A similar RGD adhesion protein that plays 
a role in bone is Vitronectin. Vitronectin has shown to stimulate osteogenic 
differentiation through integrin receptors [70]. Vitronectin has shown to play a major role 
in osteoclast resorption through its primary receptor αvβ3 . Furthermore, Vitronectin has 
shown to play a major role in podosome and ruffled border formation and in the release 
of tartrate-resistant acid phosphatase (TRAP) in osteoclasts [71]. Fibrillin-1/2 are 
extracellular matrix proteins that interact with and regulate other growth factors and 
cytokines in the bone matrix.  Fibrillin-1 mutations have been linked to the human 
disease Marfan syndrome in which patients suffer from cardiovascular, eye, lung, and 
skeletal defects [72]. Marfan syndrome patients have decreased bone mineral density 
(BMD) in the femur and spine.  Fibrillin-1 mice are neonatally lethal [73], and Fibrillin-2 
knockout mice have significantly less bone compared to wild types due to their ability to 
modulate bioavailability of transforming growth factor-β (TGF-β) and bone 
morphogenetic proteins (BMPs).  
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 A small subset of NCPs in bone matrix that are regulated by Vitamin-K 
dependent carboxylases are members of the Gamma-Carboxy Glutamic Acid or Gla 
proteins. The Gla residues are important for hydroxyapatite binding and critical for these 
subsets of proteins to function. Two specific Gla proteins that have been extensively 
studied are Matrix Gla Protein (MGP) and Osteocalcin (bone Gla protein; BGP;OCN). 
MGP is expressed primarily in vascular smooth muscle cells and chrondrocytes [74] and 
has been shown to be an inhibitor of extracellular matrix mineralization. Mutations in the 
MGP gene have been shown to be linked to the human disease Keutel syndrome, a 
rare autosomal recessive condition in which patients show symptoms of abnormal 
calcification in soft tissues [75]. MGP deficient mice have a short life span of 8 weeks 
due to excess vascular calcification leading to vessel rupture [76]. MGP mice also have 
premature mineralized growth plates and have significantly less bone due to impaired 
osteoblast function [74, 77]. Osteocalcin is expressed in both mature mineralizing 
osteoblasts and osteocytes [78, 79]. Osteocalcin is a circulating molecule thought to be 
a marker for bone formation and has been used as a clinical maker for testing bone 
mineral density [80, 81]. Osteocalcin deficient mice develop normally until 6 months of 
age and thereafter begin to develop in osteopetrotic phenotype [82]. Although the exact 
mechanism of Osteocalcin is still unclear, it is believed to be a signal in the bone 
turnover cascade between bone formation and bone resorption.  
 There are several other elements within the bone microenvironment that play a 
role in bone homeostasis. Many enzymes and growth factors are located within the 
bone matrix or on the cell surface and play a major role in bone homeostasis. Water 
accounts for roughly 10% of the bone volume and serves a variety of functions, 
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including control of ion flux, cell and matrix nutrition, and maintenance of collagen 
structure [32]. Water has been used to test the mechanical properties of bone. It has 
been well documented that following the dehydration of bone, the stiffness, tensile 
strength, and hardness increase while the strain and energy to fracture decreases [83]. 
Lipids also play a role in bone homeostasis. Several factors that influence lipid 
metabolism such as Sphingomyelinase [84, 85], Caveolins [86], and Phospholipase D 
[87] all have unique effects on bone development. 
 Sphingolipid biosynthesis and metabolism has been shown to be an important 
regulator of skeletal development [85, 88]. In a previous study, deletion of the gene 
encoding sphingomyelin phosphodiesterase 3 resulted in Osteogenesis Imperfecta 
indicating the importance of sphingomyelinase enzymes in bone homeostasis [85]. 
Sphingomyelinase enzymes are responsible for the cleavage of sphingomyelin which 
generates ceramide and phosphocholine [89]. Ceramide itself has been shown to 
induce apoptosis in osteoblasts; however, ceramide derivatives sphingosine and 
sphingosine-1-phosphate (S1P) have been shown to enhance osteoblast migration and 
early stage osteoblast differentiation [90, 91].   
 Recent evidence suggests that dysfunction of enzymes that influence lipid 
metabolism may also influence bone metabolism. Previous literature has shown that an 
association between lipid and bone metabolism disorders such as atherosclerosis and 
osteoporosis exist [92, 93]. Furthermore, increase in adipocyte levels correlate with a 
decreased level of bone mineral density and increased bone loss. During aging, the 
hyperaccumulation of lipids leads to the pathogenesis of athlerosclerosis and 
osteoporosis. One of the primary class of drugs used to treat athlerosclerosis are 
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members of the statin family (Simvastatin, lovastatin) which act to lower cholesterol by 
inhibiting the enzyme 3-hydroxy-3-methyl-glutaryl-CoA reductase important for the 
cholesterol biosynthesis pathway [93]. Interestingly statins have been shown to have a 
positive effect on bone formation and bone mineral density [94, 95]. Previous literature 
has shown that statins positively affect osteoblast differentiation and function and 
negatively affect osteoclast proliferation and differentiation [96-98]. 
2.3 Cellular and Molecular Determinants of Bone 
 Mesenchymal stem cells (MSCs; marrow stromal cells) are pluripotent cells 
located throughout the body. Pluripotent stem cells (PSC’s) in the bone marrow have 
the potential to differentiate into multiple cell lineages, including muscle, bone, cartilage, 
adipose, ligaments, and tendons [99, 100]. The potential for these cells to differentiate 
towards a certain lineage is based upon the cytokines, growth factors, and transcription 
factors specific to that tissue. The ability for MSCs to differentiate into a variety of cell 
lineages makes them an ideal candidate to help regenerate a variety of connective 
tissues. Several potential applications for the use of stem cell therapies for regenerative 
medicine have already begun [101]. In several animal studies, MSCs expanded ex vivo 
and placed back into the animal were able to differentiate into cells of the residing 
tissue, repair the damaged tissue, and help restore function in tissues including bone 
and cartilage [102, 103]. The use of MSCs in orthopedic medicine is of great interest 
due to the growing rate of osteoporosis and osteoarthritis. MSCs hold a potential role to 
help accelerate bone healing in cases of non-union fractures. In order for MSCs to play 
a role in bone regeneration, they must first have the ability and potential to differentiate 
into the bone matrix and mineralizing cells, the osteoblasts. 
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 Osteoblasts are bone matrix secreting cells arising from the mesenchymal stem 
cell lineage. In order for MSCs to differentiate into osteoblasts, certain environmental 
cues that include cytokines, growth factors, and transcription factors must be expressed 
[104]. Osteoblasts undergo specific stages of differentiation which include proliferation, 
matrix deposition, matrix maturation, and mineralization (Figure 2.6) [105]. During 
proliferation osteochondrogenic precursors and pre-osteoblasts will continue to 
mitotically divide until given the molecular cue to stop. Once proliferation has ceased, 
immature osteoblasts begin secreting organic bone matrix proteins comprised primarily 
of type I collagen in a process known as matrix deposition. The unmineralized bone 
matrix during this stage is known as osteoid. After the osteoid layer has been secreted, 
mature late-stage osteoblasts begin depositing mineralized matrix composed primarily 
of hydroxyapatite [106, 107]. After the mineralization process there are three routes 
osteoblasts can undergo: they can become embedded within the bone matrix and 
transition into osteocytes, become bone lining cells, or undero apoptosis [108]. There 
are several markers that are used to assess different stages of osteoblast differentiation 
which include, ALP, Osteocalcin, type I collagen, Bone Sialoprotein, Osteopontin, and 
PTH [109]. These markers are transcriptionally regulated by several factors; however, 
the most well studied transcription factors controlling different stages of osteoblast 
differentiation are Runx2 and Osterix. 
 Runx2 (Osf2/Cbfa1) is a master transcriptional regulator of osteoblast 
differentiation expressed only in bone, which was discovered from the promoter analysis 
of the osteocalcin gene 2 (OG2) [110]. Runx2 belongs to the Runx family of 
transcription factors homologous to Runt, a Drosophila gene product [111]. Mice 
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deficient in Runx2 fail to form hypertrophic chondrocytes and completely lack 
osteoblasts as the mice only produce a cartilaginous skeleton that is completely devoid 
of bone matrix [112]. Mutations within the Runx2 gene in humans lead to a rare disease 
known as Cleidocranial Dysplasia characterized by complete or partial absence of the 
collar bones and defective development of the cranial bones [113]. Since its critical role 
in bone was first discovered, Runx2 has been shown to interact with other 
transcriptional regulators and signaling molecules important for bone formation [114]. 
These interactions can either be stimulatory or repress osteoblast specific genes that 
include type I collagen, Osteocalcin, Osteopontin, ALP, Osteonectin, and Bone 
Sialoprotein.  
 Osterix (Osx; Sp7) is a zinc finger transcription factor, critical for osteoblast 
differentiation. In mice lacking Osterix there is a complete absence of bone indicating 
that  Osterix acts as a master transcription for bone formation [115]. Similar to Runx2, 
Osterix has been shown to interact with and regulate several important factors important 
for osteoblast differentiation. Previous literature has shown that the Osterix promoter 
contains a Runx2 binding domain, indicating that Runx2 acts upstream and regulates 
Osterix expression in osteoblasts [116]. There are several cytokine and growth factors 
that stimulate signaling pathways that mediate both Osterix and Runx2 activity and drive 
osteoblast differentiation and function. These include members of the BMP, TGF-β, 
Wnt, and FGF families. 
 Bone morphogenetic proteins (BMPs) are members of the TGF-β superfamily 
that were first detected in extracts taken from bone at ectopic sites [117, 118]. BMPs 
are ubiquitously expressed in a variety of tissues, including bone, and have shown to 
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play a critical role in osteoblast differentiation. Abnormalities in the BMP signaling 
pathway in humans can lead to the disease Fibrodysplasia Ossificans Progressiva 
(FOP) in which mutation in the BMP receptor leads to active bone formation at ectopic 
sites [119]. BMP signaling is stimulated through the binding of its heterodimeric 
serine/threonine kinase receptor (BMP receptors I (BMPR-I) and BMP receptors II 
(BMPR-II) complex which results in downstream Smad signaling. Upon stimulation of 
BMP, constitutively active BMPR-II phosphorylates and stimulates BMPR-I, which 
subsequently stimulate regulatory Smad 1, 5, and 8 by phosphorylation at their C-
termini [120]. The receptor stimulated Smads associate with Smad 4 which then 
translocates to the nucleus and interacts with other transcription factors and bind to 
promoters of osteoblast specific genes. Previous literature has shown that BMPs 
cooperate with Runx2 and regulate expression of genes related to osteoblast 
differentiation and function [121, 122]. Interestingly, BMP2 was shown to induce Osterix  
expression through the MAPK pathway and stimulate osteoblast differentiation and 
function, indicating that BMPs are capable of interacting with and stimulating multiple 
signaling pathways related to osteoblast differentiation [123, 124].  
 Transforming growth factor (TGF-β) family of cytokines are largely abundant 
within the bone matrix and have shown to have both a negative and positive effect on 
bone formation. The signaling pathway for TGF-β is similar to that of BMPs; however, 
upon stimulation of the TGF-β type I receptor, regulatory Smads2 and 3 are activated 
and interact with Smad 4 to regulate transcription of osteoblast related genes [125, 
126]. Interestingly, activated Smad3 inhibits Runx2 activation and expression resulting 
in decreased Osteocalcin expression and osteoblast mineralization [127]. Previous 
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literature has shown that TGF-β can also stimulate recruitment and proliferation of 
osteoblasts [128, 129], indicating a dual role for TGF-β during osteoblast differentiation.  
 The Wnt family of proteins are secreted glycoproteins that regulate several 
cellular functions through activation of its 7 transmembrane receptor frizzled and co-
receptor LRP5/6 [130]. There are several downstream mediators of Wnt signaling. In 
the absence of Wnt, the transcription factor β-catenin complexes with Adenomatous 
Polyposis Coli (APC), Glycogen Synthase Kinase-3 (GSK3), Casein Kinase-1 (CK1), 
and Axin phosphorylating β-catenin tagging it for degradation [131]. When Wnt signaling 
is active, β-catenin does not get phosphorylated and instead accumulates in the nucleus 
where it regulates transcription of certain target genes along with other co-transcription 
factors TCF/Lef1. Wnt signaling has been shown to be a critical pathway during 
osteoblast differentiation.  
 The importance of Wnt signaling in bone came from studies using lipoprotein 
receptor-related protein (LRP) knockout and transgenic mice. LRP5 and LRP6 are part 
of a family of low density lipoprotein co-receptors for the Wnt family of ligands [132]. 
LRP5 deficient mice at 8 weeks of age were shown to have a significant reduction in 
trabecular bone volume due to a reduction in mineral formation and osteoblast 
proliferation [133]. Further evidence of the importance of LRP5 has been linked to the 
human disorder Osteoporosis Pseudoglioma Syndrome (OPPG), in which patients with 
a mutation in LRP5 resemble an osteoporotic phenotype [134, 135]. Similarly LRP6 
deficient mice also reveal an osteoporotic phenotype. LRP6 homozygous knockouts are 
lethal at birth containing severe developmental abnormalities in the skeleton; however, 
the LRP6 heterozygous mice are viable but still exhibit significant decreases in bone 
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mineral density at 9 weeks age [136, 137]. Furthermore, LRP5-/- and LRP6+/- double 
knockout mice have a more dramatic phenotype than LRP5-/- or LRP6+/- mice alone, 
indicating that LRP5 and LRP6 co-operate and interact with each other to regulate bone 
mass [138]. There have been several studies revealing the importance of the β-catenin 
transcription factor during osteoblastogenesis. Conditional deletion of β-catenin in early 
progenitor cells using the Prx promoter revealed β-catenin is critical for osteoblast 
differentiation. These mice have significant skeletal abnormalities during development 
as osteochondral progenitor cells differentiate into chondrocytes instead of osteoblasts 
[139].  
 As the role of Wnt signaling is becoming inevitably important, the use of Wnt 
ligands to stimulate bone formation is becoming an intriguing idea. Of all the Wnt family 
members, Wnt10b has been the most well studied to induce bone formation [140]. 
Transgenic expression of Wnt10b in mice revealed a four-fold increase in trabecular 
bone volume and decrease in adipose tissue, indicating that this ligand enhances 
osteoblastogenesis while suppressing adipogenesis [140, 141]. Mice deficient in 
Wnt10b show a 30% reduction in trabecular bone volume with no difference in cortical 
bone volume or tartrate-resistant acid phosphatase (TRAP5b) serum levels indicating 
that Wnt10b seems to be an osteoblast specific molecule. Although most literature 
indicates Wnt signaling’s importance in osteoblast differentiation, recent evidence 
indicates Canonical Wnt signaling inhibits osteoclastogenesis through Frizzled receptor 
8 and Wnt3a [142]. There is also evidence that inhibition of the Wnt signaling pathway 
has an effect on bone remodeling.  
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 The family of Wnt inhibitory factors (WIFs) include Secreted Frizzled-Related 
Proteins (SFRPs), Sclerostin (SOST), Connective Tissue Growth Factor (CTGF), and 
Dickkopf proteins (DKKS) [137]. Loss of SFRP-1 in mice enhances osteoblast 
differentiation and proliferation, indicating that SFRP Wnt antagonist regulates cells of 
the osteoblast lineage during bone remodeling [143]. Sclerostin is an osteocyte specific 
marker that plays a role in negatively regulating bone formation and stimulating bone 
resorption. Deletion of Sclerostin in mice under the SOST promoter revealed 
significantly more bone by µCT and DXA scanning in 16 week old male and female 
mice [144]. Furthermore, Sclerostin antibody treatment has shown to significantly 
increase bone formation, mass, and strength in a postmenopausal rat model [145]. 
These results indicate that both agonists and antagonists of the Wnt signaling pathway 
may potentially be used as a therapeutic to help treat bone disease in the case of 
osteoporosis.  
 Parathyroid hormone (PTH) is an 84-amino acid single chain polypeptide 
hormone expressed primarily by the parathyroid glands. PTH and parathyroid hormone 
related peptide (PTHrP) have both anabolic and catabolic effects on bone metabolism. 
PTH secretion is regulated by several different mechanisms, including extracellular 
calcium levels, 1, 25(OH)2 vitamin D, and Fibroblast Growth Factor 23 (FGF23) [146].  
PTH signals through its 7-transmembrane receptor PTH1R and stimulates downstream 
PKA and PKC signaling which converge on the Runx2 and regulate osteoblastogenesis 
[147]. Mice deficient in PTH show a moderate phenotype with slightly large hypertropic 
zones in the growth plate [148]; however, mice deficient in parathyroid hormone related 
peptide (PTHrP) die perinatally, most likely due to abnormalities in endochondral 
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ossification [149]. Abnormalities in PTH signaling has been linked to the human disease 
Blomstrand Lethal Osteochondrodysplasia in which patients suffer from premature 
ossification and advancement of the skeleton due to a loss of function mutation in 
PTH1R [150]. There have been several mechanisms predicted of the role of PTH in 
enhancing bone formation.  The effects of PTH and PTHrP seem to be context 
dependent. The actions of PTH on bone are cell type, dosage, exposure, and cell stage 
dependent.  Previous literature indicates that PTH may have an effect on osteoblast 
proliferation, differentiation, and/or viability; however, PTH has also shown to play a role 
in osteoclast differentiation [151]. 
 The Fibroblast Growth Factor (FGF) family of proteins has shown to play an 
important role in osteoblast differentiation and function. The FGF ligands bind to their 
corresponding tyrosine kinase receptors (FGFR) which dimerize upon ligand binding 
and stimulate downstream signaling pathways [152].  Several of the FGF ligands and 
their receptors (FGFR) are expressed during osteoblastogenesis. The FGF2 ligand 
(basic FGF) and its receptor (FGFR2) have been shown to be important modulators of 
bone development. Mice deficient in FGF2 at 4 weeks have significantly less trabecular 
bone by microCT, a lower mineral apposition rate (MAR), and less mineralization in vitro 
compared to controls [153]. Furthermore, FGFR2 homozygous mice die embryonically 
[154]; however, conditional mice deficient in FGFR2 reveal significantly impaired 
proliferation of osteoprogenitor cells and dysfunction of mature osteoblasts [155]. 
Dysfunction in the FGFR2 gene has been correlated with several human 
craniosynostosis disorders [156], indicating the importance of the FGF2 signaling 
pathway and osteoblasts. FGF2 administration in an overectomized rat model was 
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shown to restore bone mass [157], indicating the potential for FGF2 to be used as a 
therapeutic for treatment of osteoporosis. FGF2 downstream was also found to 
stimulate the MAPK/Runx2 pathway in osteoblasts [158]. Interestingly, the FGF 
pathway was found to interact with other molecules, such as integrins and heparin 
sulfate proteoglycans, to induce downstream signaling. The FGF3 ligand and receptor 
are also expressed in osteoblasts. FGFR3 deficient mice at a young age were shown to 
exhibit severe bone dysplasia and enhanced endochondral growth [159]; however, at an 
older age (16 weeks), FGFR3 deficient mice develop osteopenia and defective bone 
mineralization [160]. This indicates that the role of FGFR3 in bone remodeling is age 
dependent.  FGF18 ligand plays a role in both osteoblast and chondrocyte 
development. Previous literature has shown that FGF18 deficient mice have delayed 
osteogenesis and increased proliferation and differentiation of chondrocytes [161]. This 
indicates that FGF18 is a positive regulator of bone formation and a negative regulator 
of chondrogenesis. Certain FGF receptor ligands have been shown to be important 
regulators for phosphate and vitamin D metabolism. FGF23 deficient mice have been 
shown to have significantly higher vitamin D and phosphate levels [162]. Furthermore, 
the authors concluded that FGF23 inhibits reabsorption of phosphate ions in the kidneys 
indicating a link between bone and kidney. This indicates that FGF23 is a key regulator 
in maintaining proper vitamin D and phosphate homeostasis. Several FGF ligands and 
their receptors have been shown to play a role in multiple systems including bone. 
Further research needs to be done to determine the role of other FGF ligands and their 
receptors in bone homeostasis. 
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 There are several cellular and molecular determinants that have a diverse effect 
on osteoblasts (Figure 2.7). All of the pathways described have a major role on not only 
osteoblasts, but also a variety of cells within the bone microenvironment. The 
importance of determining the involvement of these molecules is crucial when 
determining new bone anabolic therapies to treat bone disease. The discovery of new 
anabolic factors that influence osteoblast differentiation and function independent or in-
conjunction with these pathways is vital. 
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Figure 2.6: Schematic diagram depicting the different stages and known markers 
of osteoblast differentiation. Osteoblasts arise from mesenchymal stem cell 
precursors and require the critical transcription factors Runx2 and Osterix in order to 
differentiate into this lineage. In culture experiments, after a week, cells begin depositing 
an extracellular organic matrix (ECM) also known as osteoid. As the osteoblast begins 
to mature minerals are deposited which primarily consist of hydroxyapatite. Once these 
processes have ceased, the osteoblast has 3 potential fates. The osteoblast may 
undergo apoptosis, become an osteocyte; or enter a quiescent state and may lie flat on 
the bone surface and become bone lining cell. -=little to no expression; +=moderate 
expression; ++=relatively high expression; +++=very high expression. 
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Figure 2.7: Schematic diagram indicating the important receptor-ligand 
interactions critical for osteoblast differentiation and function. Several signaling 
pathways have been found to be important for osteoblast differentiation and function. 
Runx2 is the critical transcription factor that most signaling pathways converge. 
Interestingly, Runx2 has been shown to regulate Osterix activity; however certain 
signaling pathways have been shown to act independently of Runx2 and mediate 
osteoblast differentiation and function through Osterix alone.  
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 The process of bone remodeling requires both bone formation from the 
osteoblasts and bone resorption by the osteoclasts (Figure 2.8). In order to maintain 
proper bone homeostasis, bone formation and resorption acquire a balance between 
them. Once this balance is disrupted, pathological conditions within bone arise. In the 
more common pathological conditions, bone resorption by the osteoclasts exceeds 
bone formation leading to a reduction in bone mass. The osteoclast is a member of the 
monocyte/macrophage family arising from the hematopoietic stem cell lineage; it is 
found within the bone microenvironment that undergoes a series of differentiation 
processes to become a multinucleated cell [163]. The process of osteoclast 
differentiation is dependent on several cytokines within the bone microenvironment. The 
two essential cytokines for osteoclast differentiation are Receptor Activator of Nuclear 
Factor kappa-B ligand (RANKL) and Macrophage Colony Stimulating Factor (M-CSF; 
CSF-1) [164]. RANKL, also known as TNFSF11, is a member of the TNF superfamily 
and the critical cytokine involved in osteoclastogenesis due to its ability to direct 
precursor cells into the osteoclast lineage. M-CSF contributes to a series of events 
important for the proliferation, differentiation, and survival of the osteoclasts [165]. 
These two cytokines are both secreted and membrane bound, and are expressed by 
several other cells in the microenvironment, including osteoblasts, osteocytes, and 
immune regulator cells [166]. The RANKL and M-CSF ligands bind to their respective 
receptors, RANK and c-FMS, and activate signals to induce differentiation of 
osteoclasts. The series of events from osteoclast precursor to mature bone resorbing 
osteoclast require the involvement of several osteoclast-specific genes that are tightly 
coordinated and regulated. 
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 Osteoclast formation is controlled by several factors and cells within the 
microenvironment. The osteoblasts are a major source of RANKL controlling osteoclast 
differentiation. The osteoblast also secretes a RANKL decoy receptor known as 
Osteoprotegerin (OPG), shown to inhibit RANKL induced osteoclastogenesis [167]. The 
RANKL/OPG axis is an important regulator of osteoclast differentiation. Previous 
literature has shown that OPG deficient mice develop early onset osteoporosis due to 
increased osteoclast activity [168]; therefore, when OPG levels are significantly reduced 
compared to RANKL, there is a significant increase in the number of osteoclasts. When 
OPG levels are significantly higher than RANKL, there is a significant reduction in the 
number of osteoclasts, indicating that the RANKL/OPG axis is an indicator of the 
relative number of osteoclasts. Although the RANKL/OPG axis is the key regulator of 
osteoclastogenesis, there are several other factors important for osteoclast 
differentiation.  
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Figure 2.8: Summary of bone remodeling cycle. Osteoblasts differentiated from 
mesenchymal stem cell precursors secrete cytokines M-CSF and RANKL to stimulate 
osteoclast differentiation and bone resorption. Osteoblasts also secrete OPG, a 
negative regulator of osteoclast differentiation, to regulate RANKL activity. Osteocytes 
have also been shown to regulate osteoclast differentiation by secreting RANKL. Mature 
osteoclasts have been shown to secrete clastokines (molecules released by osteoclasts 
that affect osteoblasts) to regulate osteoblast differentiation and function.  
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 There are several stages involved in the process of osteoclast differentiation, 
which include the proliferation, commitment, fusion, and activation. The earliest 
identifiable stage of the osteoclast is the granulocyte- macrophage colony forming cell 
(CFU-GM;BMM) which proliferate and differentiate to form a committed osteoclast 
precursor [169]. Early transcriptional regulation of osteoclast differentiation is controlled 
by PU.1 and MITF. PU.1 deficient mice have severe osteopetrosis due to a failure to 
generate bone marrow macrophages (BMM) [170]. PU.1 effects on early osteoclast 
differentiation are in part due to its interaction with the Microphthalmia (MITF) family of 
transcription factors. The lack of MITF (MITFmi/mi) in mice leads to severe osteopetrosis 
due to the absence of mature osteoclasts; however, these mice are still able to generate 
macrophages, indicating that MITF is activated prior to PU.1 [171]. The M-CSF/c-FMS 
signaling axis is important for early stage osteoclast differentiation.  The importance of 
M-CSF in osteoclastogenesis has risen from op/op mice that contain a mutation in the 
M-CSF gene leading that to a truncated version of the protein resulting in osteopetrosis 
due to lack of osteoclasts [172]. Interestingly, the skeletal phenotype of these mice 
resolves with age due to compensatory cytokines GM-CSF and VEGF [173, 174]. 
Previous literature has shown that M-CSF signaling regulates MITF and anti-apoptotic 
factor Bcl-2, indicating that M-CSF plays a role in both early commitment and apoptosis 
of osteoclasts [175, 176].  
 The final commitment stage from BMM to osteoclast precursor cell (OCP) is 
primarily controlled by RANKL/RANK signaling. The activation of RANK recruits 
members of the TNF Receptor-Associated Factor (TRAF) family of adaptor proteins 
[177]. The TRAF family contains seven members; however, the primary TRAF protein 
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associated with RANK signaling is TRAF6, which has three distinct binding domains to 
RANK [178]. Several groups have independently characterized the skeletal phenotype 
of TRAF6 deficient mice with slightly different results, but the accepted result is that 
these mice are severely osteopetrotic due to severe dysfunctional osteoclast 
differentiation [179-181]. The binding of TRAF6 to RANK leads to the activation of the 
NF-КB and MAPK pathways. The NF-КB pathway consists of a family of dimeric 
transcription factors that regulate several osteoclast specific genes. There are 5 NF-КB 
proteins which include Rel, RelA (p65), RelB, NF-КB1 (p50), and NF-КB2 (p52) [182]. In 
unstimulated cells these proteins remain in the cytoplasm; however, upon stimulation 
they translocate to the nucleus and regulate several different genes.  
 There are two different pathways of NF-КB activation: the classical and 
alternative. The classical, or canonical pathway involves activation of the IKK complex 
that phosphorylates and degrades IКB [183]. Unphosphorylated IКB binds to p50 and 
RelA and upon its degradation by the IKK complex, releases p50 and RelA, which 
translocate to the nucleus. In the alternative pathway, NF-КB-inducing kinase (NIK) 
stimulates the IKK complex to process p100 to release RelB to the nucleus, where 
along with p52, regulate a variety of genes [177]. Several of the proteins involved in the 
NF-КB pathway have resulted in an osteopetrotic phenotype due to impaired osteoclast 
differentiation [184-186]. The critical target gene of the NF-КB pathway is nuclear factor 
of activated T-cells-1 (NFATc1). The induction of NFATC1 is the hallmark event in the 
determination of BMM into osteoclasts, and its promoter contains NF-КB binding sites 
[187, 188]. NFATc1 binds to and regulates several osteoclast-specific genes, including 
TRAP [189], Calcitonin Receptor [190], Cathepsin K [191], β3 integrin [192], and 
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OSCAR [189]. Activation of RANK in osteoclasts has not only shown to stimulate 
members of the NF-КB family, but also members of the MAPK family. 
 There are four groups within the MAPK pathway, which include p38 (α,β,ᵧ,ᵟ), 
JNK1/2/3, ERK1/2, and ERK 5 [193]. Previous literature has been documented 
explaining the importance of the MAPK pathway during osteoclastogenesis [194-196]. 
The MAPK pathway has shown to regulate the transcription factor complex AP-1 
through the induction of its subunit c-Fos [197]. The AP-1 is a dynamic complex 
consisting of Fos (c-Fos, FosB, Fra-1, Fra-2, ), Jun (c-Jun, JunB, JunD), and ATF 
(ATFa, ATF2, ATF3, ATF4, B-ATF) proteins [198]. Mice deficient in c-Fos are severely 
osteopetrotic due to lack of osteoclasts, indicating that this factor is an important 
regulator of osteoclast differentiation [199]. Interestingly, it has been shown that 
members of the AP-1 complex cooperate with members of the NF-КB pathway to 
regulate NFATc1 along with other osteoclast-related genes, indicating the importance of 
both pathways for osteoclastogenesis [188]. As shown, several regulatory mechanisms 
are required for the commitment of osteoclast precursor cells. Once the commitment 
into the osteoclast lineage is complete, the osteoclasts must bind to the bone surface, 
fuse, and begin the secretion of degradative enzymes.  
 Before the osteoclast begins its bone degradation process, it must first be able to 
attach to the bone surface. The recognition between the bone surface and the 
osteoclast cell membrane is controlled through integrins. Integrins are composed of αβ 
heterodimers that transduce signals between the extracellular matrix and the inner 
cytoplasm of the cell. The principle integrin mediating attachment in osteoclasts is αvβ3 
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[200]. Mice deficient in β3 integrin have increased bone mass due to dysfunctional 
osteoclasts [201]. The integrin family members are able to recognize extracellular matrix 
proteins through the amino acid motif Arg-Gly-Asp (RGD). Several extracellular matrix 
proteins, such as Osteopontin and Bone Sialoprotein, have been shown to interact with 
αvβ3 allowing for cell adhesion and attachment to the bone surface [62].  
 The attachment of integrins within the osteoclast to extracellular matrix proteins 
results in the beginning steps of the formation of a sealing zone, one of the critical steps 
for bone resorption. In order for osteoclasts to resorb, they must first become polarized. 
The osteoclast cytoskeleton is a key mediator for its polarization and resorption. In the 
beginning stages of resorption, an acidified microenvironment is created by several 
components. Carbonic anhydrase II (CAII) and V-ATPase are the two main enzymes 
responsible for lowering the pH of the microenvironment by secreting H+ and HCl. 
Furthermore, acidifed vesicles transported along microtubules within the cell containing 
degradative enzymes Cathepsin K and matrix metalloproteinases (MMPs) are carried to 
the plasmalemma and deposited onto bone matrix at what is known as the ruffled 
border [202]. The area between the ruffled border and the degraded bone matrix in 
which degradative enzymes and acidic molecules are being deposited is known as the 
Howship’s lacunae [203].  
 Mutations in several osteoclast resorptive genes have been identified and 
correlated with human osteopetrosis. The degradation of bone matrix results in the 
release of minerals and collagen that accumulate within the blood stream.  The 
increased concentration of minerals, such as calcium, triggers the secretion of specific 
hormones, such as calcitonin, to be expressed. Calcitonin binds to its receptor 
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(Calcitonin Receptor) which signals to the osteoclast to halt resorption [204]. Other 
hormones such as estrogen regulate osteoclast resorption by triggering apoptosis. 
Imbalance or loss of these factors can have severe consequences for bone 
homeostasis and lead to pathological conditions.  
 Although the RANKL/RANK signaling axis is the key regulatory factor for both 
osteoclast differentiation and function, several other inflammatory cytokines can 
contribute as well. The inflammatory cytokines of the tumor necrosis and interleukin 
families have shown to play a role in osteoclast differentiation and function.  Previous 
literature has shown TNF-α, IL-1β, and IL-6 bind to their respective receptors TNFR and 
ILR and mediate downstream signaling [205, 206]. These factors along with RANKL can 
act as a synergistic effect during osteoclast differentiation and function. 
 The process of osteoclast differentiation and function is complex and regulated 
by several different cell types. Imbalance of the bone homeostatic mechanism between 
osteoclasts and other cell types can result in pathological conditions; therefore, the 
understanding of all aspects within the bone microenvironment and how they signal 
between each other is important for identifying new factors that may contribute to the 
process of bone remodeling. 
 Osteocytes comprise the greatest percentage of all bone cells (~90%) within the 
microenvironment [207, 208]. Osteocytes reside within the mineralized matrix of bone 
and form connections with each other and cells on the bone surface through dendritic 
processes [32]. The osteocyte cell body itself is encased within a structure known as the 
lacuna. Through their network of dendritic processes, osteocytes relay signals not only 
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to other osteocytes, but also to cells on the bone surface and within the bone marrow. 
The osteocytes arise from the mesenchymal stem cell and osteoblast lineages. One of 
the first proposals of osteocytogenesis stated that a subpopulation of osteoblasts 
become passively encased in osteoid which then becomes mineralized by neighboring 
osteoblasts [209, 210]. Other mature subpopulations of osteoblasts that do not under 
osteocytogenesis undergo apoptosis instead.  
 As a cell undergoes osteocytogenesis, the cell develops a polarity relative to the 
surface of the bone and develops dendritic processes that extend to other cells and the 
bone surface. Osteocytes express several cell specific markers. E11/gp38/Podoplanin 
is a marker expressed on the cell surface in embedded osteoid osteocytes [211]. 
Targeted deletion of this molecule in mature osteoblasts resulted in significantly fewer 
canaliculi per osteocyte and increased trabecular bone [209]. Several other osteocyte 
markers include PHEX, MEPE, DMP-1, FGF-23, Sclerostin, and ORP150. Osteocytes 
have been shown to have a large impact on bone remodeling through a variety of 
mechanisms which include regulation of the RANKL and Wnt/β-Catenin pathways and 
as sensors for biomechanical stimuli.  
 Osteocytes have been shown to secrete factors that stimulate both osteoclast 
and osteoblast differentiation. The number of healthy osteocytes and their ability to 
sense a variety of external stimuli can be correlated with the quality of bone. Osteocyte 
cell death can be associated with skeletal pathologies such as osteoporosis and 
osteoarthritis [212].  Osteocyte apoptosis can occur by several mechanisms, including 
microdamage, aging, glucocorticoid treatment, and estrogen withdrawal. In cases of 
microdamage to bone tissue, osteocyte apoptosis occurs, resulting in the release of 
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inflammatory cytokines within the microenvironment. Previous literature has shown that 
apoptotic osteocytes secrete large amounts of RANKL to recruit osteoclasts to the site 
of damage [213].  
 Prolonged use of glucocorticoids has been shown to inhibit bone formation, 
stimulate resorption, and cause osteonecrosis [212]. Glucocorticoid treatment in MLO-
Y4 osteocyte-like cell line resulted in an increase in Fas/CD95 and Caspase 8 
expression [214]. This mechanism may explain the link between prolonged use of 
glucocorticoids and osteocyte cell death. Estrogen withdrawal has been linked with an 
increase of proinflammatory cytokines. During post-menopausal periods, the lack of 
estrogen leads to an increase in TNF-alpha and interleukin-1 which have been shown to 
induce osteocyte apoptosis [215]. Several agents have been shown to reverse the 
effects of osteocyte cell apoptosis. These include Calcitonin, CD40 ligand, 
bisphosphonates, and estrogen modulators [209]. Interestingly, osteocytes also seem to 
be involved in osteoblast and MSC differentiation. The conditioned media collected from 
the MLO-Y4 cell line has been shown to stimulate MSC proliferation and differentiation 
[216]. This indicates that osteocytes may play a role in both bone formation and 
resorption. 
 One of the more well-known and primary functions of osteocytes is their ability to 
sense mechanical stimuli and regulate bone remodeling. The adult skeleton is able to 
adapt to mechanical loading by which new bone is added or removed based on the 
amount of stress placed on the tissue. Loading and unloading of bone tissue changes 
the gene expression in osteocytes in vivo, indicating that load effects osteocyte function 
[217]. In order to increase bone mass in vivo by mechanical strain, the ideal intensity, 
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frequency, and timing of loading must be within a certain range [218, 219]. One of the 
challenges that remain is to correlate what is known in vivo and translate it to in vitro 
parameters. Fluid-flow shear stress models are the gold standard in determining the 
role of osteocytes as mechnosensory cells. As mechanical strain is applied to bone, this 
causes a fluid flow through the canaliculi around the osteocyte resulting in shear stress 
and deformation of the cell membrane. The mechanical strain is sensed through the 
dendritic processes and cilia of the osteocyte [220]. In response to shear stress, 
osteocytes release NO, prostaglandin, and ATP [221, 222]. This mechanism may 
explain the effect of osteocyte mechanical loading on new bone formation in vivo and in 
vitro.  
 Osteocyte related proteins have shown to be important mediators of mineral 
metabolism. Osteocyte proteins DMP-1, PHEX, and FGF-23 have shown to regulate 
phosphate levels and biomineralization [223]. In the case of hypophosphatemic rickets, 
patients contain a mutation DMP-1 which regulates FGF-23 [66]. Under normal 
circumstances, DMP-1 down regulates FGF-23 allowing reabsorption of phosphate by 
the kidneys which in turn maintain appropriate phosphate levels for normal mineral 
homeostasis in bone. In the DMP-1 mutant condition, FGF-23 levels are high in 
osteocytes leading to phosphate excretion by the kidneys and impairment in 
biomineralization due to the lack of circulating phosphate. A similar condition with 
elevated FGF-23 levels is seen in patients with chronic kidney disease (CKD) [224]. 
Progression of CKD is correlated with increased levels of FGF-23. This indicates that 
osteocytes may act as an endocrine system that target distant tissue such as the 
kidney. 
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 Osteocytes have multifunctional roles in bone remodeling. The maintenance and 
integrity of bone can in part be determined by osteocyte health, status, and viability. 
Osteocytes are involved in many pathological conditions including osteonecrosis, 
hyper/hypophosphatemia, and osteoporosis. Previous literature has shown that 
osteocytes may have a potential role as an endocrine organ in both the kidney and 
cardiovascular system [225]. Currently therapeutics to treat bone disease have been 
discovered from factors secreted by osteocytes. It will be interesting to determine if 
other factors expressed by osteocytes yet to be discovered will have an impact on bone 
remodeling. 
2.4 Osteoporosis 
 As the longevity and quality of life improves in humans, age-related pathologies 
such as osteoporosis, have become a problem. Osteoporosis can be defined as a skeletal 
disorder in which bone integrity and strength are compromised, predisposing an individual 
to an increased risk of fracture [226]. In the United States in 2005, two million fragility 
fractures were reported and is predicted to increase to three million by 2025 unless more 
preventative measures take place [227]. Half of these fractures occur in patients with 
significantly low bone mass, and the other half occur in patients diagnosed with 
osteopenia.  
 The most common types of fractures seen in patients with osteoporosis include 
hip, vertebral, and distal forearm. The survival rates for patients five years after hip and 
vertebral fractures are roughly 80% compared to those men and women of similar age 
without fracture [228]. In terms of morbidity, 7% of survivors of all types of fracture have 
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in some instance permanent disability and 8% require nursing home care [229]. There is 
a broad use of terminology when describing osteoporosis. The terms used to describe 
cases of osteoporosis include postmenopausal, senile, and idiopathic [32]. The first two 
terms are synonymous, whereas idiopathic osteoporosis refers to premenopausal women 
and younger men. The pathogenesis of osteoporosis arises due to four basic 
mechanisms. The four basic mechanisms include accelerated bone loss due to increased 
osteoclast activity, inadequate bone formation by the osteoblasts, increased falls, and, 
most importantly, a failure to achieve optimal peak bone mass and strength [227]. These 
mechanisms are influenced by several factors, including genetics, nutrition, and lifestyle. 
 Genetics are the major determinant of peak bone mass and strength. As the 
individual ages, changes in gene expression occur that can eventually cause age- 
related pathologies such as osteoporosis. There are several important factors within the 
bone microenvironment that change overtime that will influence the bone remodeling 
process. Several genome-wide studies have been conducted to identify specific gene 
loci that regulate bone mineral density. The polymorphisms that occur within these loci 
are genes important for both bone formation and bone resorption. A few examples of 
polymorphisms that are correlated with osteoporosis and are important for osteoblast 
function are COL1A1, vitamin D receptor (VDR), and LRP5. Polymorphisms within the 
COL1A1 gene have been thought to be linked to skeletal fragility [230]. Multiple 
polymorphisms in the COL1A1 gene have been described [231, 232]. Changes in the 
COL1A1 gene effect critical functions of collagen within the bone matrix. For example, 
previous literature has shown that polymorphisms in COL1A1 result in an imbalance in 
α1 and α2 chains contributing to the impairment of the bone by reducing mineralization 
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resulting in decreased bone integrity and strength [233]. LRP5 is a co-receptor involved 
in the Wnt signaling pathway important for osteoblast differentiation and function. There 
are several studies that have recently been published showing evidence between 
polymorphisms in LRP5 and bone mineral density (BMD) [234, 235]. The mechanism in 
which the polymorphisms effect LRP function are not yet known; however, certain 
evidence has revealed that the polymorphisms in LRP5 effect its interaction with LRP6 
[235]. VDR was one of the first candidates to be studied in relation to bone mineral 
density. Several polymorphisms in the VDR gene have been identified. One in particular 
polymorphism has been characterized within the promoter region that affects binding of 
the transcription factor Cdx-2 [236]. This polymorphism has been associated with BMD 
in Japanese subpopulations; however, in other subpopulations this polymorphism is 
associated with fracture but not BMD [237].  
 There are other polymorphisms linked to changes in BMD that are important for 
osteoclast differentiation and function. Previous literature has investigated the 
polymorphisms in oestrogen receptor α, TCIRG1, CLCN7, and Sclerostin [231]. One of 
the primary causes of postmenopausal osteoporosis is due to the lack of estrogen being 
produced. Estrogen regulates osteoclast viability and its withdrawal leads to a 
significant enhancement of bone resorption [238]; therefore, it can be expected that 
polymorphisms within the estrogen receptor would influence BMD in the aging adult. 
TCIRG1 and CLCN7 are both important mediators of osteoclast resorption. Inactivating 
mutations of either of these genes results in severe osteopetrosis [239, 240]. Currently 
there is little evidence to support any true correlation of polymorphisms within these 
genes and BMD. Sclerostin is an osteocyte specific marker that has been shown to 
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inhibit bone formation and stimulate bone resorption. SOST polymorphisms have been 
correlated with BMD in a study of both elderly men and women [241]. Future studies 
should emphasize the importance of the genetic basis of osteoporosis. This will 
increase the understanding of the mechanisms underlying the pathophysiology and help 
determine new markers to assess BMD and risk of fracture. 
 In addition to the importance of determining the genetic basis of osteoporosis, 
lifestyle choices can also be a determining factor for the onset of the disease. Physical 
activity, calcium, and vitamin D levels are primary determinants of bone mass and 
strength [242]. There are several environmental influences that may affect bone quality. 
These include smoking, excessive alcohol consumption, and immobilization [243]. 
Exercise and physical activity have shown to prevent and ameliorate osteoporosis in 
postmenopausal women [244]. Quality nutrition also has a large impact on the 
prevention of osteoporosis. Calcium and vitamin D intake are critical nutrients to prevent 
the onset of osteoporosis. During osteoporosis, increased osteoclast activity is seen 
due to a lack of calcium and vitamin D which leads to secondary hyperparathyroidism 
[242]. Previous literature has shown that calcium and vitamin D supplementation is not 
only important for the prevention of the disease, but can alsoactually reverse the effects 
[245]. Other nutritional benefits that can help alleviate the symptoms of the disease 
include protein intake, B vitamins, and vitamin K [246, 247]. Milk and dairy products 
along with fruit and vegetable consumption have been positively associated with bone 
health. It is necessary to incorporate all factors- genetic, environmental, and diet- when 
trying to prevent the onset of this disease.  
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2.5 Osteopetrosis 
 Osteopetrosis is a genetic disease characterized by a high bone mass phenotype 
due to a lack of bone resorption by osteoclasts [248]. It is a rare inherited disorder with 
an incidence of 1:250,000 effecting primarily cultures of Middle East and Northern 
European descent. There are two recognized forms of the disease. The autosomal 
dominant (benign) type, which has few symptoms, and the autosomal recessive infantile 
(malignant) type, which is typically fatal if not treated [249]. Common symptoms of the 
disease include an increase in BMD resulting in macrocephaly causing mental 
retardation, exophthalmos, micrognathia, and frontal bossing [250]. Secondary 
characteristics include low serum calcium levels resulting in hyperparathyroidism and 
neurological defects, including retinal atrophy and cranial nerve compression. Several 
mutations in osteoclast related genes important for differentiation and function that 
result in the osteopetrotic phenotype have been described [249, 251, 252]. In patients 
with osteopetrosis, there are two possible scenarios with respect to osteoclasts. In one 
instance osteoclasts are present but non-functional, and in the other they are relatively 
absent, although the mechanisms are different, the result is the same.    
 There are several mutations in osteoclast resorption genes that result in the 
osteopetrotic phenotype. Roughly 70% of the patients with this disease have mutations 
in either the TCIRG1 or CLCN7 gene [250] . The TCIRG1 gene encodes a 116 kDa 
isoform of the vacuolar (V)-ATPase proton pump, and CLCN7 (ClC-7) encodes the H+-
Cl- exchange transporter 7 [239, 253, 254]. Both of these molecules are crucial for the 
formation of the ruffled border and lysosomal trafficking in osteoclasts. Other 
osteopetrotic genes related to dysfunction of the ruffled border include OSTM1, 
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PLEKHM1, and SNX10. OSTM1 encodes the β subunit of ClC-7 and prevents ClC-7 
degradation by glycosylating the N-terminus [255]. OSTM1 is also thought to be 
important for Cl- exchange [253]. PLEKHM1 is a 117 kDa cytosolic protein important for 
endosomal and lysosomal trafficking through Rab7 binding [256]. Mutations in 
PLEKHM1 lack the binding site for Rab7 resulting in an accumulation in the cytoplasm 
and an impairment of the osteoclast ruffled border. Mutations in the gene SNX-10 was 
only just recently found to be correlated with the osteopetrotic phenotype [257]. SNX-10 
is a member of a family of proteins characterized by a PX domain, a phospholipid 
binding domain. The function of SNX-10 is still unclear; however, there is evidence that 
the PX domain within SNX-10 interacts with v-ATPase indicating that SNX-10 is an 
important regulator in subcellular trafficking [258].  
 Loss of function mutations involved in osteoclast differentiation can also lead to 
an osteopetrotic phenotype. Mutations within the RANK genes TNFRSF11A (RANK) 
and TNFSF11 (RANKL) result in a significantly reduced number of osteoclasts in vivo 
[259, 260]. Several of the characterized mutations within these genes have revealed 
that the mutation affects protein structure allowing inefficient binding of the respective 
proteins. Changes in protein structure are primarily due to either folding or improper 
glycosylation of RANKL [261]. Developing targets for RANK-RANKL interactions may 
potentially be used as a new treatment option for osteopetrosis. 
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Table 2.1 Summary of Described Molecules in Introduction: Function and Skeletal 
Phenotype of Mouse Models 
Protein/Gene Animal 
Model  
Function Bone 
Phenotype 
Reference 
α2-HS-
glycoprotein 
Knockout Regulates matrix 
mineralization 
Ectopic 
calcification 
33 
Biglycan Knockout Positive regulator 
of bone formation; 
binds collagen 
and other growth 
factors 
Osteopenic, 
short stature, 
decreased 
mineral content 
36 
Alkaline 
Phosphatase 
(ALP) 
Knockout Hydrolyzes 
mineral inhibitor 
pyrophosphates 
by increasing 
phosphate 
concentration 
Decreased 
Mineralization; 
Impaired growth 
40 
Osteonectin Knockout Stimulates 
osteoblast 
proliferation and 
matrix 
Severe 
osteopenia, 
decreased bone 
mineral content 
42 
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mineralization; 
Regulates 
osteoclasts 
Bone Sialoprotein 
(BSP) 
Knockout Stimulates 
osteoblast matrix 
mineralization; 
stimulates 
osteoclast 
differentiation 
16 week animals 
have higher 
trabecular bone 
density, shorter 
femurs and body 
length 
47,48 
Osteopontin 
(OPN) 
Knockout Stimulates 
osteoclast 
resorption and 
osteoblast matrix 
mineralization 
Develop 
normally; 
however 
ovarectomized 
mice are 
resistant to bone 
loss 
50,51 
Dentin Matrix 
Protein (DMP-1) 
Knockout Regulates 
osteoblast 
mineralization; 
important 
Severe 
osteomalacia, 
abnormal tooth 
development 
52, 53 
 55 
 
regulator of 
osteocyte function 
Fibrillin-1 and 
Fibrillin-2 
Knockout Regulate the 
bioavailability of 
other growth 
factors such as 
TGF-β and BMP-
2 
Fibrillin-1 
knockouts are 
lethal;Fibrillin-2 
have significantly 
less bone 
60 
Matrix Gla 
Protein 
Knockout Negative 
regulator of 
chondrocyte and 
bone 
mineralization 
Lethal at 8 weeks 
due to 
calcification of 
vessels; 
premature 
growth plate 
mineralization 
resulting in less 
bone 
63,64 
Osteocalcin  Knockout Believed to be 
transition signal 
from bone 
Normal until 6 
months and then 
develop 
osteopetrosis 
69 
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formation to bone 
turnover 
Runx2 Knockout Critical 
transcription 
factor for 
osteoblast 
differentiation; 
regulates several 
important 
osteoblast and 
chondrocyte 
genes 
Lethal; 
Completely lack 
osteoblasts and 
fail to form 
hypertrophic 
chondrocytes 
85,87 
Osterix Knockout Master 
transcription 
factor in 
osteoblasts; 
regulates several 
genes important 
for osteoblasts 
Lethal; Complete 
absence of bone 
89 
LRP5 Knockout Positive regulator 
of osteoblast 
Significantly 
reduced 
107 
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differentiation and 
proliferation 
trabecular bone 
volume 
LRP6 Knockout Positive regulator 
of osteoblast 
differentiation and 
proliferation 
LRP6 KO is 
lethal; but 
heterozygote is 
viable and 
reveals 
significantly less 
bone 
110, 111 
Sclerostin Knockout Negative 
regulator of bone 
formation and 
positive regulator 
of bone resorption 
Deletion under 
the SOST 
promoter reveals 
significantly more 
bone by microCT 
118 
FGF2 Knockout Positive regulator 
of bone formation 
Global knockout 
is lethal; 
conditional 
knockouts have 
significantly less 
trabecular bone 
and impaired 
127-129 
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osteoprogenitor 
cells 
FGFR3 Knockout Positive regulator 
of osteoblast 
differentiation 
At 4 weeks 
develop bone 
dysplasia and 16 
weeks are 
osteopenic due 
to defective 
osteoblast 
mineralization 
133,134 
FGF18 Knockout Positive regulator 
of osteoblast 
differentiation and 
negative regulator 
of 
chondrogenesis 
Decreased bone 
mass; increased 
chondrocyte 
differentiation 
135 
FGF23 Knockout Essential 
regulator of 
phosphate and 
Severe growth 
retardation and 
abnormal bone 
136 
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vitamin D 
metabolism 
growth; short 
lifespan 
PU.1 Knockout Positive regulator 
of osteoclast 
differentiation; 
transcription 
factor regulates 
several important 
osteoclast genes 
Severe 
osteopetrosis 
due to inability to 
generate BMM 
144 
MITFmi/mi Knockout Positive regulator 
of osteoclast 
differentiation; 
transcription 
factor regulates 
several important 
osteoclast genes 
Severe 
osteopetrosis 
due to inability to 
generate mature 
osteoclasts 
145 
op/op Mutant Positive regulator 
of osteoclasts 
Osteopetrotic 
due to lack of 
osteoclasts 
resulting from a 
146 
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mutation in the 
M-CSF gene 
TRAF6 Knockout Positive regulator 
of osteoclast 
differentiation and 
function; Subunit 
of RANK receptor 
Osteopetrotic 
due to 
dysfunctional 
osteoclast 
differentiation 
153-155 
β3 Integrin Knockout Positive regulator 
of osteoclast 
resorption and 
ruffled border 
formation 
Osteosclerotic 
and osteopetrotic 
due to 
dysfunctional 
osteoclast 
resorption 
175 
TCIRG1 Mutant Positive regulator 
of osteoclast 
resorption; 
Subunit of proton 
pump 
Severely 
osteopetrotic due 
to lack of 
osteoclast 
resorption 
211 
CLCN7 Mutant Positive regulator 
of osteoclast 
resorption; 
Severely 
osteopetrotic due 
to lack of 
225,226 
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Important for 
H+/Cl- Exchange 
osteoclast 
resorption 
TNFRSF11A 
(RANK) 
Mutant Positive regulator 
of osteoclast 
differentiation and 
resorption  
Severely 
osteopetrotic due 
to lack of 
osteoclast 
number and 
resorption 
231 
TNFSF11 
(RANKL) 
Mutant Positive regulator 
of osteoclast 
differentiation and 
resorption  
Severely 
osteopetrotic due 
to lack of 
osteoclast 
number and 
resorption 
232,233 
Caveolin-1 Knockout Believed to play a 
role in regulating 
both osteoblast 
and osteoclast 
differentiation 
Increased bone 
size and 
stiffness; 
increased bone 
mass at 5 and 8 
weeks 
73 
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CD44-/--hTNF-Tg Mutant Plays an 
important role as 
an anti-
inflammatory 
receptor 
Mice have 
severe arthritis 
and are 
osteopenic due 
to high levels of 
inflammation 
362 
 
2.6 Bone Fracture 
 The unique structure of bone tissue allows it to withstand harsh mechanical 
forces and external physical stimuli. Unfortunately, in some instances bone tissue is 
unable to withstand the mechanical strain of certain forces, and a fracture develops. 
Fractures can be caused by several reasons, but the two most common are increased 
bone fragility due to age, or pathological condition, and severe skeletal trauma. There is 
a positive correlation with age and the potential risk of fracture. There have been 
several models proposed to assess the potential risk of fracture, but the two most 
common indicators are volumetric bone mineral density (vBMD) and cortical thickness 
measured by quantitative computed tomography (QCT), or high-resolution peripheral 
QCT (HRpQCT) [262]. The types of fractures can be classified based on several 
different criteria.  
 Fracture classification is complex; however, a set of guidelines designed by the 
Orthopaedic Trauma Association (OTA) and the OA pediatric group have attempted to 
unite a common diagnosis [263]. These guidelines include several factors, such as the 
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type of bone, location, morphology, and severity. All of these criteria are important for 
the prognosis and treatment options. In Muller’s AO classification of fractures for long 
bones, in each long bone the regions of the bone are named and numbered (proximal, 
diaphyseal, distal) [264]. Based on the type of bone, what segment the fracture is 
located, and the fracture morphology determine the type of fracture.  In long bones the 
section is first identified (proximal, diaphyseal, or distal), followed by the severity and 
morphology (commonly referred to as simple, partial/wedge, and complete/complex in 
order of severity). This is a general explanation: fractures can be further subdivided and 
there are also exceptions.  Based on these criteria clinicians can make decisions for 
treatment options.  Treatment options can vary from casting to surgical intervention. 
Understanding the underlying mechanisms responsible for skeletal healing will allow for 
the discovery of new treatment options.   
 The process of skeletal repair is critical for reconstitution of bone integrity after 
trauma or surgical intervention. Skeletal repair at the cellular level requires two distinct 
processes called intramembranous and endochondral ossification [265]. During 
intramembranous ossification a foundation of MSCs becomes vascularized and 
differentiates into mature matrix secreting osteoblasts [266]. This type of development is 
seen in flat bones such as the scapula and craniofacial bones and has no cartilage 
foundation. During endochondral ossification a cartilaginous template is developed first 
followed by vascular invasion, MSC differentiation into mature matrix secreting 
osteoblasts, and remodeling by resorptive osteoclasts. Within the fracture site 
endochondral bone formation typically takes place closest to the fracture site due to low 
oxygen tension and vascular disruption, whereas intramembranous bone formation 
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occurs distal to the site where vasculature is still present. The primary source of 
osteoprogenitor cells during fracture repair comes from the periosteum. The periosteum 
contains two distinct layers: an outer fibrous layer containing fibroblasts that connect to 
underlying cortical bone and an inner cambium layer consisting of multiple MSCs and 
osteoprogenitor cells responsible for healing [267]. During fracture repair a unique 
series of events takes place to repair the defect. Immediately following trauma 
vascularization is disrupted and a hematoma begins to form. Progenitor cells within the 
periosteum are recruited to the fracture site. In areas of low oxygen tension MSCs begin 
to differentiate into chondrocytes, and in areas where oxygen tension and vasculariztion 
are normal, MSCs directly differentiate into osteoblasts and begin forming new bone 
[268]. Endochondral formation continues as chondrocytes begin to mature and 
mineralize, while simultaneously vascularization begins to ensue at the fracture site. 
With the emergence of a new vascular system, MSCs migrate to the area and begin to 
differentiate into osteoblasts and form a callus at the injured site [32]. The process 
proceeds as osteoblasts and osteoclasts remodel the newly formed woven bone into 
organized lamellar bone until anatomical restructuring is complete. The amount of time 
this process takes varies based on the severity of the fracture. There are also genetic 
and environmental factors that may influence this process. 
 The skeletal repair process involves multiple cell types and therefore involves 
multiple genetic determinants.  Growth factors and cytokines important for the regulation 
of osteoblast differentiation and function are important mediators for skeletal repair. 
These mediators include BMP-2, TGF-β, Wnt, FGF, and IGF family of proteins [269]. 
BMP-2 is one of the more notable factors involved in skeletal healing as expression is 
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high in early callus formation just slightly after the time of fracture [270]. Previous 
literature has also shown that elimination of BMP-2 in limb buds disrupts fracture 
healing, indicating the importance of BMP-2 in the repair process [271]. The presence of 
angiogenic factors for vascularization at the fracture site is also important for healing. 
Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) are upregulated 
during the repair process. Exogenous administration of VEGF in a mouse fracture 
model accelerates vascular growth into the callus and promotes bone formation in the 
area [272]. The accumulation of VEGF at the fracture site is thought to be in response 
to BMP-2, indicating a direct link between both osteogenic and angiogenic factors in the 
repair process.  
 Inflammatory cytokines important for bone turnover are important for skeletal 
healing. During the stage in which cartilage begins to mineralize, a turnover stage 
occurs that requires the upregulation of RANKL, M-CSF, OPG, and TNF-α [273]. The 
inflammatory cytokines IL-1 and IL-6 are also upregulated during the remodeling 
process and are believed to be important factors for osteoclast recruitment [274]. Cox-2, 
an enzyme responsible for catalyzing prostaglandins into arachidonic acid, has also 
shown to play a role in the repair process. Previous literature has shown that Cox2-/- 
mice have delayed bone repair compared to wildtype [275]. Histological analysis 
revealed delayed chondrogenesis from the fracture callus, indicating this molecule is an 
important mediator of chondrogenesis during fracture repair. Future studies should 
focus on determining other important factors involved in all phases of skeletal repair.  
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2.7 Current and Future Therapies 
 The prevention and treatment of osteoporosis requires several different 
approaches that include changes in lifestyle, diet, and pharmacological intervention. 
Exercise and maintaining appropriate muscle tone is often overlooked as a method of 
preventing the onset of osteoporosis. Several studies have shown that bone structure is 
enhanced by exercise and is compromised by immobility [276]. During the aging 
process, bone loss is inevitable and exercise through mechanical strain can counteract 
the effects of bone loss. Several studies have shown that most people, especially 
women, do not acquire the recommended levels of calcium and vitamin D in their diet 
[277, 278]. The recommended calcium and vitamin D intake from the U.S. National 
Academy of Sciences (NAS) varies based on age. The recommended intakes of 
calcium for ages 51+ are 1,200 mg/d, whereas vitamin D levels for this same age are 
approximately 10 µg/d [279]. The consumption of a proper diet in combination with a 
daily supplemental regiment can aid in acquiring the appropriate calcium and vitamin D 
levels. There have been several pharmacological compounds developed to help treat 
osteoporosis within the past few decades. These compounds can be categorized based 
on their target. These two categories include the anti-resorptive drugs (inhibit osteoclast 
function) and the anabolic agents (stimulate bone formation). 
 Anti-resorptive therapies are the most commonly used pharmacological 
compounds used to treat osteoporosis. Hormone therapy is the earliest recognized 
treatment for osteoporosis. Estrogen is important for maintaining normal bone 
homeostasis by acting on both osteoblasts and osteoclasts. Estrogen and its receptor 
are expressed in osteoblasts and play a role in enhancing the proliferation and 
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differentiation while inhibiting apoptosis in these cells [280, 281]. Previous literature has 
shown that estrogen treatment given at the onset of menopause completely prevents 
bone loss and fractures in women [282]. Estrogen treatment in women postmenopausal 
over a period of ten years revealed an increase in bone density of the spine and a 
reduction in spine and hip fracture by 33% [283, 284]. There are, however, several 
adverse events when using estrogen therapy. There have been several cases of 
endometrial carcinoma, thromboembolisms, stroke, and myocardial infarction [284]. 
These adverse events have led to the development of a new class of drugs for the 
treatment of osteoporosis known as selective estrogen receptor modulators (SERMs). 
These compounds have a mixture of antagonistic and agonistic functions properties 
based on tissue type [285]. The first SERM that was shown to have positive effects on 
bone mass was tamoxifen, used in the treatment of breast cancer [286]. Since then 
several other SERM therapies have been developed to help combat osteoporosis. 
Raloxifene has also shown to have effects with reducing bone resorption and has been 
shown to reduce the incidence of vertebral fractures [287]. This drug, however, has 
been linked to fatal strokes and thromboembelisms [288]. Currently there are a few 
other SERMs in clinical trials for the treatment of osteoporosis. Clinical data on 
basedoxifene and lasofoxifene are currently being obtained to determine their effects on 
bone mass [289]. These drugs have comparable effects to those seen in Raloxifene. 
Future studies need to focus on identifying other SERMS that stimulate bone mass to 
help treat osteoporosis. 
 The bisphosphonate compounds have been the most commonly used anti-
resorptive drug for the treatment of osteoporosis. Bisphosphonates consist of a central 
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carbon atom with two adjacent negatively-charged phosphate groups which allows for 
high affinity for positively-charged hydroxyapatite in the bone matrix [284]. 
Bisphosphonates accumulate on the bone surface and become ingested within 
osteoclasts. Once accumulated within the osteoclast, these drugs interfere with 
metabolic pathways important for osteoclast function. The primary target is the 
mevalonate pathway in which the farnesyl pyrophosphate synthase (FPPS) enzyme that 
regulates cholesterol and isoprenoid metabolism necessary for prenylation of GTPases 
such as Ras, Rab, and Rho important for the osteoclast cytoskeleton, is inhbited [290]. 
Impairment of the cytoskeleton effects osteoclast attachment to the bone resulting in 
increased apoptosis. Currently there are several Bisphosphonates prescribed for the 
treatment of osteoporosis that include alendronate (Fosamax®), risedronate (Actonel®), 
zoledronic acid (Reclast®), ibandronate (Boniva®), and etidronate (Didronel®) [291]. 
Bisphosphonates have shown to rapidly reduce bone resorption and balance the 
increase in osteoclast activity due to the onset of menopause. They have shown to 
significantly reduce the risk of vertebral fractures [292, 293] and non-vertebral fractures 
[294-296]. Bisphosphonates have also been shown to increase bone mineral density in 
the spine and hip compared to placebo [297]. There are, however, several adverse side 
effects related to bisphosphonate treatment. The two most common side effects 
reported are gastrointestinal inflammation [298]  and osteonecrosis of the jaw [299].  
 There are other anti-resorptive compounds that have potenitial use for the 
treatment of osteoporosis. Denosumab (Prolia®) is a RANKL antibody approved for the 
treatment of osteoporosis by subcutaneous injection. Previous literature has shown a 
90% reduction in osteoclast biomarkers and comparable results to those seen by 
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bisphosphonates. The adverse side effects include muscle pain, hypocalcemia, and 
increased risk of infection [300]. Inhibitors against the osteoclast degredative enzyme 
Cathepsin K have also shown some potential. Odanacatib® is a Cathepsin K inhibitor 
developed by Merck that is under clinical trials. In a two year study Odanacatib was 
shown to increase spine and hip bone mineral density [301, 302]; however, predicted 
side effects include stroke, atrial fibrillation, and atypical fractures. 
 Although the primary source of treatments are anti-resorptive and affect 
osteoclasts, there are few anabolic factors that affect osteoblasts. Currently teriparatide 
(Forteo®) [PTH(1-34)] is the only anabolic drug to treat osteoporosis. In a world-wide 
study of postmenopausal women, PTH injections showed a 13% and 6% increase in 
lumbar spine BMD (LS-BMD) and femoral neck BMD (FN-BMD) respectively [303]. The 
drug also revealed a 69% and 54% decrease in vertebral and non-vertebral fractures 
respectively. Another study showed that PTH is able to increase cortical thickness and 
cross-sectional bone area [304]. Although PTH has several benefits for increasing BMD, 
there are a few adverse effects. One of the more severe side effects reported in long-
term PTH use is osteosarcoma [305]. Since PTH affects both osteoblasts and 
osteoclasts, long-term use can actually stimulate osteoclasts and result in 
hypercalcemia; therefore, PTH treatment needs to be monitored to determine 
appropriate dosing and timing. Although PTH is the only FDA approved anabolic agent 
for the treatment of osteoporosis, there are other compounds currently in clinical trials. 
 Strontium ranelate has been thought to be a perfect candidate as it shows both 
antiresorptive and anabolic responses [306]. In clinical trial strontium ranelate taken 
daily decreased the risk of vertebral fractures in postmenopausal women by 40% [307]. 
 70 
 
Strontium renelate is currently available in Europe but not in the U.S. due to the adverse 
effects of heart attack and thrombosis noticed in patients. An exciting new therapy that 
is being developed is the use of anti-sclerostin antibodies for the treatment of 
osteoporosis. Currently the anti-sclerostin antibody romosozumab is under phase II 
clinical trials [308]. The drug is interesting as it has both anabolic and anti-resorptive 
functions in bone by stimulating the Wnt pathway. With the emergence of new anabolic 
agents coming into clinical trials, it will be interesting to see what new therapies will 
emerge. 
 Treatments provided for patients with osteopetrosis can vary greatly based on 
the symptoms and mutation of the specific gene. The most common and successful 
treatment option for osteopetrosis is hematopoietic stem cell transplants (HSTC). The 
use of HSTC for treating the osteopetrotic phenotype came from the use of animal 
models in which bone marrow or splenic cells were transplanted from a healthy donor 
into the osteopetrotic mouse [309]. The first successful human transplant using HLA-
identical marrow along with total body irradiation and cyclophosphamide therapy was 
reported a few years later [310]. Studies suggest that patients who receive HLA-
identical HSCT have an estimated 88% chance of having a five year disease-free state 
[311]. Although HSCT transplants have a high success rate, there are a few caveats 
with this treatment option. Certain types of osteopetrosis based on the mutation contain 
neurodegenerative symptoms that cannot be reversed with HSCT treatment. With the 
use of HSCT, there is also the possibility of rejection; therefore, new and alternative 
treatment options need to be developed for those specific conditions.  
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 Other alternative methods include the use of gene therapy, In utero HSCT, and 
treatments exploiting the RANKL pathway. Genetically modifying HSCs through the use 
of gene therapy could serve as a viable option as obtaining CD34+ cells is less invasive 
than transplantation. Previous literature has shown the efficacy of gene therapy through 
the use of animal models in which HSCs were programmed to overexpress TCIRG1 
through retroviral expression [312]. These osteopetrotic mice showed improvement in 
bone resorption; however, the use of oncogenic viral vectors raises serious concerns for 
secondary adverse effects. In utero HSCT provides a viable treatment option as 
patients who undergo transplantation earlier have much better outcomes. Animal 
models using In utero HSCT in TCIRG1 deficient mice showed complete rescue in 35% 
of the implanted mice [313]. The caveats for using In Utero treatments are the use of 
reliable genetic tests to determine if the disease will be present along with the 
probability that neurological symptoms related to osteopetrosis will still remain 
unalleviated. The use of RANKL systemically to help restore osteoclast activity is also 
being examined as an alternative treatment option. Previous literature has shown that 
RANKL administration in TNFSF11 (RANKL) deficient mice at the correct dose and time 
rescued the bone phenotype [314]. Interestingly, RANKL administration was able to 
improve function of other haematopoietic organs, such as the thymus and spleen. 
Determining RANKL dose and timing in humans will be a challenge as overuse of 
RANKL will lead to a variety of adverse events.   
 Current treatments of severe trauma rely on bone grafting procedures. 
Historically, harvesting iliac crest bone graft (ICBG) has been the gold standard for 
treating massive bone grafting procedures; however, ICBG harvest is limited by the 
 72 
 
amount of graft available as well as a relatively high complication rate.  The discovery of 
potential molecules to enhance bone formation following skeletal trauma is crucial. 
 Currently, the only FDA treatment approved therapy is recombinant BMP-2 
(rhBMP-2) marketed by Medtronic as INFUSE® [315]. INFUSE combines the rhBMP-2 
with an absorbable collagen sponge and is approved for interbody spinal fusions in 
clinical use with the potential for tibial fractures and craniofacial bone repair in future 
applications. Previous literature has shown a number of positive outcomes with the use 
of INFUSE® as a bone graft substitute [316-318]. Recently, however, there is evidence 
of adverse events caused by INFUSE®, including overgrowth of bone, inflammation, 
edema, neurological impairment, and carcinogenicity [319]. The clinical and cost 
effectiveness of INFUSE® has also been a subject of much debate [320]. Although PTH 
has been approved only for the treatment for osteoporosis, the idea of its use to 
accelerate skeletal healing has also been tested. Recent evidence has revealed a 
positive effect for bone regeneration in a fracture model [321]. PTH treatment has 
shown to stimulate both chondrogenesis and MSC proliferation through upregulation of 
Sox9 indicating that PTH may play a role in the early process of skeletal healing [322]. 
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Table 2.2 Summary of Pharmaceutical Compounds used to treat bone disease 
Name Brand Name Class Mechanism Progress 
Estrogen Premarin®,  
Estratab® 
Anti-
resorptive 
Stimulates 
apoptosis of 
osteoclasts 
Available on 
market 
Selective estrogen 
receptor modulators 
(SERM) 
Tamoxifen®, 
Raloxifene®, 
Basedoxifene®, 
Lasofoxifene® 
Anti-
resorptive 
Estrogen 
receptor 
agonist 
Some currently 
available 
others in 
clinical trials 
Bisphosphonates Fosamax®, 
Actonel®, 
Reclast®, 
Boniva®, 
Didronel® 
Anti-
resorptive 
Target 
mevalonate 
pathway;inhibit 
GTPases 
important for 
osteoclast 
cytoskeleton 
Available on 
the market 
Denosumab Prolia® Anti-
resorptive 
RANKL 
antibody 
Available on 
the market 
Odanacatib MK-0822 Anti-
resorptive 
Cathepsin K 
inhibitor 
Phase III 
clinical trials 
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Teriparatide (PTH 
1-34) 
Forteo® Anabolic Stimulate both 
osteoblast and 
osteoclast 
differentiation; 
sensitive based 
on dosage and 
timing 
Available on 
the market 
Strontium renelate Protelos Anabolic Enhances 
collagen 
production 
Approved in 
Europe; not 
approved in 
U.S. due to 
cardiac 
complications 
Romosozumab Marketed by 
Amgen 
Anabolic 
and Anti-
resorptive 
Sclerostin 
antibody 
Phase II clinical 
trials 
rhBMP-2 bone graft Infuse® Anabolic Recombinant 
BMP-2 
stimulates 
osteoblast 
differentiation 
Available on 
the market 
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2.8 Osteoactivin 
 As described previously, with the aging population growing, the search for new 
therapeutics is at its peak. Through the use of genetically manipulated animals to 
mimic disease state, new molecules important for bone development have been 
discovered. Osteoactivin (OA) was first discovered in a model of the op osteopetrotic 
rat [1]. Osteoactivin, also known as Glycoprotein Non-Metastatic Melanoma Protein 
B (GPNMB), is located on chromosome 7p15 and has high homology with other 
proteins, including Dendritic Cell Heparin Sulfate Proteoglycan Integrin Dependent 
Ligand  (DC-HIL;88% homology), Human Hematopoietic Growth Factor Inducible 
Neurokinin (HGFIN; 77%), and Pmel-17/gp100 melanocyte protein (60%) [3]. The 
Osteoactivin cDNA has an open reading frame of 1,716 base pairs and encodes a 
115 kDa type transmembrane protein (~572 amino acids) that is heavily glycosylated 
with several functional domains. Bioinformatic analysis of the Osteoactivin protein 
has identified a signal peptide (1-23), a polycystic kidney disease domain (PKD; 
263-319), a proline-rich repeat domain (PRRD; 320-345), a transmembrane domain 
(500-521) and a dileucine signal on the C-terminal domain (Figure 2.9) [3, 323]. The 
protein is heavily glycosylated with a predicted 11 N-linked and 19 O-linked 
glycosylation sites. In order to understand potential functional roles of Osteoactivin, it 
is important to know how these domains and glycosylation sites correlate with cell 
structure and function.  
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Figure 2.9: Diagram depicting the domains and glycosylation sites of full 
length, recombinant, and mutant Osteoactivin (OA). The full length Osteoactivin 
is 574 amino acids and has several different domains and glycosylation sites. The N-
terminal extracellular domain of Osteoactivin (1-502) contains a signal peptide (1-
22), and RGD domain, a polycystic kidney disease domain (PKD; 256-316), a 
proline rich repeat domain (PRRD; 320-345), and several O- and N- linked 
glycosylation sites. The transmembrane domain of Osteoactivin is 20 amino acids 
(503-523). The C-terminal intracellular domain (524-547) contains an hemITAM 
motif and Di-leucine signal [324]. The recombinant Osteoactivin represents the N-
terminal portion of the molecule (23-502). It is derived from a mouse myeloma cell 
line and contains all of the same extracellular domains and glycosylation sites as the 
full length protein. 
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 Osteoactivin and its homologs have been described in several different tissues. 
Following the discovery of Osteoactivin in bone, a previous report showed that 
certain bone-related genes are expressed in advanced malignancies and induce 
cancer metastasis and invasion [325]. This group revealed that bone related genes 
Osteonectin and Osteoactivin are highly expressed in a glioma human cancer 
model, and induce metastasis through increased MMP production, specifically MMP-
3 and MMP-9. This indicates that Osteoactivin plays a role in cancer metastasis. 
Furthermore, another previous report has shown that Osteoactivin is highly 
expressed in breast cancer cells that metastasize to bone [326]. This group 
developed a model in which breast cancer cells overexpressing Osteoactivin 
enhanced the formation of osteolytic bone metastasis in vivo. The mechanism 
involved in Osteoactivin induced breast cancer tumor growth and metastasis is 
believed to involve an interaction with neuropilin-1 and α5β1 [327]. Since the 
discovery of Osteoactivin and its role in breast cancer metastasis, several other 
groups have published the role of Osteoactivin in other cancer tissues, including 
prostate [328], pancreas [329], liver [330, 331], lung [332], melanoma [333-335], 
brain [336], and colon [337]. This indicates that Osteoactivin may serve as a 
potential target for treating several different types of cancers. Currently, there is an 
Osteoactivin antibody-drug conjugate (Glembatumumab Vedotin) in phase II clinical 
trials for the treatment of advanced and local breast cancer and melanoma [338-
340]. Although Osteoactivin has been shown to act as a potential oncogene, 
Osteoactivin has also shown to play a vital role in a variety of processes important 
for cellular function.  
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 Osteoactivin has shown to have a role as an anti-inflammatory agent in several 
different tissue types. Previous reports have shown that expression of Osteoactivin 
is high in response to injury seen in the liver [341, 342], muscle [343, 344], kidney 
[345, 346], and brain [347-349]. In response to injury within the liver, Osteoactivin 
expression was immediately high and was correlated with accumulation of 
inflammatory cells [341]. Interestingly, treatment with lipopolysaccharide (LPS), a 
known toxin, decreased Osteoactivin expression. This indicates the importance of 
Osteoactivin as an anti-inflammatory molecule. Furthermore, transgenic 
overexpression of Osteoactivin has been shown to attenuate liver fibrosis in a rat 
model [342]. In muscle, Osteoactivin expression was shown to be high in cases of 
denervated skeletal muscle [343]. In this study Osteoactivin was shown to increase 
the infiltration of fibroblasts into the area and increase matrix remodeling genes 
MMP-3, MMP-9, and type I collagen. This indicates that Osteoactivin may play a role 
in the regulation of matrix remodeling.   
 Osteoactivin has also been shown to act as a neuroprotective factor in 
neurodegenerative disease such as Amyotrophic Lateral Sclerosis (ALS) [348]. In 
this study Osteoactivin extracellular fragments were shown to rescue motor neurons 
by attenuating cell toxicity by superoxide dismutase-1. Another group showed that 
Osteoactivin acts as a neuroprotective factor in cases of cerebral ischemia 
reperfusion injury through an AKT and ERK mechanism [349]. The role of 
Osteoactivin in tissue repair may best be explained through the correlation of 
Osteoactivin expression and the accumulation of immune regulatory macrophages. 
A previous study revealed that Osteoactivin overexpression in the 
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monocyte/macrophage RAW264.7 cell line resulted in the reduction of inflammatory 
cytokines IL-6 IL-12p40 and NO production [350]. Furthermore, Osteoactivin was 
shown to play a role as a phagocytic protein important for phagocytosis of cellular 
debris in a renal injury model [351]. These data indicate that Osteoactivin has a 
large role in response to tissue injury. Based on these findings Osteoactivin may 
have a dual role as an anti-inflammatory molecule and as an oncogene.  
 Osteoactivin has been shown to be highly expressed in bone tissue. Initial 
studies of Osteoactivin and bone were discovered in osteoblasts [1, 352], and 
expression was shown to increase over the course of differentiation.  The 
importance of Osteoactivin during osteoblast differentiation was first shown through 
the use of Osteoactivin antibodies.  Osteoactivin antibodies added in culture resulted 
in an inhibition in osteoblast differentiation in vitro by ALP staining and activity and 
mineralization [2]. Furthermore, Osteoactivin overexpression in vitro in both MC3T3-
E1 and C2C12 cell lines resulted in enhanced osteoblast differentiation [3, 4]. These 
reports indicate that Osteoactivin plays an important role in osteoblast differentiation. 
As previously mentioned, Osteoactivin has shown to increase during osteoblast 
differentiation. Previous reports from our lab have shown that BMP-2 regulates 
Osteoactivin by increasing its expression through homeodomain transcription factors 
DLX-3, DLX-5, and MSX-2 during osteoblast differentiation [353, 354]. Further 
evidence of the importance of Osteoactivin comes from the use of animal models in 
vivo. Overexpression of Osteoactivin under the CMV promoter (OA-Tg) in mice 
resulted in increased bone mass in vivo and ex vivo osteoblast differentiation [5]. A 
previous study generated an Osteoactivin mutant model that contains a missense 
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mutation in the Osteoactivin gene resulting in a truncated 150 amino acid protein. 
These mice (D2J) were shown to have early onset pigmentary glaucoma and 
hearing loss [355, 356]. Our lab was the first to characterize the bone phenotype in 
the D2J mice. D2J mice have an intrinsic impairment of osteoblast differentiation 
both in vitro and in vivo [6]. D2J have reduced bone mass by microCT and histology 
in vivo and dysfunctional osteoblastogenesis ex vivo. Furthermore, D2J osteoblasts 
were shown to have higher levels of TGF-β receptor which may explain the inhibition 
of osteoblast differentiation. Osteoactivin has shown to play an important role in 
osteoblasts; however, Osteoactivin also plays an important role in osteoclasts. 
 The role of Osteoactivin and osteoclasts was first determined in vitro through the 
use of anti-Osteoactivin antibodies. This group revealed that Osteoactivin increases 
during osteoclastogenesis, and that addition of anti-Osteoactivin antibodies inhibits 
osteoclast differentiation through its interaction with β1 and β3 integrin [8]. 
Furthermore, this group showed that overexpression of Osteoactivin in tissue 
specific mice using the TRAPC promoter resulted in less bone mass in vivo due to 
enhanced osteoclast differentiation and resorption [9]. Interestingly, another group 
recently published that the Osteoactivin mediated increased resorption is initiated 
through binding of αvβ3 integrin [10]. Our group has also examined the effects of 
Osteoactivin using D2J mice. Interestingly we found D2J have less trabecular bone 
in vivo but thicker cortical bone and narrow medullary areas [7]. This indicates that 
there is impairment in both osteoblasts and osteoclasts due to lack of functional 
Osteoactivin. Osteoactivin plays different roles in osteoclast differentiation and 
function. D2J osteoclasts ex vivo differentiate more and are larger in size indicating 
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that Osteoactivin negatively regulates osteoclast differentiation and size. Osteoclast 
resorption is severely impaired in the D2J mice indicating that Osteoactivin plays a 
role in stimulating osteoclast resorption. Although controversy in the role of 
Osteoactivin in osteoclast differentiation remains, it seems that numerous sources 
confirm that Osteoactivin positively regulates osteoclast resorption. Further evidence 
into the mechanisms that regulate Osteoactivin mediated osteoclast differentiation 
need to be explored. 
 As previously described, Osteoactivin has shown to play a role in bone formation. 
Angiogenesis has been shown to be a critical factor in bone formation and fracture 
healing [357, 358]. Early evidence indicating the role of Osteoactivin in the 
endothelium arose from a study showing that dendritic cells expressing Osteoactivin 
bind to heparin sulfate proteoglycans on the surface of endothelial cells in an RGD 
dependent fashion [359]. Addition of recombinant Osteoactivin was shown to 
stimulate angiogenesis in vitro using human umbilical vein endothelial cells [360]. 
These studies reveal that Osteoactivin may play a role in angiogenesis. There exists 
a link between angiogenic factors and tumor growth. Osteoactivin extracellular 
domain has been shown to be shed from the membrane of breast cancer cells by 
ADAM10, a metalloproteinase involved in the shedding of several different 
molecules from the cell membrane, and stimulate the migration of endothelial cells 
[17]. Furthermore, this group also showed that Osteoactivin cooperates with 
neuropilin-1 and α5β1 to potentiate VEGF signaling [327]. This indicates that 
Osteoactivin may play a role in regulating critical angiogenic factors such as VEGF. 
As previously described Osteoactivin has shown to play a role in tissue repair. 
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Osteoactivin has been shown to be highly expressed in a hyperoxia model and 
addition of recombinant Osteoactivin promoted endothelial tube formation in vitro 
and in vivo [361]. Osteoactivin has been shown to play a role in both angiogenesis 
and injury repair. It will be interesting to determine the role of Osteoactivin in the 
molecular mechanisms and cross-talk that exist between angiogenesis and tissue 
repair. 
 Several different cell types and growth factors are involved in the repair of a bone 
fracture. Osteoactivin has shown to play an important role in osteoblasts, 
osteoclasts, and angiogenesis. Osteoblasts, osteoclasts, and endothelial cells are all 
involved in the process of fracture repair; therefore, it would make sense that 
Osteoactivin would play a role in this process. Our group has shown that 
Osteoactivin is highly expressed in post fracture calluses in a fracture model [362]. 
In this study, Osteoactivin was expressed in osteoblasts, osteoclasts, and 
osteocytes at the bony callus indicating that Osteoactivin may play a role in all three 
cell types during repair. Furthermore, Osteoactivin was shown to stimulate bone 
regeneration in a critical size defect in the rat [363] and mouse [360] model.  
 Large fractures such as non-unions are difficult to treat and mostly require 
invasive surgeries. Several treatment options combining the use of scaffolds, stem 
cells, and growth factors are being developed to treat large bony defects [364]. 
Osteoactivin was shown to have comparable effects on MSC differentiation on cells 
grown on hydrogels asBMP-2 [365]. This study also showed that bolus rather than 
continuous administration produces a more profound result. Furthermore, MSCs 
taken from human placenta and fetal membrane show an enhancement in 
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osteogenic differentiation when stimulated with recombinant Osteoactivin [366]. This 
data indicates that Osteoactivin may be used as a potential treatment for the 
acceleration of fracture healing and can be combined with other biomaterials, cells, 
and growth factors as a delivery method. 
 Although there is an abundant amount of literature describing the role of 
Osteoactivin in bone remodeling, little is known about the Osteoactivin induced 
signaling mechanism behind osteoblast and osteoclast differentiation and function. 
Our group has shown that Osteoactivin interacts with αvβ1 and heparin sulfate 
proteoglycans (HSPG) to activate osteoblast adhesion [367]. Furthermore, another 
group has described that Osteoactivin interacts with FGF1R to stimulate 
downstream signaling [360]. In osteoclasts, only the signaling pathway involved in 
osteoclast resorption has been described. Previous literature has shown that 
Osteoactivin binds to αvβ3 and that addition of chondroitin sulfate-3 halts osteoclast 
resorption [10]. A novel receptor involved in both osteoblast and osteoclast 
differentiation has not yet been described. Downstream signaling molecules and 
regulatory genes involved in Osteoactivin mediated osteoblast and osteoclast 
differentiation have also not been described. 
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Table 2.3 Osteoactivin/GPNMB Animal Models 
Protein/Gene Animal Model  Phenotype Reference 
Osteoactivin-Tg Transgenic-
CMV Promoter 
Increased trabecular 
bone volume due to 
enhanced osteoblast 
proliferation and 
differentiation. 
Protects skeletal 
muscle in cases of 
denervation 
8,315 
Osteoactivin-TgTRAPC Transgenic-
TRAPC 
Promoter 
Decreased bone 
volume due to an 
enhancement in 
osteoclast 
differentiation and 
resorption 
12 
D2J Mutant Decreased trabecular 
bone volume at 8 and 
16 weeks and 
increased cortical 
thickness; impaired 
osteoblast 
differentiation and 
osteoclast resorption 
but enhanced 
osteoclast 
differentiation 
9,10 
Osteoactivin-KO Knockout Increased bone mass 
at 4 and 12 weeks; 
impaired osteoblast 
differentiation and 
osteoclast function 
Unpublished Data 
SOD1G93/GPNMB Transgenic Neuroprotective 
effect in 
neurodegenerative 
disease amytrophic 
lateral sclerosis (ALS) 
319 
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2.9 CD44 
 Clustering domain-44 (CD44) is a type I transmembrane glycoprotein that 
participates in several cellular processes, including adhesion, survival, proliferation, 
differentiation, and migration [368]. It was first discovered in white blood cells and 
ranges in size from 80-200 kDa based on alternative splicing on its N-terminal 
extracellular domain. The standard CD44 isoform (CD44s) is the smallest and most 
basic isoform consisting of a heavily glycosylated amino terminal domain, a short stem 
structure, a transmembrane domain, and a short C-terminal domain with multiple motifs 
[368]. The amino terminal domain is a stretch of roughly 90 amino acids that is heavily 
glycosylated with several disulphide linkages forming a globular like structure. This 
portion of CD44 serves as the primary docking site for several extracellular matrix 
proteins, including hyaluronan, collagens, laminins, and fibronectins [369]. There have 
been other ligands that interact with CD44 including Osteopontin [370], Serglycin [371], 
and galectins [372]. The stem structure is a short 46 amino acid structure located 
adjacent to the plasma membrane. The stem size can vary based on the variant isoform 
(v1-10) and contains a few glycosylation sites important for heparin sulfate interactions 
[373]. The transmembrane domain of CD44 consists of 23 hydrophobic amino acids and 
is believed to be important for its incorporation into lipid raft complexes [374, 375]. The 
C-terminal domain is a short amino acid sequence; however, it contains multiple motifs 
that allow interaction with the actin cytoskeleton. Several actin cross-linking proteins 
from the Ezrin, Radixin, and Moesin (ERM) family and ankyrin have been shown to 
interact with the cytoplasmic tail of CD44 and link it with the cytoskeleton [376-378]. 
These interactions have been implicated to be involved in cell migration and adhesion. 
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The CD44 cytoplasmic tail also contains phosphorylation sites at Ser291 and Ser325 
regulated by PKC, which influence its interactions with ERM proteins [379].  
 CD44 plays a role in several signal transduction pathways. Several pathological 
conditions, primarily cancer, have been associated with changes in CD44 and its 
signaling. There are three proposed mechanisms in which CD44 can stimulate signal 
transduction pathways. These mechanisms include acting as a ligand binding receptor 
by interacting with ECM proteins by serving as a docking platform, acting as a co-
receptor to modulate the activation of other receptors, and lastly as an organizer of the 
cytoskeleton [368]. 
 The stimulation of signal transduction pathways is a complex process. Upon 
stimulation, the receptors can be found to associate with and may require several other 
molecules or co-receptors in order to function. Co-receptor signaling involves binding of 
soluble ligands and regulation of ligand binding through corresponding receptors [380]. 
The function of CD44 as a co-receptor may provide the best evidence of how CD44 
influences cellular signaling as CD44 does not have any intrinsic catalytic domains. The 
direct signal transfer, however, cannot be ruled out as CD44 has been shown to interact 
with several intracellular signaling proteins, such as Ras, Rho, Src, Fyn, and PKC, at its 
cytoplasmic tail [381-383]. CD44 has shown to interact with ERBB family members and 
mediate downstream signaling which is important for cell proliferation, survival, and  
differentiation [384]. Interestingly, CD44 has been shown to interact with several signal 
transduction pathways important for bone cell differentiation and function. 
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 The first evidence of CD44 expression in bone was shown in osteocytes and was 
proposed as a marker for osteocyte formation [385]. Several other publications have 
shown that the CD44s protein is expressed in osteoblasts [386-388], mesenchymal 
stem cells [389], and osteoclasts [390]. Studies from CD44 deficient mice have shown 
an impairment in osteoblast differentiation ex vivo but no difference in osteoclast 
differentiation both in vivo or in vitro [391-393]. This data indicates that CD44 may be an 
important regulator of osteoblastogenesis. The level of CD44 in osteoblasts has shown 
to increase during differentiation [394]. This indicates that CD44 may play a role during 
osteoblast differentiation. 
 CD44 has shown to play a large role as a co-receptor in several signal 
transduction pathways important for osteoblast differentiation. CD44 has been shown to 
be involved in BMP signaling. Galectin-9 has been shown to induce osteoblast 
differentiation through the CD44/Smad pathway [395]. This group has shown that CD44 
and BMPR clustering is necessary for Galectin-9 induced osteoblast differentiation 
through the Smad 1,5,8 pathway. Another group has stated that hyaluronic acid 
enhancement of osteoblast differentiation through CD44 downregulates BMP 
antagonists Noggin and Follistatin [396]. CD44 has also shown to be involved in the 
mechanisms connecting both osteoblasts and osteoclasts. Stimulation of CD44 by 
hyaluronan, the major ligand of CD44, enhanced the expression of Intracellular 
Adhesion Molecule-1 (ICAM-1) and Vascular Cell Adhesion Molecule-1 (VCAM-1) and 
that anti-CD44 antibody addition augmented its expression [397]. Furthermore, 
stimulation of CD44 in osteoblasts resulted in the adhesion of osteoblasts to monocytic 
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precursors indicating that CD44 may play a role in the intracellular signaling pathway 
that interlinks osteoblasts and osteoclasts. 
 CD44 has shown to play a large role in osteoclasts and osteoclast signaling. 
Several studies involving CD44 and osteoclasts have shown that CD44 interacts with 
αvβ3 and Osteopontin [398, 399]. Osteopontin has shown to stimulate osteoclast 
migration through CD44 and αvβ3 [400]. Furthermore, Osteopontin deficient mice are 
hypomotile and have decreased levels of CD44 indicating the importance of these two 
molecules in osteoclast migration [401]. There have been discrepancies involving the 
activation of CD44 and its role in osteoclast differentiation and function [402-404]. 
Previous literature has shown that CD44 stimulation by hyaluronan inhibits the migration 
of osteoclasts by down regulating MMPs [405]. This data indicates that CD44 activation 
may act as a “stop” signal for osteoclast resorption. Furthermore, it has been shown that 
CD44 ligands hyaluronan, chondroitin sulfate, and Osteopontin prevent 
macrophage/monocyte multinucleation [406]. This data indicates that CD44 activation 
may prevent fusion of multinucleated cells of the macrophage lineage. Overall the 
discrepancies in the activation of CD44 in osteoclasts can best be explained by ligand 
specific interactions.  
 Since CD44 has been shown to be involved in several different cell types in the 
bone microenvironment, activation of this receptor may play a role in several different 
bone pathologies. CD44 expression along with Osteopontin was shown to be highly 
expressed in osteoprogenitor cells, osteoclasts, and osteocytes in fracture calluses 
[407]. This indicates that CD44 may play a potential role in fracture healing. Migration of 
MSCs into the fracture site is critical in order for proper formation of new bone. As 
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discussed previously, Osteopontin and CD44 interact to stimulate the migration of a 
variety of cell types [398, 408, 409]. Osteopontin deficient mice have impaired fracture 
healing thought to be the result of reduced CD44 expression or the interaction with 
CD44 and other co-receptor interactions [410]. This data indicates that Osteopontin and 
CD44 interaction may be necessary for proper callus formation. During fracture repair or 
bone remodeling, osteocytes secrete chemotactic factors to stimulate the recruitment of 
stem cells. In a previous report, osteocytes under stress of hypoxia were shown to 
stimulate MSCs through an Osteopontin/CD44 mediated pathway [411]. Currently, 
therapies are being developed to target progenitor cells into areas of injury. A previous 
report has shown that the HA/CD44 interaction along with SDF-1 is important for the 
migration and homing of progenitor cells to the bone marrow [412]. Furthermore, ex vivo 
engineering of CD44 in human MSCs can target the cells to bone tissue [413]. It will be 
interesting to determine if targeting CD44 in MSCs and delivering them in large fracture 
defects will accelerate the healing. Future studies need to focus on the role of CD44 
with other ligands in bone repair. 
2.10 Lipid Raft  
 The proposed model of the phospholipid bilayer of the cell membrane is that all 
proteins are uniformly dispersed among a “sea” of lipids. This model predicts the 
plasma membrane as an unordered state; however, recent evidence suggests there 
exists regions within the membrane that are ordered that contain a specific and unique 
arrangement. Certain microdomains of the plasma membrane are enriched with 
sphingolipids and cholesterol allowing for less fluidity and a more ordered state. These 
microdomain structures are now termed lipid rafts, and their purpose is to organize the 
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plasma membrane into discrete microdomains for a variety of cellular functions [414]. 
Lipid rafts can serve a variety of functions, including vesicular trafficking endocytosis, 
regulation of cholesterol and calcium homeostasis, and stimulating signal transduction 
pathways. Caveolin-1 was the first protein to be discovered within the lipid raft, and 
integration with these proteins results in the formation of caveolae [415]. One of the key 
characteristics of lipid rafts is that it contains several proteins important for intracellular 
signaling. The proteins found within the lipid raft must have a particular affinity to exist 
within them. Examples of these proteins include GPI-anchored proteins, cholesterol-
linked proteins, double acylated proteins (Src family kinases), and palmitoylated 
transmembrane proteins [416, 417]. Many of these proteins act as receptors in several 
signal transduction pathways related to bone. Recently there has been a new 
understanding in the role of the lipid raft in bone.  
 Caveolin proteins are a major component in the formation of lipid raft 
microdomains. There are three distinct caveolin proteins (Caveolin-1, Caveolin-2, 
Caveolin-3) that have been identified within the lipid raft [418]. The role of these proteins 
in bone is just recently being understood. Previous literature has shown that murine and 
human osteoblasts express high levels of caveolin proteins, predominantly Caveolin-1 
and Caveolin-2 [419, 420]. The caveolin rich lipid rafts were also shown to have several 
important signal transduction molecules, including PDGF receptor, Src family of 
nonreceptor tyrosine kinase, Fyn,Ras, and other heterotrimeric G proteins [421]. This 
indicates that lipid rafts may be important for signal transduction pathways related to 
osteoblast differentiation and function.  
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 Different groups have shown controversial results when determining the role of 
Caveolin-1 in osteoblasts. Caveolin-1 deficient mice were shown to have increased 
bone size and stiffness compared to controls [86]. These mice had significantly higher 
bone mass by microCT at 5 and 8 weeks of age and had impaired osteoblastogenesis 
with no effect on osteoclasts ex vivo. This indicates that Caveolin-1 may play a role in 
negatively regulating osteoblast differentiation. Another group has shown that Caveolin-
1 is highly expressed in extracellular matrix vesicles, and that Caveolin-1 expression 
increases over the course of osteoblast differentiation [422]. Furthermore, 
overexpression of Caveolin-1 in MC3T3-E1 cells resulted in enhanced mineralization 
while siRNA treatment inhibited mineralization in a Src dependent manner. This data 
indicates that Caveolin-1 plays a large role in late stage osteoblast differentiation. 
Previous reports have shown that calcium signaling is important for osteoblasts and that 
there are receptors along the plasma membrane responsible for determining calcium 
levels in the extracellular environment [423, 424]. Calcium sensing-receptors (CSR) 
have been shown to be regulated by and complex with Caveolin-1 in human 
osteosarcoma cells [425]. This indicates that caveolins may play a role in regulating 
osteoblasts through their interaction with calcium receptors.  
 Caveolin proteins have also shown to play a role in osteoclasts. Previous 
literature has shown that both Caveolin-1 and Caveolin-2 are highly expressed upon 
RANKL stimulation in osteoclasts and that disruption of lipid raft integrity led to reduced 
osteoclast formation [426]. This notion is supported by the idea that disruption of the 
lipid raft inhibits the RANK signaling axis and that bone resorption and actin ring 
formation are highly dependent on lipid raft membrane activity [427]. Furthermore, 
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osteoclast formation and survival are highly reliant on a source of exogenous 
cholesterol, as depletion of cholesterol in the lipid raft membrane by the drug methyl-β-
cyclodextrin (MβCD) results in increased osteoclast apoptosis [428]. These data 
indicate that the lipid raft and its integrity play numerous roles in osteoclasts that include 
differentiation, resorption, and survival.  
 The lipid raft has been shown to play a large role in signal transduction 
pathways. Several of these pathways have been shown to be related to bone cell 
differentiation and function. The activation of receptors can result in the recruitment of 
these activated receptors along with other signaling molecules within the lipid raft; for 
example, a previous report has shown that activation of FGFR2 results in the 
recruitment of FGFR2 and Cbl into lipid rafts [429]. Upon FGFR2 activation, Cbl binds to 
PI3K and attenuates its response, resulting in decreased osteoblast survival. This 
indicates that the lipid raft may play a role in the regulation of osteoblast survival. BMP 
signaling has also been shown to play a role in lipid raft signaling in osteoblasts. 
Treatment of MC3T3-E1 cells with recombinant BMP-2 resulted in cell migration, which 
was abolished upon MβCD treatment and restored upon exogenous cholesterol addition 
[430]. Furthermore, BMP-2 addition increased the incorporation of β1 integrin into lipid 
rafts, indicating that the lipid raft may be important for cell adhesion and migration. Lipid 
raft signaling has also shown to be important for osteoblast proliferation [431]. In this 
study, the addition of Galectin-9, a β-galactoside-binding lectin, led to an increase in 
osteoblast proliferation in a Src/ERK dependent mechanism. Furthermore, addition of 
Galectin-9 induced clustering of lipid rafts and disruption of lipid rafts by MβCD 
treatment led to an inhibition of Galectin-9 mediated osteoblast proliferation. These 
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results indicate that certain growth factors can stimulate a variety of cellular functions, 
including proliferation, migration, adhesion, and viability through lipid raft signaling.  
 The role of the lipid raft and the family of caveolin proteins in bone cells has only 
recently been discovered. Although caveolin proteins and lipid rafts have been studied 
for some time now, their role in musculoskeletal physiology and disease state is now 
only recently starting to be understood. Most of the literature that has been described on 
the role of caveolins in disease states has come from muscle. Caveolin-3, the 
predominant caveolin in muscle, has been linked to several diseases [418]. Mutations 
within Caveolin-3 have been linked with the muscle diseases autosomal dominant Limb 
Girdle Muscular Dystrophy (LGMD), rippling muscle disease, hyper-CKemia, and distal 
myopathy [432-434]. Interestingly, caveolins, in particular Caveolin-1, are highly 
expressed during musculoskeletal repair. In muscle, overexpression of Caveolin-1 in 
satellite cells -the cells that are activated in response to injury- fail to differentiate into 
multinucleated myotubes [435]. In bone, Caveolin-1 expression was found to be 
upregulated in peripheral blood mononuclear cells (PBMNs) during fracture repair [436]. 
These results show that Caveolin-1 may have a potential role as a therapeutic for 
musculoskeletal repair. 
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Chapter 3 
Materials and Methods 
3.1 Cell Culture and Reagents 
 The MC3T3-E1 osteoblast like cell line was purchased from ATCC (Manassas, 
VA). Recombinant Osteoactivin was purchased from R&D Technologies (Minneapolis, 
MN). The osteogenic differentiation factors β-Glycerophosphate, L-Ascorbic Acid, and 
Dexamethasone were purchased from Sigma (St. Louis, MO). The Osteoactivin 
antibodies used were purchased from Bioss (Woburn, MA) and R&D Technologies. The 
CD44 antibody was purchased from Calbiochem (San Diego, CA). The antibodies 
pERK, ERK, pP38, P38, GAPDH were purchased from Cell Signaling (Danvers, MA). 
The β-Actin, Ki-67, and Tubulin antibodies were purchased from Bioss. Caveolin-1 
antibody was from Assay Biotechnology (Sunnyvale, CA). Secondary fluorescent 
antibodies Alex flour-488 and Alexa flour-594 were purchased from Cell Signaling. The 
ERK inhibitor U0126 was purchased from Cell Signaling. Lipid raft inhibitors nystatin 
and Methyl-β-cyclodextrin (MβCD) were purchased from Calbiochem and Sigma 
respectively. Alexa flour-488-labeled cholera toxin B, deoxycholic acid, and Percoll® 
were purchased from Sigma. The trichloroacetic acid and tricene were purchased from 
Fisher Scientific (Waltham, MA). DAPI used for immunofluorescence was purchased 
from Abcam (Cambridge, UK). The rhodamine phalloidin was purchased from 
Cytoskeleton, Inc. (Denver, CO). Tween-20 was purchased from Fisher Scientific.
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RANKL, M-CSF, and Hyaluronan (High Molecular Weight) were purchased from R&D 
Technologies. The antibodies pPLCᵧ2, PLCᵧ2, pIКβ, IКβ, pJNK, JNK, pERK, ERK, pP38, 
P38, pAKT, AKT, NFAT, LC3,and GAPDH were purchased from Cell Signaling 
(Danvers, MA). The p-nitrophenyl phosphate (p-NPP), Fast Red Violet Salt, and WGA 
Lectin HRP (from Triticum vulgaris) were all purchased from Sigma (St. Louis, MO).  
3.2 Mice 
 C57Blk6 (WT) and CD44-/- (CD44KO-global) were purchased from Jackson 
Laboratory. Both 8 and 16 week males were used. All mouse colonies were housed and 
maintained at Northeast Ohio Medical University according to the guidelines set by the 
Institutional Animal Care and Use Committee (IACUC). 
3.3 MicroCT 
 Femurs from 8 and 16-week-old male WT and CD44KO mice (n=6) were 
analyzed using a SkyScan 1172 high-resolution microtomography system (Bruker, 
Billerica, MA). Trabecular measurements of femurs were analyzed as previously 
described [6, 437]. Briefly, trabecular measurements were taken 400 µm below the 
distal growth plate in 750 consecutive slices of 7.6-µm resolution over a distance of 
5,700 µm. The volumetric regions were rendered as 3D arrays using SkyScan NRecon 
software. Percentage of bone volume per tissue volume (BV/TV; %), bone area (B.Ar; 
mm2), bone perimeter (B.Pm; mm) trabecular number (Tb.N; no./mm), trabecular 
separation (Tb.Sp.; mm), and trabecular thickness (Tb.Th; mm) were measured and 
calculated using SkyScan CT software. Three-dimensional reconstructed images of the 
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saggital and axial planes of the femoral metaphysis were generated using SkyScan 
CTvox software version 2.4. 
3.4 ELISA 
 Serum samples were obtained from 8- and 16-week-old male WT and CD44KO 
mice (n ≥ 5). Serum P1NP (MyBiosource, San Diego, CA), Osteoclacin (Biomedical 
Technologies, Stoughton, MA), CTX-1 (MyBiosource), RANKL, and OPG (R&D 
Technologies) were measured by enzyme-linked immunosorbent assay (ELISA) 
according to the manufacturer’s guidelines. The Osteoactivin ELISA (R&D) was also 
used to determine the concentration of the protein in osteoclast cell cultures.   
3.5 Tissue Preparation and Bone Histomorphometry 
 Femurs from 8-week-old male WT and CD44KO (n≥4) were dissected, fixed in 
4% paraformaldehyde, dehydrated, and embedded undecalcified in plastic 
methylmethacrylate resin as previously described [6]. Saggital sections (5 µm thick) 
were stained with Von Kossa-toluidine blue [438]. Quantitative histomorphometry was 
performed in an area from 100-600 µm proximal to the growth plate using 
OsteoMeasure software version 3.2.1 (Osteometrics, Decatur, GA) as previously 
described [439]. Images were acquired with a brightfield microscope (Olympus, Center 
Valley, PA). Three-dimensional and two-dimensional parameters were measured and 
calculated in three sections per animal. The 3D parameters were trabecular number 
(no./mm) [Tb.N=(4π) x 0.5 x (B.Pm/T.Ar)] and trabecular separation (µm) [Tb.Sp= 
(1/Tb.N) x (1,000-Tb.Th)]. The 2D parameters were bone perimeter per tissue area 
(B.Pm/T.Ar; mm/mm2), trabecular number per tissue area (Tb.N/T.Ar; no./mm2), 
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osteoblast number per bone perimeter (N.Ob/B.Pm no./mm), and percent osteoblast 
surface per bone surface (Ob.S/B.S.;%).  
 For dynamic histomorphometry, 7-week-old male WT and CD44KO mice (n=4 
per group) were injected intraperitoneally with 10 mg/kg calcein AM (ThermoFisher 
Scientific) 7 and 2 days before termination. Femurs were collected and 
histomorphometric analysis of undecalcified sections of the distal femur using a Nikon 
Eclipse Ti epifluorescent microscope (Nikon, Melville, NY; Tokyo, Japan) was 
performed. Single-labeled surface, double-labeled surface, mineralizing surface 
[MS=dLS + (sLS/2)], mineral apposition rate (MAR) and bone formation rate (BFR; MAR 
X MS) were measured and calculated.  
3.6 Osteoclast Culture 
 Mouse bone marrow-derived stem cells were isolated from 8 week male WT and 
CD44KO mice as previously describe [7]. To generate osteoclasts, bone marrow cells 
were plated at a cell density of 1.2X105 cells in a 96 well plate and primed with M-CSF 
(20ng/mL) for the first 3 days. M-CSF dependant bone marrow macrophages (BMM) or  
osteoclast precursors (OCP) were then given RANKL (40ng/mL) and M-CSF (20ng/mL) 
and a second dose of RANKL and M-CSF was given again 48 hours later. In parallel 
cultures, OCP were treated with recombinant Osteoactivin along with RANKL and M-
CSF. At day 7 cells were fixed, and TRAP activity and staining was assessed. TRAP 
positive osteoclast (n>3 nuclei) images were taken using a Nikon Ti Eclipse inverted 
microscope. TRAP positive osteoclast differential count and size were calculated using 
the NIS-Elements software. 
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3.7 TRAP Staining and Activity 
 Mature osteoclasts plated in 96 well plates were fixed with 10% formalin, washed 
with dH20, and allowed to air dry. For TRAP activity assays Methanol:Acetone was 
added to cultures followed by incubation with TRAP buffer (52 mM of Na-tartrate in 0.1 
M Na-acetate buffer pH 5.2) containing 0.1 mg/mL of p-nitrophenyl phosphate (p-NPP). 
The reaction was stopped by adding 1 N NaOH and read at an potical density of 405 
nm using a BioTek Synergy microplate reader. For TRAP staining, mature osteoclasts 
were incubated with TRAP buffer containing 1.5 mM naphthol AX-MX phosphate and 
0.5 mM Fast Red Violet LB Salt. 
3.8 In vitro Osteoclast Resorption Assays 
 BMM isolated from WT and CD44KO were plated on Corning ® OsteoAssay 
surfaces (Corning) for 4 days with M-CSF (20ng/mL) and RANKL (50ng/mL). In parallel 
cultures, rOA (100ng/mL) was added to cultures 48 hours before termination. On the 
fourth day, osteoclast cultures were terminated using 10% bleach. Resorption from 
osteoclasts was analyzed by quantitation of the resorbed area of the well over the total 
area using the NIS-Elements software. Additionally, BMM from WT and CD44KO were 
cultured on collagen coated 6 well plates and given M-CSF (20ng/mL) and RANKL 
(50ng/mL) for 48 hours. Mature osteoclasts on collagen coated plates were removed 
using 2.5mg/mL collagenase in dissociation buffer (Life technologies) and seeded on 
bovine cortical slices in 96 well plates along with M-CSF and RANKL. In parallel 
cultures, rOA (100ng/mL) was added to osteoclasts seeded on cortical slices. Cells 
were fixed with 4% paraformaldehyde, permeabilized with triton X-100, and incubated 
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with rhodamine phalloidin followed by counterstaining with DAPI mounting media to 
visualize actin ring formation. Images were taken using the Olympus 100 confocal 
microscope. After staining for actin ring formation, osteoclasts on cortical slices were 
TRAP stained and counted (n>3 nuclei) for each condition. For analysis of the 
resorption pits on the cortical slices, osteoclasts were removed with a soft brush and 
slices were incubated with 200µg/mL lectin-HRP for one hour at room temperature. 
Slices were then incubated with 0.52mg/mL 3,3’-diaminobenzidine for 30 minutes. 
Images were taken using  a Nikon Ti Eclipse inverted microscope and resorption pit 
area and %resorbed area were measured sing the NIS-elements software. 
3.9 Calvarial Bone Resorption Assay 
 A mouse model of RANKL-induced bone loss from the calvaria was used as 
previously described [440]. A collagen sheet (100mm2) (Medline) was soaked with PBS 
(control), RANKL (50µg/mL), or RANKL and rOA (100µg/mL) in 30µL volume and 
placed on the center of the calvaria in 5 week WT or CD44KO mice (n=5). After 7 days, 
the mice were sacrificed and the calvaria were removed and fixed in 4% 
paraformaldehyde and stained for TRAP. Images were taken using a Nikon SMZ 800 
stereomicroscope. The TRAP + stained area was quantified using the NIS-Elements 
analysis software. Micro-computated tomography (µCT) was also performed using the 
SkyScan 1172 microCT system (Skyscan, Aartselaar, Belgium; 72kV, 113µA, 7.7-µm 
sections). Three dimensional reconstructed images of the calvaria were generated 
using SkyScan CTvox software. 
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3.10 Immunofluorescence 
 WT primary osteoblasts, MC3T3-E1 cells, or BMM form WT mice were cultured 
in 4-well 1.7 cm2 chamber slides (BD Falcon, Corning, NY) with α-MEM media 
supplemented with 10% serum. Cells were then fixed with 4% paraformaldehyde (PFA) 
and permeabilized using 0.5% Triton X-100 in PBST (Tween-20; 0.1%). Primary 
osteoblasts were then blocked with 5% BSA in PBST followed by overnight incubation 
of the primary antibodies CD44 (1:500), Osteoactivin (1:250), Caveolin-1 (1:250). The 
next day corresponding secondary antibodies Alexa flour-488 and Alexa flour-568 (Cell 
Signaling) were incubated for 2 hours in a humidified chamber followed by 
counterstaining with diamidino-2-phenylindole (DAPI) mounting media. For visualization 
of the lipid raft Alexa flour-488 conjugated CTX-B (1:100) was added for 2 hours at 
room temperature prior to termination. Images were taken using a Nikon Ti Eclipse 
inverted microscope. 
3.11 Mass Spectroscopy Analysis 
 Biotinylation of recombinant Osteoactivin (R&D Technologies) was carried out 
using the EZ-Link NHS-Biotin Kit (ThermoScientific). Briefly, 25 µg/mL recombinant 
Osteoactivin was added to 10 mM Biotin dissolved in DMSO and allowed to incubate for 
2 hours at room temperature and dialyzed overnight. Freshly labeled biotinylated 
Osteoactivin was then added to protein cell lysates in RIPA buffer and allowed to 
incubate for 1 hour at 40C on an orbital rocker. To purify biotinylated proteins, the NHS-
Biotin labeled cell lysates were incubated with streptavidin beads (Pierce) for 1 hour at 
40C on an orbital rocker. The cell lysate slurry was then transferred to an Ultrafree-MC 
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centrifugal filter tube and subjected to a series of 3 washes using RIPA lysis buffer. The 
purified labeled protein was then eluted with β-mercaptoethanol in laemelli buffer boiled 
at 950C and proteins separated by SDS-PAGE. The gel was then silver stained, 
digested and analyzed by LC-MS/MS Mass Spectroscopy by the Ohio State 
Spectrometry and Proteomics Facility.  The tandem mass spectrometry data were 
processed using Mascot Distiller to form a peaklist and analyzed using the MASCOT 
tandem mass spectrometry search engine and Turbo SEQUEST algorithm in the 
BioWorks 3.1 software as previously described [441]. 
3.12 Immunoprecipitation 
 Total cell lysate from primary osteoblast and pre-osteoclast culture was pre-
cleared with 20 l protein A-Sepharose beads (Sigma; 50% slurry in PBS) end-over-end 
at 4oC for 1 hour. Cell lysates were then incubated with 3 g anti-CD44 antibody or 
corresponding IgG isotype control (Abcam) end-over-end at 4oC overnight. The 
immune-complexes were captured by 25 l protein A-Sepharose beads with end-over-
end mixing for 1 hour at 4oC. Beads were washed four times by centrifugation (400x g, 
5 minute) in cell lysis buffer and then boiled at 95oC for 5 minutes in 20 l reducing 
SDS-sample buffer inducing the elution of the captured proteins. Beads were removed 
by centrifugation, and the supernatant was analyzed by Western blot. 
3.13 Western Blot Analysis 
 Total protein was isolated from osteoblast cultures using 
radioimmunoprecipitation (RIPA) assay buffer (Millipore, Billerica, MA) with 
phosphatase inhibitor cocktail (Pierce, Rockford, IL). Protein concentration was 
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determined using the Pierce BCA protein Assay kit. Protein samples (25-40µg) were 
subjected to separation SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) 
membranes (BioRad, Hercules, CA) by the Trans-Blot Turbo system (BioRad). 
Membranes were probed overnight with the following primary and secondary antibodies 
as listed in Table 3.1 and Table respectively. The signal was developed with 
chemiluminescent substrate (Pierce) and detected using the Syngene PXi system 
(Syngene, Rockville, MD). Densitometric analysis was performed by the optical density 
of the phosphorylated protein over the total using the Syngene software analysis. 
Table 3.1 List of Primary Antibodies 
 
 
 
Primary Antibody Source Company 
Osteoactivin Rabbit Bioss, R&D Technologies 
CD44 Rat Calbiochem 
pERK Rabbit Cell Signaling 
ERK Rabbit Cell Signaling 
pP38 Mouse Cell Signaling 
P38 Mouse Cell Signaling 
pJNK Rabbit Cell Signaling 
JNK Rabbit Cell Signaling 
pIКβ Rabbit Cell Signaling 
IКβ Rabbit Cell Signaling 
pPLCᵧ2 Rabbit Cell Signaling 
PLCᵧ2 Rabbit Cell Signaling 
pAKT Rabbit Cell Signaling 
AKT Mouse Cell Signaling 
NFAT2 Rabbit Cell Signaling 
LC3 Rabbit Cell Signaling 
GAPDH Rabbit Cell Signaling 
Tubulin Rabbit Bioss 
β-Actin Rabbit Bioss 
Ki-67 Rabbit Bioss 
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Table 3.2 List of Secondary Antibodies 
Secondary Antibody Conjugate Company 
Anti-Rabbit HRP Cell Signaling 
Anti-Rat HRP Cell Signaling 
Anti-Mouse HRP Cell Signaling 
Anti-Rabbit Alexa flour-488 Cell Signaling 
Anti-Rat Alexa flour-594 Cell Signaling 
 
3.14 Transfection 
 MC3T3-E1 cells were transfected with 100 nM scramble siRNA or CD44 siRNA 
(Dharmacon, Lafayette, CO) using Lipofectamine (Invitrogen). After 48 hours, cells were 
treated with recombinant Osteoactivin, ERK inhibitors (10µM), or in combination for 24 
hours. After the 24 hour period RNA was isolated and qPCR was performed. For 
Western blot analysis, cells were treated with recombinant Osteoactivin for 10 minutes 
and protein isolated by RIPA. The efficiency of CD44 knockdown was determined by 
Western blot analysis.  
 
3.15 Quantification of Matrix Deposition and Mineralization 
 Matrix deposition and maturation in osteoblast and bone marrow derived 
mesenchymal stem cell cultures were determined by ALP staining and activity. ALP 
staining was performed at day 7 using an ALP staining kit (Sigma), according to the 
manufacturer’s protocol. ALP-positive cells are stained purple. In parallel cultures, ALP 
activity was determined using an ALP activity kit (Anaspec, Fremont, CA) based on the 
manufacturer’s recommendations.  Briefly, 100 µL of total protein cell lysate from each 
sample was added to a 96 well plate in triplicates along with 50 µL working solution. 
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Absorbances were measured over time starting at 0 to 60 minutes. ALP activity is 
expressed nmol per minute per total microgram protein. Absorbance values were 
normalized to the total protein using BCA.  
 In order to assess mineralization, osteoblasts were differentiated in culture for 21 
days and stained for Von kossa. Briefly, cells were fixed with 10% formalin for 20 
minutes and stained with 5% silver nitrate solution under UV exposure for 30 minutes. 
Cells were washed 3 times followed by the addition of sodium carbonate and 5% 
sodium thiosulfate to visualize the mineralized nodules. Mineralized nodule count was 
assessed using the Nikon Ti Eclipse analysis software. 
3.16 RT-qPCR 
 Total RNA was isolated from proliferating and differentiated osteoblasts grown in 
6 well dishes by adding 1 mL Qiazol (QIAGEN, Hilden, Germany). Total RNA was 
purified using an RNA extraction kit (QIAGEN). RNA concentrations were determined 
using a NanoDrop 2000 Spectrophotometer (ThermoScientific). Following RNA isolation 
cDNA was prepared using a High Capacity cDNA Reverse Transcription kit (Life 
Technologies). Quantitative (q) RT-PCR was performed with the Step-one qPCR 
system in duplicate with 2X SYBR Green PCR Master Mix (Life Technologies). qPCR 
cycles consisted of an initial 50oC cycle for 2 minutes, followed by a second cycle of 
95oC for 10 minutes, followed by 40 cycles of 95oC for 15 seconds, and a final cycle of 
60oC for 1 minute. Samples were analyzed using a 7900 Fast Real Time PCR System 
(Applied Biosystems), and relative gene expression was determined using the ▲▲CT 
method using GAPDH as an internal control. The sequences for oligonucleotide primers 
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(Integrated DNA technologies, Coralville, IA) for osteoblasts and osteoclasts are lasted 
in Table 3.2 and Table 3.3, respectively.  
Table 3.3 Osteoblast Primers used for qPCR  
Primers Sequence 
Runx2 5’-GACGAGGCAAGAGTTTCACC-3’ 
(Runx2 forward) 
5’-GGACCGTCCACTGTCACTTT-3’ 
(Runx2 reverse) 
Osterix 5’-GCAACTGGCTAGGTGGTG                     
GTC-3’ (Osterix forward) 
5’-GCAAAGTCAGATGGGTAAGTAGGC-
3’ (Osterix reverse) 
Alkaline Phosphatase (ALP) 5’-CCGATGGCACACCTGCTT-3’         
(ALP forward) 
5’-GGAGGCATACGCCATCACAT-3’          
(ALP reverse) 
Osteocalcin (OCN) 5’-CTGACAAAGCCTTCATGTCCAA-3’ 
(Osteocalcin forward) 
5’-GCGCCGGAGTCTGTTCACTA-3’ 
(Osteocalcin reverse) 
Type I Collagen (Col1α1) 5’-CCTGAGTCAGCAGATTGAGAACA-3’ 
(Col1α1 forward) 
5’-CCAGTACTCTCCGCTCTTCCA-3’ 
(Col1α1 reverse) 
Osteoactivin 5’-AATGGGTCTGGCACCTACTG-3’ 
(Osteoactivin forward) 
5’-GGCTTGTACGCCTTGTGTTT-3’ 
(Osteoactivin reverse) 
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Table 3.4 Osteoclast Primers used for qPCR 
Primers Sequence 
RANK 5’-AGTTTAAGCCAGTGCTTCACG-3’ 
(RANK forward) 
5’-ACGTAGACCACGATG ATGTCG-3’ 
(RANK reverse) 
TRAP 5’-GCAGTATCTTCAG GACGAGAAC-3’ 
(TRAP forward) 
5’-TCCATAGTGAAACCGCAAGTAG-3’ 
(TRAP reverse) 
DC-STAMP 5’-TGTATCGGCTCA TCTCCTCCAT-3’ 
(DC-STAMP forward) 
5’-GACTCCTTGGGTTCCTTGCTT-3’ 
(DC-STAMP reverse) 
NFATc1 5′-CTCGAAAGACAGCAC TGGAGCAT-3′ 
(NFATc1 forward) 
5′-CGG CTGCCTTCCGTCTCATAG-3’ 
(NFATc1 reverse) 
OSCAR 5′-CTGCTGGTAACGGATCAGTC 
CCCAGA-3′ (OSCAR forward) 
5′-CCAAGGAGCCAGAACCTTCGAAACT-
3’(OSCAR reverse) 
Calcitonin Receptor (Calcitonin Rec.) 5′-AGTTGCCCTCTTATGAAGGAGAAG-3′ 
(Calcitonin Receptor forward) 
5′-GGAGTGTCGTCCCAGCACAT-3′ 
(Calcitonin Receptor reverse). 
 
3.17 Lipid Raft Isolation 
 Membrane raft proteins were isolated by sucrose density fractionation as 
previously described [442]. Briefly, MC3T3-E1 cells were isolated and scraped into an 
ice-cold detergent-free Tricine Buffer and centrifuged to eliminate the nuclear material. 
The supernatant was removed and mixed with 30% Percoll® diluted in Tricene buffer 
and centrifuged at high speed (77,000 g) for 30 minutes. The separated plasma 
membranes were collected, sonicated, and mixed with 60% sucrose before being 
overlaid with a 35-5% step sucrose gradient and subjected to overnight centrifugation 
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(88,000g). Fractions were collected from the top sucrose layer, and proteins were 
precipitated using 0.1% deoxycholic acid in trichloroacetic acid. Samples were then 
ready to be used for SDS-PAGE and immunoblotting. 
3.18 Luciferase Analysis 
 The Osterix (Osx; -1269/+91) luciferase construct was a kind gift donated by 
Mark Nanes (Emory University). Briefly, MC3T3-E1 cells were plated at 2.5x105 cells in 
6 well plates and transfected with either Osx or PGL3 basic (control) using 
Lipofectamine2000 (Invitrogen, Carlsbad, CA). Forty-eight hours after transfection, cells 
were harvested and assayed using firefly luciferase and Renilla luciferase substrates in 
the Dual Luciferase assay system (Promega, Madison, WI). The luciferase values were 
normalized based on Renilla values to correct for variation in transfection efficiency.  
3.19 Cell Proliferation and Viability Assays 
 For proliferation assays, MC3T3-E1 cells were plated at 5.0 x103 cells in 96 well 
plates  in 6 replicates using α-MEM media supplemented with 10% serum. Cells were 
switched to low serum media (2.5% FBS) alone (control) or supplemented with different 
concentrations of recombinant Osteoactivin for 48 hours. Total DNA content was 
measured using a CyQuant NF cell proliferation assay kit (Life Technologies, Carlsbad, 
CA), according to the manufacturer’s guidelines. Briefly, the media was aspirated and 
replaced with 1X dye binding solution and incubated at 37oC for 1 hour. Flourescent 
intensity was measured using the BioTek Synergy H4 microplate reader (BioTek 
Instruments, Winooski, VT) with excitation at 485 nm and emission detection 530 nm. 
Furthermore, the number of Ki-67 % cells was quantified as previously described [443]. 
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Briefly, MC3T3-E1 cells were plated at a density of 5.0x103 on coverslips and cultured 
with α-MEM media supplemented with 10% serum. Cell were switched to low serum for 
24 hours and then treated with different concentrations of recombinant Osteoactivin for 
an additional 24 hours. Cells were then fixed with 4% PFA, permeabilized with Triton X-
100 in PBST, and blocked with 5% BSA in PBST for 1 hour. Cells were then incubated 
with anti-Ki-67 (Bioss) overnight. The next day cells were washed 3X, incubated with 
secondary Alexa flour-568 (Abcam), and counterstained with DAPI mounting media. 
The total number of Ki-67 + cells were counted and calculated as a percent over the 
total number of nuclei (Ki-67 % positive cells) at 10X magnification using a Nikon 
Eclipse Ti epifluorescent microscope. A minimum of 200 total cells were counted per 
condition in triplicates.  
 For cell viability assays, MC3T3-E1 cells were cultured in 96 well plates using α-
MEM media supplemented with 10% serum. Cells were switched to low serum media 
(2.5% FBS) alone (control) or supplemented with different concentrations of 
recombinant Osteoactivin for 48 hours, and viability was assessed using Alamar blue as 
previously described [444]. Briefly, medium was aspirated and replaced with a 10% 
Alamar blue solution diluted in 1X Hank’s media. Cells were incubated at 37oC for 4 
hours, and reduction of Alamar blue was determined colorimetrically by use of a 
spectrophotometer. The percent viability was expressed as fluorescence counts in the 
presence of recombinant Osteoactivin as a percentage of that in the control. For the cell 
apoptosis assay, levels of Caspase 3 in MC3T3-E1 cells were determined using the 
Caspase-Glo 3/7 assay (Promega). Briefly, MC3T3-E1 cells were cultured with α-MEM 
media supplemented with 10% serum and then switched to low serum media (2.5% 
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FBS) alone (control) or supplemented with 50 ng/mL recombinant Osteoactivin for 48 
hours. Medium was removed and replaced with Caspase-Glo 3/7 reagent, and cells 
were then incubated at 37oC for 4 hours. Luciferase activity was measured using a 
BioTek plate reader with excitation at 485 nm and emission 530.  
3.20 Statistical Analysis 
 For all generated data, differences between individual groups were analyzed 
using the Prism 5 software version 5.04 (GraphPad, La Jolla, CA). Individual 
experiments were repeated a minimum of three times with similar results. In cases 
when multiple groups were being compared, a one-way analysis of variance (1-way 
ANOVA) was employed followed by a Tukey’s multiple comparison post hoc test. In the 
cases involving the comparison of two groups, an unpaired t-test was performed. All 
differences where p<0.05 were regarded as statistically significant.  Group means or 
means ± standard error of the mean (±SEM) was graphed. 
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Chapter 4 
Results 
4.1 Mesenchymal Stem Cell and Osteoblast Differentiation 
 Mesenchymal stem cells (MSCs) have the ability to differentiate into several 
different lineages important for musculoskeletal development and repair. In order for 
MSCs to be able to differentiate into a specific cell lineage, certain transcription factors 
must be expressed (Figure 4.1). For the osteoblast lineage, Runx2 and Osterix are the 
critical transcription factors important for MSC differentiation into osteoblasts. Once 
MSCs have committed to the osteoblast lineage, the osteoblasts undergo a specific 
series of differentiation stages.  
 During osteoblast differentiation several important growth factors are expressed 
that can serve a variety of roles important for osteoblast differentiation and function. 
Osteoactivin is a type I transmembrane glycoprotein shown to be expressed in both 
osteoblasts and osteoclasts. The role of Osteoactivin and its importance in osteoblast 
differentiation and function both in vivo and in vitro have already been described [3-6]; 
however, the signaling mechanism involved in Osteoactivin mediated osteoblast 
differentiation and function has not yet been investigated.
 111 
 
  In this study we used the recombinant Osteoactivin (rOA) to study the role of 
Osteoactivin mediated signaling in both MSCs and osteoblasts. The recombinant 
Osteoactivin is the entire extracellular portion of the molecule and contains several 
domains and glycosylation sites. Our data shows that the recombinant Osteoactivin 
stimulates osteoblast differentiation through a CD44 dependent mechanism.   
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Figure 4.1: Schematic diagram showing the potential lineages of mesenchymal 
stem cell differentiation. There are a variety of different cell types important for 
musculoskeletal development. The above diagram depicts the different cell types that 
arise from the same MSC cell lineage and the critical transcription factors (next to 
arrows) necessary in order for those cells to differentiate into that particular cell type. 
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4.2 Osteoactivin has no Effect on MC3T3-E1 Osteoblast Proliferation and Viability 
 In order to investigate the role of recombinant Osteoactivin in osteoblast function, 
we wanted to determine its effect on osteoblast proliferation and viability using the 
MC3T3-E1 osteoblast-like cell line. We examined the role of recombinant Osteoactivin 
in osteoblast proliferation using CyQuant assay and Ki-67 immunoflourescent staining. 
CyQuant quantitatively measures the total DNA content, whereas Ki-67 staining 
indicates cells in a proliferating, non-quiescent state [445]. Both CyQuant assay (Figure 
4.2A) and Ki-67 staining (Figure 4.2B) revealed that there were no significant changes 
in osteoblast proliferation with increasing concentrations of recombinant Osteoactivin. 
This indicates that recombinant Osteoactivin has no effect on osteoblast proliferation. 
 Next, we examined the role of recombinant Osteoactivin on osteoblast viability 
using the Alamar blue and Caspase 3/7 apoptosis Glo assays. The Alamar blue assay 
is an assessment of mitochondrial activity that fluoresces and changes color upon 
reduction in living cells, whereas the Caspase 3/7 Glo assay measures the activity of 
these enzymes which are important for cell apoptosis [444, 446]. Both Alamar blue 
(Figure 4.3A) and Caspase 3/7 Glo (Figure 4.3B) assays revealed no significant 
differences in cell viability when osteoblasts were treated with recombinant 
Osteoactivin. This indicates that recombinant Osteoactivin has no effect on osteoblast 
viability and survival. 
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Figure 4.2: Recombinant Osteoactivin has no effect on MC3T3-E1 proliferation. 
(A) CyQuant analysis of MC3T3-E1 cells plated at a seeding density of 5,000 cells per 
well in 96 well plates and serum starved overnight prior to addition of recombinant 
Osteoactivin for 48 hours. Following the 48 hour incubation period, proliferating cells 
were measured by quantitating the fluorescently-labeled DNA. (B) Quantitation of 
fluorescently labeled MC3T3-E1 cells with Ki-67. Cells were plated on coverslips and 
either left untreated (control;CTL) or treated with different concentrations of recombinant 
Osteoactivin for 24 hours. Cells were then fixed and incubated with a primary 
fluorescent antibody against the nuclear antigen Ki-67 followed by secondary incubation 
with Alexa-flour 594 and DAPI. The proportion of Ki-67 positive cells over the total 
number of nuclei (DAPI) was calculated. The experiments were run in triplicates and 
with 3 replicates per condition with similar results. Data presented in all graphs 
represent Mean ± SEM. 
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Figure 4.3: Recombinant Osteoactivin has no effect on MC3T3-E1 cell viability. (A) 
Alamar Blue analysis of MC3T3-E1 cells plated in 96 well plates and serum starved 
overnight prior to the addition of different concentrations of recombinant Osteoactivin for 
48 hours.  Mitochondrial activity and cell viability/apoptosis in cells untreated 
(control;CTL) and treated with recombinant Osteoactivin was determined by 
spectrophotometry. (B) Caspase-Glo 3/7 activity of MC3T3-E1 cells plated in 96 well 
plates. Briefly, cells were serum starved overnight and either left untreated (control; 
CTL) or treated with recombinant Osteoactivin (50ng/mL) for 48 hours. Luminescent 
activity was determined using a luminometer. The experiments were run in triplicates. 
Data presented in all graphs represent Mean ± SEM. 
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4.3 Osteoactivin Stimulates Osteoblast Matrix Deposition and Mineralization 
 In previous studies, loss of function of Osteoactivin through the use of blocking 
antibodies resulted in the inhibition of osteoblast differentiation [2]. In the present study, 
we wanted to determine if recombinant Osteoactivin stimulated osteoblast differentiation 
and function in vitro. Recombinant Osteoactivin added during osteogenic differentiation 
with β-Glycerophosphate and Ascorbic Acid resulted in a substantial increase in 
Alkaline phosphatase (ALP) staining in both C57Blk6 (WT) MSCs (Figure 4.4A) and 
MC3T3-E1 osteoblast like cells (Figure 4.4B). Furthermore, recombinant Osteoactivin 
treatment significantly increased ALP enzyme activity in both WT MSCs (Figure 4.4C) 
and MC3T3-E1 cells (Figure 4.4D). This indicates that recombinant Osteoactivin 
stimulates early matrix deposition in vitro. 
 Next, we saught to determine if recombinant Osteoactivin had an effect on late 
stage osteoblast matrix mineralization. Recombinant Osteoactivin was added to 
osteogenic media for 21 days and resulted in a substantial increase in matrix 
mineralization in both WT MSCs (Figure 4.5A) and MC3T3-E1 cells (Figure 4.5B). This 
indicates that recombinant Osteoactivin stimulates both matrix deposition and matrix 
mineralization during osteoblast differentiation. 
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Figure 4.4: Recombinant Osteoactivin enhances osteoblast matrix deposition in 
both MSCs and MC3T3-E1 cells. (A-B) ALP staining in C57Blk6 (WT) MSCs (A) and 
MC3T3-E1(B) cells treated with recombinant Osteoactivin and osteogenic differentiation 
factors β-Glycerophosphate (10mM) and Ascorbic Acid (50µg/mL) or osteogenic 
differentiation factors alone (CTL). Briefly, 100K cells pre well were plated in 24 well 
plates and cultured for 7 days before termination for ALP staining. (C-D) ALP activity in 
WT MSCs (C) and MC3T3-E1 (D) cells. Briefly, day 7 differentiated cell lysates from 
untreated and recombinant Osteoactivin treated cells were used to determine the 
activity levels of ALP using a spectrophotometer.  The experiment was repeated 3 times 
with similar results. Data presented in all graphs represent Mean ± SEM.  ***=p<0.001. 
Scale bars: 1,000µm (A,B Top panel)  and 250µm (A,B Bottom panel). 
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Figure 4.5: Recombinant Osteoactivin enhances osteoblast matrix mineralization 
in both MSCs and MC3T3-E1 cells. (A-B) Von kossa staining in WT MSCs (A) and 
MC3T3-E1 (B) cells treated with recombinant Osteoactivin and osteogenic 
differentiation factors β-Glycerophosphate (10mM) and Ascorbic Acid (50µg/mL) or 
osteogenic differentiation factors alone (CTL). Briefly, 100K cells per well were plated in 
24 well plates and cultured for 21 days before termination for Von kossa staining. Notice 
the increase in mineral deposition in Osteoactivin treated samples. The experiment was 
repeated 3 times with similar results. Scale bars: 1,000µm (A,B Top panel)  and 250µm 
(A,B Bottom panel). 
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4.4 Osteoactivin Stimulates MSC and MC3T3-E1 Osteoblast Related Gene 
Expression  
 There are several osteoblast markers that have been shown to be upregulated 
during osteoblast differentiation. In this study, we wanted to determine the effect of 
recombinant Osteoactivin on osteoblast related gene expression during the course of 
osteoblastogenesis. The addition of recombinant Osteoactivin (50ng/mL) to WT MSCs 
resulted in a significant increase in osteoblast related genes Runx2 (Figure 4.6A), 
Osterix (Osx) (Figure 4.6B), ALP (Figure 4.6C), and Osteocalcin (OCN) (Figure 4.6D). A 
similar trend was also seen in MC3T3-E1 osteoblast like cells as recombinant 
Osteoactivin was shown to significantly upregulate osteoblast specific genes Runx2 
(Figure 4.7A), Osterix (Figure 4.7B), ALP (Figure 4.7C), and Osteocalcin (Figure 4.7D). 
These results indicate that Osteoactivin is able to increase osteoblast differentiation by 
upregulating osteoblast related markers. 
As previously described, Osterix is a critical transcription factor necessary for osteoblast 
differentiation. Our data indicates that recombinant Osteoactivin significantly 
upregulates Osterix expression by qPCR. To further elaborate on this idea, we 
transfected MC3T3-E1 cells with the full length -1269/+91 Osterix luciferase promoter 
and treated the cells with recombinant Osteoactivin. MC3T3-E1 cells transfected with 
Osterix luciferase vector and treated with recombinant Osteoactivin showed a significant 
upregulation of Osterix promoter activity compared to MC3T3-E1 cells transfected with 
control vector (Figure 4.8). This indicates that Osteoactivin may play a role in the 
regulation of Osterix promoter activity and expression.  
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Figure 4.6: Recombinant Osteoactivin stimulates osteoblast related genes in WT 
MSCs during osteogenic differentiation. (A-D) qPCR analysis of osteoblast related 
genes in WT MSCs treated with different concentrations of recombinant Osteoactivin 
and differentiation factors or differentiation factors alone (CTL). WT MSCs were cultured 
with or without Osteoactivin for 7 and 14 days prior to termination. Osteoactivin 
upregulated several important factors important for osteoblast differentiation that include 
Runx2 (A), Osterix (Osx) (B), ALP (C), and Osteocalcin (OCN) (D). The experiment was 
repeated 3 times with similar results. Data presented in all graphs represent Mean ± 
SEM. *=p<0.05, ***=p<0.001. 
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Figure 4.7: Recombinant Osteoactivin stimulates osteoblast related genes in 
MC3T3-E1 osteoblast like cells during osteogenic differentiation. (A-D) qPCR 
analysis of osteoblast related genes in MC3T3-E1 cells treated with different 
concentrations of recombinant Osteoactivin and differentiation factors or differentiation 
factors alone (CTL). Osteoactivin upregulated several important factors important for 
osteoblast differentiation that include Runx2 (A), Osterix (Osx) (B), ALP (C), and 
Osteocalcin (OCN) (D). The experiment was repeated 3 times with similar results. Data 
presented in all graphs represent Mean ± SEM. *=p<0.05, **=p<0.01, ***=p<0.001. 
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Figure 4.8: Osteoactivin regulates Osx promoter activity in MC3T3-E1 cells. 
Osteoblasts were seeded at 200K cells per well in 6 well plates. After 24 hours, cells 
were transiently transfected with either PGL3 control empty vector or the -1269/+91 Osx 
full length promoter reporter. 48 hours after transfection, cells were serum starved for 8 
hours followed by treatment with either recombinant Osteoactivin (50ng/mL) or left 
untreated for 24 hours. Following treatment, cells were harvested and assayed using 
firefly luciferase and Renilla luciferase substrates with the Dual Luciferase assay 
system. Luciferase values were normalized to Renilla luciferase data to correct for 
variation in transfection efficiency. The experiment was repeated 3 times with similar 
results. Data presented in all graphs represent Mean ± SEM. *=p<0.05. 
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4.5 Osteoactivin Binds to and Interacts with CD44 in Osteoblasts 
 There is very little literature describing the signaling pathway of Osteoactivin in 
bone cells. In order to determine a novel receptor for Osteoactivin, we biotinylated 
recombinant Osteoactivin and added it to MC3T3-E1 cells. The isolated protein was 
purified with streptavidin, and mass spectroscopy analysis was performed. Mass 
spectroscopy analysis identified several proteins that bound to and interacted with 
Osteoactivin. Among these identified proteins, CD44 and Caveolin-1 were found to have 
a significant interaction with recombinant Osteoactivin (Figure 4.9).  
 To confirm the CD44-Osteoactivin interaction, we immunoprecipitated 
biotinylated recombinant Osteoactivin treated cells with a CD44 antibody and analyzed 
samples by Western blot. Immunoprecipitation analysis revealed that Osteoactivin 
interacts with CD44 (Figure 4.10). Furthermore, immunofluorescent analysis revealed 
co-localization of CD44 and Osteoactivin along the osteoblast cell membrane (Figure 
4.11). This indicates that Osteoactivin may interact and bind to CD44. Further 
information is needed on the role of CD44 in bone cells.  
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Figure 4.9: Streptavidin affinity purification of N-hydroxysuccinimidbiotin (NHS-
Biotin) labeled recombinant Osteoactivin. MC3T3-E1 cells were treated with NHS-
Biotin labeled recombinant Osteoactivin for 30 minutes. Following treatment, protein 
was isolated and subjected to streptavidin affinity purification. After the purification, 
NHS-Biotin labeled recombinant Osteoactivin proteins were separated by 10% SDS-
PAGE and silver stained to visualize bands. The bands were subjected to Nano-
LC/MS/MS analysis to determine potential receptors for recombinant Osteoactivin. The 
stain identifies multiple bands, however, analysis revealed CD44 (top arrow) and 
Caveolin-1(bottom arrow) as potential receptors for Osteoactivin. 
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Figure 4.10: Biotinylated recombinant Osteoactivin binds to CD44 in MSCs. MSC 
cell lysates treated with biotinylated recombinant Osteoactivin were isolated and 
immunoprecipitated (IP) with either IgG (control) or anti-CD44 antibodies for 1 hour at 
4oC. Following immunoprecipitation, proteins were subjected to Western blot for 
Streptavidin (53kDa) and CD44 (80kDa). 
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Figure 4.11: CD44 and Osteoactivin colocalize at the cell membrane in MC3T3-E1 
cells. Immunoflourecent analysis of the localization of CD44 and Osteoactivin. MC3T3-
E1 cells were seeded at a density of 10K cells per well and cultured in chamber slides. 
Cells were fixed, stained with anti-CD44 or anti-Osteoactivin, and counterstained with 
DAPI in order to visualize the localization of these molecules in MC3T3-E1 cells. 
Merged images of CD44 (green), Osteoactivin (red), and DAPI (blue) were generated in 
order to visualize colocalization of CD44 and Osteoactivin along the cell membrane. 
Scale bars: 10µm 
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4.6 CD44 Deficient Mice have Significantly Less Bone Mass in vivo 
 The first report of CD44 expression in bone came from a study that revealed that 
CD44 is important for osteocytes and osteocyte differentiation [385]. Several studies 
have shown that CD44 is highly expressed in MSCs, osteoblasts, and osteoclasts [386, 
393, 447]. Previous studies have also shown that CD44 may have anti-inflammatory 
properties in both bone and cartilage [391, 448]. Therefore, in order to understand the 
role of CD44 in bone homeostasis, we characterized the skeletal phenotype of CD44 
deficient mice (CD44KO) both in vivo and ex vivo. MicroCT analysis revealed a 
dramatic reduction in bone mass at both 8 and 16 week male mice (Figure 4.12). The 
reduction in the bone volume/tissue volume (BV/TV) seen in CD44 deficient mice was 
approximately 30% less compared to wild type (WT) controls at 8 weeks of age and 
approximatley 20% less at 16 weeks of age (Figure 4.13A). Bone area (B.Ar), bone 
perimeter (B.Pm), and trabecular number (Tb.N) were all significantly less in CD44 
deficient mice at both 8 and 16 weeks compared to WT(Figure 4.13B-D). Trabecular 
spacing was significantly more in CD44 deficient mice compared to wild type at both 8 
and 16 weeks (Figure 4.13E). The trabecular thickness (Tb.Th) was also slightly 
decreased in CD44 deficient mice at 8 weeks but revealed no significant difference at 
16 weeks (Figure 4.13F). Several of the differences in the microCT parameters 
observed between the 8 week and 16 week mice were more pronounced in the 8 week 
age mice. This may indicate that the defect in bone homeostasis observed in CD44 
deficient mice may happen at an earlier age and that during the remodeling phase the 
bone phenotype may begin to correct itself. 
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 To further elaborate on the bone phenotype of the CD44 deficient mice in vivo, 
we performed histomorphometric analyses on 8 week WT and CD44 deficient mice. 
Von kossa staining revealed a significant reduction in mineralization in the CD44 
deficient mice (Figure 4.14). Histomorphometric analysis of CD44 deficient mice 
revealed a significant reduction in trabecular number (Tb.N), bone perimeter/total area 
(B.Pm/T.Ar), and trabecular number/total area (Tb.N/T.Ar) and an increase in trabecular 
separation (Tb.Sp) compared to WT (Figure 4.15A-D). Interestingly, there seemed to be 
no difference in the number of osteoblasts per bone perimeter (N.Ob/B.Pm) or the 
percentage of osteoblasts per bone surface (Ob.S/B.S.) (Figure 4.15E-F). This indicates 
that the reduction in bone mass in CD44 deficient mice may be due to defective 
osteoblast differentiation and function independent of osteoblast proliferation and 
number. 
 To further investigate the kinetic rate of bone formation in vivo in CD44 deficient 
mice, we performed calcein labeling and histmorphometric analysis. CD44 deficient 
mice had approximately a 30% reduction in mineral apposition rate (MAR) and bone 
formation rate (BFR) (Figure 4.16A-C). Taken together, these data indicate that CD44 
deficient mice have impaired osteoblasts which results in defective mineralization and 
bone formation in vivo.  
 Next, we performed serum analysis for osteoblast and osteoclast markers in both 
WT and CD44 deficient mice at 8 and 16 weeks by ELISA to further understand the 
bone phenotype in vivo. At 8 weeks age, osteoblast markers P1NP and Osteocalcin 
were significantly reduced in CD44 deficient mice; however, at 16 weeks, only 
Osteocalcin was significantly reduced (Figure 4.17A-B). This may be best explained as 
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an age specific bone phenotype where there seems to be more of an impairment in 
osteoblasts at 8 weeks compared to 16. Furthermore, a compensatory mechanism may 
start to take place resulting in the bone phenotype beginning to correct itself at 16 
weeks. Osteoclast serum analysis markers RANKL, OPG, and CTX-1 showed no 
significant differences between WT and CD44 deficient mice (Figure 4.18A-D). This 
indicates that the loss of bone mass in the CD44 deficient mice is primarily due to the 
osteoblasts, not the osteoclasts.  
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Figure 4.12: CD44 deficient mice have significantly less bone mass. (A-B) MicroCT 
three-dimensional reconstructed images of C57Blk6 (WT) and CD44 deficient 
(CD44KO) femurs in 8 week (A) and 16 week (B) mice. Mouse femurs (n=6 per group) 
were analyzed using a SkyScan high-resolution microtomography system. Three-
dimensional images of the sagittal planes of whole femurs (top panel) and femoral 
metaphysis (bottom panel) are shown. 
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Figure 4.13: CD44 deficient mice have significantly less bone parameters. (A-F) 
Quantification of microCT analysis of WT and CD44KO femurs (n=6 per group) in both 8 
week and 16 week old mice for BV/TV (A), B.Ar (B), B.Pm (C), Tb.N (D), Tb. Sp. (E), 
and Tb.Th (F). CD44 deficient mice had significantly less BV/TV, B.Ar, B.Pm, Tb.N, 
Tb.Th, but more Tb.Sp. compared to WT. Notice the dramatic difference at 8 weeks 
compared to 16 weeks. Data presented in all graphs represent Mean ± SEM. *=p<0.05, 
**=p<0.01, ***=p<0.001. 
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Figure 4.14: CD44 deficient mice have significantly less mineralization in vivo. 
Saggital sections from WT and CD44KO 8 week old mouse femurs (n=4) were 
sectioned and stained with Von kossa to visualize minerals (black) and counterstained 
with toluidine blue. Sections of the distal femur were imaged at 2X (left) and 10X (right) 
magnification. 
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Figure 4.15: Quantitative histomorphometric analysis reveals significantly 
decrease bone mass but no difference in osteoblast number. Sagittal sections from 
8 week old WT and CD44KO mouse femurs and were stained for Von kossa. (A-F) 
Histomorphometric parameters including Tb.N (A), Tb. Sp (B), B.Pm/T.Ar (C), and 
Tb.N/T.Ar (D) were all significantly different in CD44KO compared to wild type mice, 
however, N. Ob./B.Pm (E) and Ob.S/B.S. (F) showed no difference. Data presented in 
all graphs represent Mean ± SEM. **=p<0.01, ***=p<0.001. 
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Figure 4.16: CD44 deficient mice have a reduction in mineral apposition and bone 
formation rate in vivo. (A) WT and CD44KO 8 week old mice were injected with 
Calcein AM to label the mineralized bone surface (green). After termination, unstained 
sagittal sections were visualized under epiflourescence to observe and quantify kinetic 
histomorphometric parameters MAR (B) and BFR (C). Data presented in all graphs 
represent Mean ± SEM. *=p<0.05, **=p<0.01. 
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Figure 4.17: CD44 deficient mice have significantly less serum biomarkers for 
bone formation in vivo. (A-B) Biochemical analysis of osteoblast specific markers 
PINP (A) and Osteocalcin (B) in serum from 8 and 16 week old WT and CD44KO mice. 
Data presented in all graphs represent Mean ± SEM. *=p<0.05. 
 
 
 
 
 
 
 
 
 
 136 
 
 
Figure 4.18: CD44 deficient mice reveal no significant difference in osteoclast 
serum biomarkers compared to WT in vivo. (A-D) Biochemical analysis of osteoclast 
serum  biomarkers RANKL (A), OPG (B), ratio of RANKL/OPG (C), and CTX-1 (D) from 
8 and 16 week old WT and CD44KO mice. 
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4.7 CD44 Deficient Mice have Significantly Less Bone ex-vivo due to Defective 
Osteoblast Differentiation and Function 
 In order to explain the low bone mass phenotype observed in the CD44 deficient 
mice in vivo, we isolated bone marrow derived mesenchymal stem cells from both WT 
and CD44 deficient mice and cultured them ex vivo.  The presence or absence of CD44 
in both WT and CD44 deficient cells respectively, was determined by both qPCR and 
Western blot (Figure 4.19). In order to determine the effect of the absence of CD44 on 
osteoblast differentiation, we plated WT and CD44 deficient MSCs and treated them 
with osteogenic factors for 7 and 14 days. QPCR analysis revealed a significant 
reduction in the levels of Runx2 (Figure 4.20A), Osterix (OSX) (Figure 4.20B), ALP 
(Figure 4.20C), and Osteocalcin (OCN) (Figure 4.20D) in the CD44 deficient mice 
compared to WT. This indicates that the absence of CD44 inhibits osteogenic gene 
expression and that CD44 may play an important role during osteoblast differentiation 
 To further elaborate on the role of CD44 during osteoblast differentiation, we 
isolated MSCs from WT and CD44 deficient mice and differentiated them in culture for 7 
and 21 days in order to determine the role of CD44 in osteoblast matrix deposition and 
mineralization. CD44 deficient MSCs revealed significantly less ALP staining and 
activity compared to WT (Figure 4.21A-B). This indicates that CD44 may play a role as 
a positive regulator of osteoblast matrix deposition. Furthermore, CD44 deficient 
osteoblasts revealed significantly less mineralization by Von kossa staining (Figure 
4.21C-D). These results indicate that CD44 plays a role in both osteoblast matrix 
deposition and mineralization, and is an overall positive regulator of osteoblast 
differentiation. 
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Figure 4.19: Confirmation of the absence of CD44 in CD44 deficient osteoblasts. 
(A-B) Primary osteoblasts from WT and CD44KO were plated at a density of 200K cells 
per well in 6 well plates. The next day, RNA and protein were isolated to determine the 
absence of CD44 by qPCR (A) and Western blot (B) respectively. The experiment was 
repeated 3 times with similar results. 
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Figure 4.20: CD44 deficient MSCs show a significant reduction in osteoblast 
related gene expression during osteoblastogenesis. (A-D) qPCR analysis of mRNA 
from WT and CD44KO MSCs during osteoblast differentiation. MSCs taken from 8 week 
old WT and CD44KO male mice were plated in 6 well plates and differentiated with 
osteogenic factors for up to 14 days. RNA was isolated at days 7 and 14 from both WT 
and CD44KO MSCs and the relative expression of osteoblast related genes Runx2 (A), 
OSX (B), ALP (C), OCN (D) was determined by qPCR. Data presented in all graphs 
represent Mean ± SEM. *=p<0.05, **=p<0.01 compared to WT. 
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Figure 4.21: CD44 deficeint mice have significantly reduced matrix deposition and 
mineralization ex vivo. (A-B) WT and CD44KO MSCs were plated and differentiated 
with osteogenic factors for 7 days and terminated for ALP staining (A) and activity (B) in 
order to assess osteoblast matrix deposition. Furthermore, WT and CD44KO MSCs 
were plated and differentiated for 21 days and terminated for Von kossa staining (C) 
and quantitation of minerals (D) to assess matrix mineralization. The experiment was 
repeated 3 times with similar results.  Data presented in all graphs represent Mean ± 
SEM. *=p<0.05, ***=p<0.001 compared to WT. Scale bars: 1,000µm (Top panel) and 
250µm (Bottom panel). 
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4.8 Osteoactivin Stimulates MAPKinase Signaling in Osteoblasts through CD44  
 Previous literature has indicated that Osteoactivin may play a role in the MAPK 
pathway in several different cell types including fibroblasts, MSCs, and osteoclasts [7, 
366, 449]. In this study, we wanted to determine the effects on recombinant 
Osteoactivin treatment on downstream signaling pathways. Recombinant Osteoactivin 
treatment increased phosphorylated ERK signaling in a dose dependent and time 
dependent manner (Figure 4.22A-B). A similar response was seen in phosphorylated 
P38 (Figure 4.23A-B) but not phosphorylated JNK (data not shown). This indicates that 
recombinant Osteoactivin plays a role in stimulating certain members of the MAPK 
pathway.  
 In order to further characterize the Osteoactivin mediated signaling pathway, we 
transfected MC3T3-E1 cells with CD44 siRNA and treated cells with recombinant 
Osteoactivin and observed activation of ERK and P38 activation. MC3T3-E1 cells 
transfected with CD44 and treated with recombinant Osteoactivin revealed a significant 
reduction in both ERK and P38 phosphorylation compared to cells treated with 
recombinant Osteoactivin alone (Figure 4.24A-C). This indicates that Osteoactivin 
stimulates ERK and P38 signaling through the CD44 receptor in osteoblasts. 
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Figure 4.22: Recombinant Osteoactivin stimulates phosphoERK in osteoblasts in 
a dose and time dependent manner. (A-B) Western blot analysis of MC3T3-E1 cells 
treated with different concentrations of recombinant Osteoactivin. Briefly, MC3T3-E1 
cells were plated at 200K cells per well in 6 well plates and serum starved overnight. 
Cells were then treated for 15 minutes with different concentrations of recombinant 
Osteoactivin and protein was isolated and analyzed by Western blot. Membranes were 
probed with phosphorylated and total ERK. Western blot images (A) and densitometric 
analysis (B) revealed a significant increase in phosphorylated ERK with increasing 
concentrations of recombinant Osteoactivin. (C-D) Western blot analysis of MC3T3-E1 
cells treated with recombinant Osteoactivin. MC3T3-E1 cells were serum starved 
overnight and treated with 50 ng/mL recombinant Osteoactivin and terminated at 
different time points. The experiment was repeated 3 times with similar results.  Data 
presented in all graphs represent Mean ± SEM. *=p<0.05, **=p<0.01, ***=p<0.001 
compared to untreated control samples. 
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 Figure 4.23: Recombinant Osteoactivin stimulates phosphoP38 in osteoblasts in 
a dose and time dependent manner. (A-B) Western blot analysis of MC3T3-E1 cells 
treated with recombinant Osteoactivin with different concentrations as indicated in the 
figure. Briefly, MC3T3-E1 cells were plated in 6 well plates at a seeding density of 200K 
cells per well and serum starved overnight. Cells were then treated for 15 minutes with 
different concentrations of recombinant Osteoactivin and protein was isolated and 
analyzed by Western blot. Membranes were probed with phosphorylated and total P38. 
Western blot images (A) and densitometric analysis (B) revealed a significant increase 
in phosphorylated P38 with increasing concentrations of recombinant Osteoactivin. (C-
D) Western blot analysis of MC3T3-E1 cells treated with recombinant Osteoactivin. 
MC3T3-E1 cells were serum starved overnight and treated with 50 ng/mL recombinant 
Osteoactivin and terminated at different time points as indicated. The experiment was 
repeated 3 times with similar results.  Data presented in all graphs represent Mean ± 
SEM. *=p<0.05 compared to untreated controls. 
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Figure 4.24: Knockdown of CD44 in MC3T3-E1 cells results in a decrease in 
Osteoactivin induced phosphoERK and phosphoP38. (A) Western blot analysis of 
MC3T3-E1 cells knocked down with CD44 siRNA. Briefly, cells were plated in 6 well 
plates at a seeding density of 200K cells per well and transfected with 100 nM of either 
scrambled or CD44 siRNA for 48 hours. Protein was isolated and membranes were 
probed with antibodies against CD44 and GAPDH to confirm knockdown of CD44. (B-
C) Western blot analysis of MC3T3-E1 cells knocked down with CD44 siRNA and 
treated with recombinant Osteoactivin (50ng/mL).  Briefly, cells were transfected with 
CD44 siRNA and either left untreated (CTL and CD44siRNA) or treated with 
recombinant Osteoactivin (rOA and CD44siRNA and rOA) for 10 minutes. Protein was 
isolated and membranes were probed for phospho and total ERK (B) and phospho and 
total P38 (C). 
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4.9 Loss of CD44 Prevents the Enhancement of Recombinant Osteoactivin 
Mediated Osteoblast Differentiation 
 As previously described, recombinant Osteoactivin stimulates ALP staining and 
activity in WT MSCs and that absence of CD44 results in defective osteoblast 
differentiation. In order to confirm that Osteoactivin mediated stimulation of MSCs is 
through the CD44 receptor, we differentiated MSCs from WT and CD44KO mice and 
either left them untreated (control;CTL) or treated with recombinant Osteoactivin for 7 
days. Results from ALP staining and activity revealed that Osteoactivin stimulation of 
ALP staining and activity is abrogated in CD44 deficient MSCs (Figure 4.25A-B). This 
indicates that Osteoactivin induced stimulation of osteoblast differentiation is mediated 
through the CD44 receptor. 
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Figure 4.25: Recombinant Osteoactivin stimulation of osteoblast differentiation is 
abrogated in CD44 deficient MSCs. (A-B) WT and CD44KO MSCs were plated in 24 
well plates at a seeding density of 100K cells per well and treated with either osteogenic 
media alone (control; CTL) or osteogenic media with recombinant Osteoactivin 
(50ng/mL) for 7 days. After 7 days, the cells were terminated to assess osteoblast 
matrix deposition by ALP staining (A) and activity (B).  The experiment was repeated 3 
times with similar results.  Data presented in all graphs represent Mean ± SEM. 
***=p<0.001 when compared to WT and untreated controls. Scale bars: 200 µm (Panel 
A) 
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4.10 Recombinant Osteoactivin Induces Osteoblast Differentiation through the 
CD44-ERK Signaling Axis 
 Next, we wanted to determine if Osteoactivin mediated stimulation of ERK 
phosphorylation through CD44 had any effect on osteoblast regulatory genes. First, 
primary osteoblasts isolated from WT and CD44 deficient mice were plated and either 
left untreated (CTL) or treated with recombinant Osteoactivin. Primary osteoblasts 
treated with recombinant Osteoactivin showed a significant increase in osteoblast 
related genes Col1α1 (Figure 4.26A) and Osterix (Figure 4.26B) in WT cells by qPCR; 
however, this effect was abrogated in CD44 deficient cells treated with Osteoactivin. 
Interestingly, recombinant Osteoactivin mediated increase of Runx2 in WT cells did not 
show a difference in CD44 deficient cells treated with recombinant Osteoactivin (Figure 
4.26C). This indicates that Osteoactivin upregulation of Col1α1 and Osterix is mediated 
through CD44, and that Osteoactivin mediated stimulation of Runx2 seems to be CD44 
independent. 
 Furthermore, in order to link the CD44-ERK signaling axis to downstream 
osteoblast gene expression, we transfected MC3T3-E1 cells with CD44 siRNA and 
treated with recombinant Osteoactivin and an ERK inhibitor U0126 alone or in 
combination. Cells transfected with CD44 siRNA and treated with recombinant 
Osteoactivin resulted in a decrease in Col1α1 and Osterix compared to recombinant 
Osteoactivin treated cells alone (Figure 4.27A-B). Similarly, cells treated with U0126 
and Osteoactivin together also saw a reduction in Col1α1 and Osterix combined 
compared to Osteoactivin treated cells alone. Interestingly, cells transfected with CD44 
siRNA and treated with U0126 and Osteoactivin combined resulted in an even greater 
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inhibition of Col1α1 and Osterix. This indicates that Osteoactivin stimulates Col1α1 and 
Osterix expression through the CD44-ERK signaling axis. Osteoactivin stimulation of 
Runx2 shows a slightly different pattern. Cells transfected with CD44 siRNA and treated 
with recombinant Osteoactivin showed no difference compared to Osteoactivin treated 
cells alone, however, when pretreated with U0126 Runx2 showed a significant reduction 
compared to Osteoactivin treated cells alone (Figure 4.27C). This indicates that 
Osteoactivin induced upregulation of Runx2 is mediated through ERK signaling, but not 
through CD44. Further studies of other potential receptors responsible for Osteoactivin 
mediated upregulation of Runx2 expression in osteoblasts should be conducted. 
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Figure 4.26: CD44 deficiency abrogates recombinant Osteoactivin induced 
upregulation of Osterix and Col1α1, but not Runx2 in osteoblasts. (A-C) qPCR 
analysis of WT and CD44KO osteoblasts either left untreated (control; CTL) or treated 
with recombinant Osteoactivin (50 ng/mL) for 24 hours before termination. Briefly, 
osteoblasts were plated in 6 well plates at a seeding density of 200K cells per well and 
serum starved overnight. The next day, cells were either left untreated or treated with 
recombinant Osteoactivinfor 24 hours. Following treatment, RNA was isolated followed 
by qPCR analysis of osteoblast related genes Col1α1 (A), Osterix (B), or Runx2 (C) 
revealed that recombinant Osteoactivin upregulates these genes. This upregulation 
seems to be mediated through CD44 for Col1α1 and Osterix but not Runx2. The 
experiment was repeated 3 times with similar results.  Data presented in all graphs 
represent Mean ± SEM. **=p<0.01 ***=p<0.001 compared to WT and untreated 
controls. 
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Figure 4.27: Recombinant Osteoactivin stimulates Col1α1 and Osterix through the 
CD44-ERK signaling axis. (A-C) qPCR analysis of MC3T3-E1 cells transfected with 
either scramble (CTL) or CD44 siRNA and either left untreated or treated with 
recombinant Osteoactivin (50ng/ml) or the ERK inhibitor U0126 (20µM) alone or in 
combination. Recombinant Osteoactivin upregulated osteoblast specific genes Col1α1 
(A), Osterix (B), and Runx2 (C), however, inhibition of the ERK pathway abrogated the 
upregulation of all three genes. Interestingly, knockdown of CD44 only affected 
Osteoactivin induced upregulation of Col1α1 and Osterix, but not Runx2.   Data 
presented in all graphs represent Mean ± SEM. **=p<0.01 ***=p<0.001. 
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Figure 4.28: Schematic diagram depicting the stage at which OA-CD44 interaction 
stimulates osteoblast differentiation. Osteoactivin was shown to stimulate osteoblast 
differentiation and function. Our results indicate that during matrix deposition and 
extracellular matrix (ECM)/osteoid development Osteoactivin-CD44 interaction had its 
most potent effect. Interestingly, similar results at this stage have also been shown with 
other ligands of CD44 including Galectin-9 and Hyaluronan (HA).   
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4.11 Osteoactivin co-localizes within the Lipid Raft 
 Previous literature has shown that upon stimulation of CD44, clustering of CD44 
with other receptors within lipid raft complexes can occur [450-452]. In this study, we 
wanted to determine if Osteoactivin has an association with cholesterol rich lipid raft 
micro domains. In order to determine if Osteoactivin co-localized within lipid raft micro 
domains, we used confocal immunoflourescent analysis of Osteoactivin and cholera-
toxin B (CTX-B). CTX-B has binds to the GM1 ganglioside which has previously been 
shown to act as a resident raft marker [453, 454]. Immunoflourescent analysis revealed 
co-localization of Osteoactivin and CTX-B along the cell membrane (Figure 4.29). 
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Figure 4.29: Osteoactivin is associated with cholesterol-rich lipid raft domains in 
osteoblasts. Immunoflourescent analysis of MC3T3-E1 cells probed for Cholera toxin-
B (CTX-B; green) and Osteoactivin (OA; red). Briefly, cells were plated in chamber 
slides, fixed, and probed with an anti-Osteoactivin antibody. The next day, cells were 
treated with Alexa-flour 488 labeled CTX-B and secondary Alexa flour-568 antibody. 
Notice that OA co-localizes with CTX-B along the cell membrane. Scale bars: 10µm 
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4.12 Osteoactivin Treatment Stimulates Clustering of CD44 and Caveolin-1 in 
Lipid Rafts 
 Next, we wanted to determine if Osteoactivin treatment stimulated clustering of 
CD44 into lipid rafts. In order to determine if Osteoactivin induced clustering of CD44 
into lipid rafts, we isolated soluble (SF) and lipid raft (RF) fractions by ultracentrifugation 
untreated and treated with either H3 or recombinant Osteoactivin (OA) and subjected 
them to immunoprecipitation and Western blot (Figure 4.30). The Hermes class 3 (H3) 
is a member of a class of adhesion molecules found to bind to CD44 during lymphocyte 
homing [455]. Cells treated with IgG (negative control) showed no enhancement of 
CD44 in lipid rafts; however, cells treated with H3 (positive control) showed an increase 
of CD44 compared to IgG control. Interestingly, recombinant Osteoactivin treatment 
increased the level of CD44 in lipid raft fractions compared to control. 
 In order to further elaborate on CD44 clustering induced by Osteoactivin 
stimulation, we treated cells with recombinant Osteoactivin (50ng/mL) and observed for 
co-localization of CD44 and lipid raft marker Caveolin-1 by confocal microscopy. Upon 
Osteoactivin stimulation, we observed co-localization of CD44 and Caveolin-1 along the 
membrane (Figure 4.31). These data indicate that Osteoactivin treatment results in the 
co-localization of CD44 into Cavolin-1 rich lipid rafts. 
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Figure 4.30: Recombinant Osteoactivin treatment induces CD44 to co-localize in 
lipid raft microdomains in osteoblasts. Western blot analysis of protein cell lysates 
from soluble (SF) and lipid raft (RF) fractions and treated with either IgG (negative 
control), H3 (positive control), or recombinant Osteoactivin (OA; 50ng/mL). Briefly, cells 
were plated in 6 well plates at a seeding density of 200K cells per well and serum 
starved overnight. The next day cells were either left untreated or treated with either 
IgG, H3, or OA for 60 minutes. Cell membrane preparations were separated by 
fractionation using an OptiPrep gradient by ultracentrifugation. Protein cell lysates were 
collected and analyzed by Western blot. Membranes were probed for an antibody 
against CD44 antibody. Anti-Caveolin-1 (Cav-1) antibodywas used to detect fractions 
positive for lipid rafts. 
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Figure 4.31: Recombinant Osteoactivin treatment induces co-localization of CD44 
and Caveolin-1 in osteoblasts. Immunoflourescent analysis of MC3T3-E1 cells treated 
or untreated with recombinant Osteoactivin (rOA; 50ng/mL) and stained for CD44 and 
Caveolin-1. Briefly, cells were plated in chamber slides and serum starved overnight. 
The next day, cells were either left untreated or treated with rOA for 60 minutes at 370C. 
Cells were then fixed and stained with antibodies against CD44 and caveolin-1. The 
next day cells were treated with secondary Alexa-flour 488 and 568 antibodies. Scale 
bars: 10µm and 1µm (far right). 
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4.13 Disruption of Lipid Raft Prevents CD44 and Caveolin-1 Clustering and 
Inhibits Osteoactivin Mediated ERK Phosphorylation in Osteoblasts 
 In order to determine the role of the lipid raft in Osteoactivin/CD44 signaling, we 
used lipid raft inhibiting agents methyl-β-cyclodextrin (MβCD) and nystatin (Nyst.). 
Nystatin and MβCD have previously been reported to disrupt lipid rafts through the 
depletion of cholesterol [456-458]. First, we treated osteoblasts with recombinant 
Osteoactivin with or without MβCD to determine if disruption of the lipid raft would affect 
Osteoactivin mediated clustering of CD44 into lipid rafts. Recombinant Osteoactivin 
treatment resulted in the clustering of CD44 and Caveolin-1 by immunoprecipitation and 
Western blot analysis; however, when cells were treated with MβCD and Osteoactivin 
together, there was a reduction in CD44 and Caveolin-1 clustering compared to 
Osteoactivin treated alone (Figure 4.32).  
 Next, we wanted to determine if disruption of lipid raft affected Osteoactivin 
mediated signaling in osteoblasts. We treated cells with both recombinant Osteoactivin 
or nystatin alone or in combination to determine ERK activation by Western blot. 
Recombinant Osteoactivin, as previously shown in Figure 4.22, resulted in a dramatic 
increase in phosphorylated ERK. Interestingly, recombinant Osteoactivin when added in 
combination with nystatin resulted in a reduction in the level of phosphorylated ERK 
(Figure 4.33). In summary, these results reveal that disruption of the lipid raft results in 
the reduction of CD44/Caveolin-1 clustering and an inhibition of Osteoactivin induced 
ERK signaling. These results indicate the importance of CD44 and the lipid raft in 
Osteoactivin mediated signaling in vitro. Further evidence on the role of the lipid raft in 
Osteoactivin mediated osteoblast differentiation and function is warranted. 
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Figure 4.32: Lipid raft disruption prevents CD44 and Caveolin-1 clustering in 
osteoblasts. Western blot analysis of MC3T3-E1 cells either left untreated (control; 
CTL), treated with recombinant Osteoactivin (rOA; 50ng/mL), or treated with 
recombinant Osteoactivin and the lipid raft disrupting agent methyl-β cyclodextran 
(MβCD; 1mM). Briefly, MC3T3-E1 cells were plated in 6 well plates at a seeding density 
of 200K cells per well and serum starved overnight. The next day, the cells either 
remained untreated or treated with rOA for 60 minutes @ 370C. For disruption of the 
lipid raft, MβCD was added to cells for 60 minutes prior to the addition of rOA. Protein 
cell lysates were collected and immunoprecipitated with an anti-CD44 antibody. 
Immunoprecipitated proteins were analyzed by Western blot and membranes were 
probed for Caveolin-1 (Cav-1) and CD44. Notice the expression of Cav-1 in the rOA 
treated sample which is reduced in both rOA and MβCD treated samples.  
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Figure 4.33: Lipid raft disruption prevents recombinant Osteoactivin-mediated 
increase in ERK signaling. Western blot analysis of MC3T3-E1 cells either left 
untreated, treated recombinant Osteoactivin (rOA; 50ng/mL), or rOA with the lipid raft 
inhibitor nystatin (Nyst; 50µg/mL). Briefly, cells were plated in 6 well plates at a seeding 
density of 200K cells per well and serum starved overnight. The next day, the cells 
either remained untreated or treated with rOA for different time points and incubated @ 
370C. For disruption of the lipid raft, nystatin was added to cells for 60 minutes prior to 
the addition of rOA. Protein cell lysates were collected and analyzed by Western blot. 
Membranes were probed with antibodies against the phosphorylated and total ERK. 
Notice the decrease in phosphoERK in the rOA lipid raft disrupted samples. 
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4.14 Recombinant Osteoactivin Stimulates Autophagy in Osteoblasts 
 Previous studies have shown that caveolin rich lipid rafts can undergo 
endocytosis and stimulate cellular signaling [459]. Furthermore, previous literature has 
shown that endocytosis of caveolin-rich lipid rafts stimulate downstream signaling and 
autophagy [460, 461]. Autophagy has become an emerging new field in skeletal biology. 
Previous literature has shown that autophagy is an important regulator of osteoblast 
mineralization and bone homeostasis [462-464]. Since Osteoactivin seems to play a 
role in caveolin-rich lipid rafts, we hypothesized that recombinant Osteoactivin treatment 
may stimulate autophagy in osteoblasts.  Microtubule-associated protein light chain 3 
(LC3) is one of the most common indicators used to detect autophagy or autophagic 
flux. LC3 has two forms: LC3-I which is a cytoplasmic protein, and LC3-II which is 
conjugated to phosphatidylethanolamine on autophagosomal membranes [465]. 
Conversion of LC3-I to LC3-II is a good indicator of autophagic flux as the amount of 
LC3-II is closely correlated with the number of autophagosomes and autophagsome 
formation [466, 467]. Recombinant Osteoactivin treatment in osteoblasts displayed an 
enhancement in the conversion of LC3-I to LC3-II by Western blot analysis in a time 
dependent manner (Figure 4.34). Future studies should further examine the role of 
Osteoactivin in osteoblast autophagy.   
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Figure 4.34: Recombinant Osteoactivin stimulates autophagy in osteoblasts. (A-
B) Western blot (A) and Densitometry (B) analysis of MC3T3-E1 cells treated with 
recombinant Osteoactivin (50ng/mL) or left untreated and stained for LC3. MC3T3-E1 
cells were plated in 6 well plates at a seeding density of 200K cells per well and low-
serum (2% FBS) was added overnight. The next day, the cells either remained 
untreated or treated with rOA for different time points and incubated @ 370C. Protein 
cell lysates were collected and analyzed by Western blot. Membranes were probed with 
antibodies against LC3 and Tubulin (loading control). Notice the increase in LC3-II over 
time in the Osteoactivin treated samples.   
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Figure 4.35: Schematic diagram of Osteoactivin signaling in osteoblasts. 
Osteoactivin extracellular domain (OA-ECD) has been shown to be shed from the 
membrane by ADAM10 in osteoblasts. Since the recombinant Osteoactivin mimics the 
shed extracellular domain, we believe that upon release of Osteoactivin from the 
membrane, Osteoactivin either acts in an autocrine or paracrine fashion and binds to 
CD44 where it stimulates a signling complex within the lipid raft. This complex induces 
intracellular signaling resulting in enhanced osteoblast differentiation. Interestingly, 
preliminary data suggests that autophagy may be involved in this process.   
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4.15 Osteoactivin Expression during Osteoclastogenesis  
 Previous literature has shown that Osteoactivin is expressed in osteoclasts [7-9]. 
The role of Osteoactivin in osteoclasts has been somewhat controversial. One study 
has shown that Osteoactivin is important for both osteoclast differentiation and function 
and that this process may be mediated through αvβ3 integrin [7, 9]. Recently our lab has 
reported that mutation in Osteoactivin in D2J mice results in enhanced osteoclast 
differentiation and an inhibition in resorption both in vivo and ex vivo suggesting that 
Osteoactivin plays a role in both osteoclast differentiation and function [8]. Although 
there are a few reports regarding the role of Osteoactivin in osteoclasts, the 
downstream signaling pathways related to Osteoactivin have not yet been determined. 
In this study, we examined the effect of recombinant Osteoactivin in vitro to determine 
its role in osteoclast differentiation and function. 
 In order to differentiate osteoclasts in vitro, inflammatory cytokines M-CSF and 
RANKL are required. Figure 4.36 represents a schematic diagram of the procedure that 
is necessary to differentiate osteoclasts. Certain cytokines such as NOTCH, γ-interferon 
and CX3CL1 have shown to have different effects on osteoclast differentiation based on 
when they are added in culture [468-471]. Recent work from our lab has shown 
recombinant Osteoactivin has different effects on osteoclast differentiation depending 
on when it is added in culture (unpublished results). In this study, recombinant 
Osteoactivin was added at day 3 and day 5 of osteoclast differentiation along with 
RANKL and M-CSF just prior to and during osteoclast commitment (Figure 36). In order 
to confirm that osteoclasts were able to be successfully differentiated, qPCR analysis of 
critical osteoclast transcription factors NFATc1 [472], c-Fos [199], and MITF [473] were 
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determined over the course of differentiation (Figure 4.37A). Interestingly, endogenous 
Osteoactivin levels were drastically higher compared to NFATc1, c-Fos, and MITF. 
Furthermore, the levels of Osteoactivin protein also increased during osteoclast 
differentiation as shown by ELISA (Figure 4.37B) and Western blot (Figure 4.37C). 
Interestingly, osteoclasts when treated with RANKL and M-SCF produce a significantly 
higher amount of Osteoactivin in the cell lysate compared to the conditioned media. 
This indicates that Osteoactivin that is produced by the osteoclasts remains primarily 
within the cell and only a fraction is released into the microenvironment.  
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Figure 4.36: Schematic diagram of osteoclast differentiation and the critical 
cytokines (above arrow), transcription factors (below arrow), and osteoclast 
specific markers (below cell) involved in the process. Upon flushing of bone 
marrow, the beginning myeloid precursor starting at D0 begins to proliferate and 
differentiate with the help of the M-CSF and activated transcription factors PU.1 and 
MITF. After 72 hours bone-marrow macrophages (BMM) express high levels of c-Fms 
and RANK which stimulate downstream pathways critical for differentiation into 
osteoclast precursor cells upon M-CSF and RANKL treatment. After 48 hours of the first 
dose of RANKL and M-CSF treatment, a second dose of RANKL and M-CSF is given 
for another 48 hours in order for mature osteoclasts to develop. Recombinant 
Osteoactivin treatment is given each time RANKL and M-CSF is added. 
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Figure 4.37: Osteoactivin (OA/Gpnmb) expression increases during osteoclast 
differentiation. Bone marrow derived from C57Blk6 (WT) mice was flushed and non-
adherent cells (BMM) were cultured with 20 ng/mL M-CSF for 72 hours. Following the 
72 hour period, primed BMM were given the first dose of RANKL (40 ng/mL) and M-
CSF in order for primed cells to differentiate into pre-osteoclasts (Oc 5d). Forty-eight 
hours later pre-osteoclasts were given a second dose of RANKL and M-CSF for another 
48 hours in order to differentiate into mature osteoclasts (Oc 7d). (A) qPCR analysis of 
Osteoactivin (OA/Gpnmb) mRNA expression during osteoclast differentiation. Notice 
OA/Gpnmb expression is high compared to known osteoclast transcription factors. (B) 
ELISA analysis of OA/Gpnmb expression during osteoclastogenesis. Notice the levels 
of Osteoactivin in the cell lysate increase during osteoclastogenesis, but levels in the 
conditioned media (Cond. M/CM) remain low. (C) Western blot analysis of both mature 
(mOA) and immature (iOA) Osteoactivin at early and late stage osteoclast 
differentiation. Data presented in all graphs represent Mean ± SEM. ****=p<0.0001 
comparing cell lysate and conditioned media. 
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4.16 Osteoactivin Inhibits Osteoclast Differentiation in a Dose Dependent Manner  
 In order to determine the role of exogenous Osteoactivin treatment on osteoclast 
differentiation, we added recombinant Osteoactivin to BMM during osteoclast 
differentiation. Previous literature from our lab has shown that addition of recombinant 
Osteoactivin has no effect on BMM proliferation or survival (data not shown). 
Exogenous Osteoactivin treatment inhibited osteoclast differentiation determined by 
TRAP staining (Figure 4.38A) and activity (Figure 4.38B). Furthermore, recombinant 
Osteoactivin significantly inhibited osteoclast size and number (Figure 4.38C-F). Next, 
we wanted to determine the effect of recombinant Osteoactivin treatment on osteoclast 
related gene expression. Recombinant Osteoactivin treated BMM showed a significant 
reduction in osteoclast related gene expression of RANK, TRAP, DC-STAMP, NFATc1, 
OSCAR, and Calcitonin receptor both in a dose-dependent (Figure 4.39) and time-
dependent manner (Figure 4.40). These results indicate that recombinant Osteoactivin 
treatment inhibits osteoclast differentiation in vitro. 
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Figure 4.38: Recombinant Osteoactivin inhibits osteoclast differentiation in vitro 
in a dose dependent manner. BMM from WT cells were differentiated with M-CSF (20 
ng/mL) and RANKL (40 ng/mL) along with increasing doses of recombinant 
Osteoactivin (rOA). (A) TRAP staining of mature osteoclasts untreated (Control) and 
treated with different doses of recombinant Osteoactivin. Notice as the concentration of 
Osteoactivin increases the TRAP Activity (B) and Osteoclast size (C) significantly 
decrease. (D-F) Osteoclast differential count showing total nuclei count (D), 3-20 nuceli 
(E), and >21 nuclei (F). The experiment was repeated 3 times with similar results. Data 
presented in all graphs represent Mean ± SEM. *=p<0.05, **=p<0.01, ***=p<0.001 
comparing untreated controls (CTL) to treated samples. Scale bars: 500 µm (A, Top 
panel). 
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Figure 4.39: Recombinant Osteoactivin inhibits osteoclast related gene 
expression in a dose dependent manner.  BMM from WT cells were differentiated 
with M-CSF (20ng/mL) and RANKL (40 ng/mL) along with increasing concentrations of 
recombinant Osteoactivin (rOA). Forty-eight hours later RNA was isolated from pre-
osteoclasts (day 5) and converted into cDNA for qPCR analysis. Osteoactivin was 
shown to inhibit several important osteoclasts related markers including RANK, TRAP, 
DC-STAMP, NFATc1, OSCAR, and Calcitonin receptor in a dose dependent manner. 
The experiment was repeated 3 times with similar results. Data presented in all graphs 
represent Mean ± SEM. *=p<0.05, **=p<0.01, ***=p<0.001 comparing untreated control 
to treated samples. 
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Figure 4.40: Recombinant Osteoactivin inhibits osteoclast gene expression 
during osteoclast differentiation. BMM from WT cells were differentiated with M-CSF 
(20 ng/mL) and RANKL (40 ng/mL) along with rOA (100 ng/mL). RNA was isolated 
during different stages of osteoclast differentiation in untreated (control;CTL) and 
treated (rOA) cells. (A-D) qPCR analysis of osteoclast related genes (A) TRAP, (B) 
RANK, (C) DC-STAMP, and (D) Calcitonin Receptor in untreated and rOA treated 
osteoclasts. Notice recombinant Osteoactivin treated samples significantly inhibit 
osteoclast related genes during differentiation which was highest during late stage 
differentiation. The experiment was repeated 3 times with similar results. Data 
presented in all graphs represent Mean ± SEM. *=p<0.05, ***=p<0.001 comparing 
untreated control samples (CTL) to rOA treated samples. 
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4.17 The Effect of Recombinant Osteoactivin on RANKL Mediated Signaling 
During Osteoclastogenesis  
 The importance of the RANKL pathway including downstream signaling 
mediators and transcription factors has been previously described [164, 474, 475]. In 
order to determine the role of Osteoactivin during RANKL mediated signaling in 
osteoclasts, we pre-treated osteoclasts with recombinant Osteoactivin followed by 
RANKL treatment in a time-dependent manner and analyzed downstream mediators by 
Western blot analysis. Recombinant Osteoactivin treatment seemed to have no effect 
on either phosphoPLCγ2 (Figure 4.42A-B) or phosphoIКβ (Figure 4.43A-B) signaling. 
Further analysis on the members of the MAPK pathway revealed that recombinant 
Osteoactivin had no effect on either phosphoJNK (Figure 4.44AandD) or phosphoP38 
(Figure 4.44CandF); however, treatment with recombinant Osteoactivin significantly 
reduced the levels of phosphorylatedERK compared to untreated controls (Figure 
4.44BandE). Interestingly, AKT phosphorylation was also downregulated with the 
addition of recombinant Osteoactivin (Figure 4.45A-B). These results indicate that 
Osteoactivin inhibits RANKL mediated stimulation of the ERK and AKT pathways in 
osteoclasts. 
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Figure 4.41: Schematic diagram of RANKL-mediated signaling pathways during 
osteoclastogenesis. RANKL/RANK stimulates several pathways critical for osteoclast 
differentiation. These include the NFКB, PLCγ, PI3K/AKT, and MAPK (JNK, P38, ERK) 
pathways. Upon RANKL and RANK binding, TRAF6 activates several mediators 
including IkK, Btk/Tec, PI3K, and Ras/MEK that regulate a variety of downstream 
transcription factors including NFКB, NFATc1, and the AP-1 complex. These 
transcription factors translocate to the nucleus and regulate several osteoclast related 
genes. 
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Figure 4.42: Recombinant Osteoactivin has no effect on RANKL mediated PLCᵧ2 
signaling in osteoclasts. BMM from WT cells were treated with M-CSF (20 ng/mL) 
and RANKL (40 ng/mL) for 48 hours with or without rOA (100 ng/mL). After the 48 hour 
period pre-osteoclasts were serum starved for 4 hours prior to RANKL (50 ng/mL) 
stimulation for the indicated time points. Total cell lysates were collected for Western 
blot analysis and probed with anti-phospho PLCᵧ2 and anti-PLCᵧ2 (A). Densitometric 
analysis (B) revealed no significant difference in untreated and treated samples. The 
experiment was repeated 3 times with similar results.  Data presented in all graphs 
represent Mean ± SEM. 
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Figure 4.43:  Recombinant Osteoactivin has no effect on RANKL induced IКβ 
signaling in osteoclasts. BMM from WT cells were treated with M-CSF (20 ng/mL) 
and RANKL (40 ng/mL) for 48 hours with or without rOA (100 ng/mL). After the 48 hour 
period, pre-osteoclasts were serum starved for 4 hours prior to RANKL (50 ng/mL) 
stimulation for the indicated time points. Total cell lysates were collected for Western 
blot analysis and probed with anti-phospho IКβ and anti-IКβ (A). Densitometric analysis 
(B) revealed no significant difference between untreated and treated samples. The 
experiment was repeated 3 times with similar results.  Data presented in all graphs 
represent Mean ± SEM. 
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Figure 4.44: Recombinant Osteoactivin inhibits RANKL induced ERK activation in 
osteoclasts. BMM from WT cells were treated with M-CSF (20 ng/mL) and RANKL (40 
ng/mL) for 48 hours with or without rOA (100ng /mL). After the 48 hour period, pre-
osteoclasts were serum starved for 4 hours prior to RANKL stimulation for the indicated 
time points. Total cell lysates were collected for Western blot analysis and probed with 
anti-phospho JNK and anti-JNK (A), anti-phospho ERK and anti-ERK (B), and anti-
phospho P38 and anti-P38 (C). Densitometric analysis (D-F) revealed no significant 
difference in untreated and rOA treated samples for JNK (D) and P38 (F); however, rOA 
treatment significantly down regulated levels of phosphoERK (E). The experiment was 
repeated 3 times with similar results.  Data presented in all graphs represent Mean ± 
SEM. *=p<0.05, ***=p<0.001 comparing untreated control and rOA treated samples. 
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Figure 4.45: Recombinant Osteoactivin inhibits RANKL induced AKT signaling in 
osteoclasts. BMM from WT cells were treated with M-CSF (20 ng/mL) and RANKL (40 
ng/mL) for 48 hours with or without rOA (100 ng/mL). After the 48 hour period, pre-
osteoclasts (day 5) were serum starved for 4 hours prior to RANKL stimulation for the 
indicated time points. Total cell lysates were collected for Western blot analysis and 
probed with anti-phospho AKT and anti-AKT (A). Densitometric analysis (B) revealed a 
significant decrease in pAKT levels for recombinant Osteoactivin treated osteoclasts. 
The experiment was repeated 3 times with similar results.  Data presented in all graphs 
represent Mean ± SEM. *=p<0.05 comparing untreated control and rOA treated 
samples. 
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4.18 Osteoactivin Binds to CD44 in Osteoclasts  
 Previous work from our lab has shown that Osteoactivin binds to and interacts 
with CD44 on the osteoblast membrane (unpublished observations). In this study we 
wanted to determine if Osteoactivin interacts with CD44 on the osteoclast cell 
membrane. In order to determine if Osteoactivin colocalizes with CD44 on the 
osteoclast cell membrane, BMM isolated from wildtype mice were plated in chamber 
slides and differentiated into mature osteoclasts. Immunoflourescent analysis revealed 
that Osteoactivin and CD44 co-localize and interact on the plasma membrane of mature 
osteoclasts (Figure 4.46). Hyaluronan is the well-known and major ligand of CD44 [476]. 
In order to determine the interaction between Osteoactivin and CD44, high molecular 
weight hyaluronan was added to lysates and to cultures to show competitive binding 
between Osteoactivin and hyaluronan for CD44. Immunoprecipitation of CD44 and 
biotinylated recombinant Osteoactivin untreated and treated with high molecular weight 
hyaluronan was determined in order to assess Osteoactivin affinity for CD44. 
Immunoprecipitation analysis revealed that biotinylated recombinant Osteoactivin binds 
to CD44 and is displaced upon hyaluronan treatment (Figure 4.47). This indicates that 
Osteoactivin and hyaluronan may bind to CD44 at the same site. 
 Previous literature has shown that high molecular weight hyaluronan (1µg/mL) 
inhibits osteoclast differentiation through toll-like receptor 4 (TLR-4) in vitro [440]. In 
order to determine the interaction between hyaluronan, CD44, and Osteoactivin during 
osteoclastogenesis, we added both recombinant Osteoactivin and hyaluronan during 
osteoclast differentiation.  Recombinant Osteoactivin and hyaluronan alone inhibited 
osteoclasts as expected. Hyaluronan and recombinant Osteoactivin added in 
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combination inhibited osteoclast differentiation; however, the effect was not synergistic 
(Figure 4.48). Furthermore, we added recombinant Osteoactivin and hyaluronan to WT 
and CD44KO cells. Recombinant Osteoactivin and HA treatment showed similar 
patterns in WT as previously described. Interestingly, addition of Osteoactivin to CD44 
deficient cells had no effect on osteoclast differentiation compared to control; however, 
HA treatment alone inhibited osteoclasts, and HA in combination with recombinant 
Osteoactivin also inhibited osteoclasts. This indicates that Osteoactivin may inhibit 
osteoclasts through CD44 and that HA inhibits osteoclasts through TLR-4 not CD44 as 
previously described [440]. 
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Figure 4.46: Osteoactivin co-localizes with CD44 in mature osteoclasts. BMM from 
WT cells were differentiated into mature osteoclasts with M-CSF (20ng/ml) and RANKL 
(50ng/mL) and terminated at day 7. Immunoflourescent staining of mature osteoclasts 
was used to visualize the expression of CD44 and Osteoactivin in multinucleated 
osteoclasts. Notice that CD44 and Osteoactvin seem to co-localize primarily along the 
cell membrane. 
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Figure 4.47: Osteoactivin binds to CD44 and is displaced upon hyaluronan 
treatment. BMM from WT cells were differentiated into pre-osteoclasts with M-CSF and 
RANKL for 48 hours. After the 48 hour period, cells were serum starved and treated 
with biotinylated recombinant Osteoactivin (rOA) alone or in combination with 
hyaluronan (HA).  Protein cell lysates were collected and subjected to 
immunoprecipitation analysis. Cell lysates were incubated with IgG or CD44 antibodies 
for immunoprecipitation and subjected to Western blot analysis. Blots were probed with 
anti-streptavidin and anti-CD44. Notice that when CD44 is immunoprecipitated with rOA 
treatment alone a distinct band can be seen; however upon the addition of HA, the band 
disappears indicating HA and rOA compete for the same site of CD44. 
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Figure 4.48: The inhibition of recombinant Osteoactivin is abrogated in CD44KO 
cells alone and in combination with hyaluronan. BMM from WT and CD44KO cells 
were differentiated with M-CSF (20ng/mL) and RANKL (50ng/mL) alone (CTL) or with 
rOA (100ng/mL) and hyaluronan (HA; 1µg/mL) alone, or in combination (rOA+HA) for 7 
days to generate mature osteoclasts. (A-C) Mature osteoclasts were analyzed for TRAP 
staining (A), activity (B), and count (C) among samples to determine the effect of rOA 
and HA together. Notice that rOA and HA alone inhibit osteoclast differentiation; 
however in combination, an enhanced inhibitory response is not seen indicating a 
competition between the two ligands for the same receptor. Data presented in all graphs 
represent Mean ± SEM. *=p<0.05, ***=p<0.001. Scale bars: 500 µm (Panel A) 
comparing untreated controls (CTL) to treated samples. 
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4.19 Osteoactvin Mediated Inhibition of Osteoclastogenesis is Abrogated in CD44 
Deficient Osteoclasts 
 In order to further examine whether Osteoactivin inhibition of osteoclasts is CD44 
dependent, we used CD44 deficient mice (CD44KO) for osteoclast culture (Figure 4.49). 
Recombinant Osteoactivin added to wild type (WT) cells showed a significant reduction 
in osteoclast differentiation by TRAP staining (Figure 4.50A), activity (Figure 4.50B), 
and count (Figure 4.50C); however, this effect was abrogated when CD44 deficient 
osteoclasts were treated with recombinant Osteoactivin. This indicates that CD44 is 
involved in the Osteoactivin-mediated inhibition of osteoclastogenesis. To elaborate 
upon this idea, we repeated this same experiment with osteoclasts grown on bovine 
cortical slices in order to determine if osteoclasts grown on a surface that mimics the 
bone extracellular matrix has different effects. The results showed similar responses to 
osteoclasts grown on plastic. Osteoactivin inhibited osteoclast differentiation in WT cells 
by TRAP staining (Figure 4.51A), activity (Figure 4.51B), and count (Figure 4.51C); 
however, this effect was abrogated in CD44 deficient cells. Next, we wanted to 
determine if CD44 was responsible for the Osteoactivin-mediated inhibition of osteoclast 
gene expression. Recombinant Osteoactivin added to WT BMM inhibited osteoclast 
related genes TRAP (Figure 4.52A), NFATc1 (Figure 4.52B), RANK (Figure 4.52C), DC-
STAMP (Figure 4.52D), and calcitonin receptor (Figure 4.52E); however, when 
Osteoactivin was added to CD44 deficient cells, this effect was abrogated if not 
enhanced. This indicates that Osteoactivin-mediated inhibition of osteoclast related 
genes is through the CD44 receptor. 
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Figure 4.49: Confirmation of the absence of CD44 in CD44 deficient osteoclasts. 
BMM from WT and CD44 deficient cells (CD44KO) were differentiated with M-CSF 
(20ng/mL) and RANKL (40ng/mL) for 7 days to generate mature osteoclasts. The 
absence of CD44 was confirmed by both mRNA and protein using qPCR (A) and 
Western blot (B) analysis respectively. Notice that CD44 was undetected in the graph 
and in the blot. 
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Figure 4.50: Osteoactivin mediated inhibition of osteoclast differentiation is 
abrogated in CD44 deficient cells cultured on plastic. BMM from WT and CD44KO 
cells were differentiated with M-CSF (20ng/mL) and RANKL (40ng/mL) alone (Control) 
or in combination with rOA for 7 days to generate mature osteoclasts. (A) Microscopic 
images of TRAP positive osteoclasts show an inhibition upon rOA treatment in WT 
samples; however, in CD44 deficient cells there is no effect upon rOA treatment. (B-C) 
Osteoclast parameters reveal an inhibition of osteoclast differentiation in rOA treated 
WT cells shown by (B) TRAP activity and osteoclast count (C). This effect is abrogated 
in the CD44KO samples. The experiment had 6-replicates and was repeated 3 times 
with similar results.  Data presented in all graphs represent Mean ± SEM. *=p<0.05, 
***=p<0.001 comparing untreated controls (CTL) to treated samples. Scale bars: 100 
µm (Panel A). 
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Figure 4.51: Osteoactivin mediated inhibition of osteoclast differentiation is 
abrogated in CD44 deficient cells cultured on cortical bone slices. BMM from WT 
and CD44KO cells were differentiated with M-CSF and RANKL alone (Control) or in 
combination with rOA for 7 days to generate mature osteoclasts. (A) Microscopic 
images of TRAP positive osteoclasts show an inhibition upon rOA treatment in WT 
samples; however, in CD44KO cells there is no effect upon rOA treatment. (B-C) 
Osteoclast parameters reveal an inhibition of osteoclast differentiation in rOA treated 
WT cells shown by (B) TRAP activity and osteoclast count (C). This effect is abrogated 
in the CD44KO samples. The experiment was run in triplicates and repeated 3 times 
with similar results.  Data presented in all graphs represent Mean ± SEM. *=p<0.05. 
Scale bars: 100 µm (Panel A). 
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Figure 4.52: Osteoactivin mediated inhibition of osteoclast related gene 
expression is abrogated in CD44 deficient cells. BMM from WT and CD44KO cells 
were differentiated with M-CSF (20ng/mL) or RANKL (40ng/mL) alone (CTL) or in 
combination with rOA (100 ng/mL) for 48 hours to generate pre-osteoclasts. (A-E) 
qPCR analysis of osteoclasts from WT and CD44KO cells either treated or untreated 
with rOA to determine the relative expression of osteoclast related genes TRAP (A), 
NFATc1 (B), RANK (C), DC-STAMP (D), and Calcitonin Receptor (E). Notice upon 
treatment of rOA to WT cells osteoclast related genes are downregulated; however this 
effect is abrogated in CD44KO cells. The experiment was repeated 3 times with similar 
results.  Data presented in all graphs represent Mean ± SEM. *=p<0.05, ***=p<.001. 
 
 187 
 
4.20 Osteoactivin Inhibition of ERK Phosphorylation is mediated through CD44 
 In order to determine the signaling pathway involved in Osteoactivin mediated 
osteoclast inhibition, we used WT and CD44 deficient mice and examined RANKL-
mediated stimulation of osteoclast signaling in response to osteoactivin. Previous 
literature has shown that loss of CD44 has no effect on osteoclast differentiation in vitro 
[393]. Similarly, we have shown that loss of CD44 has no effect on RANKL-mediated 
osteoclast signaling in vitro (Figure 4.53). In Figure 4.44, we have shown that addition of 
recombinant Osteoactivin in RANKL stimulated osteoclasts inhibits ERK 
phosphorylation. Addition of Osteoactivin in WT cells inhibited ERK phosphorylation as 
expected. Interestingly, the addition of Osteoactivin to CD44 deficient osteoclasts 
resulted in restoration of ERK phosphorylation (Figure 4.54). This indicates that 
Osteoactivin inhibition of ERK phosphorylation is mediated through CD44. 
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Figure 4.53: RANKL induced signaling is unaltered in CD44 deficient osteoclasts. 
BMM from WT and CD44KO cells were treated with M-CSF (20ng/mL) and RANKL 
(40ng/mL) for 48 hours in order to generate pre-osteoclasts. After the 48 hour period, 
cells were serum starved for 4 hours prior to the addition of RANKL (50 ng/mL) for the 
indicated time periods. Total protein cell lysates were collected and analyzed by 
Western blot. Blots were probed for antibodies of the MAPK family. Notice there does 
not seem to be a difference in endogenous RANKL signaling between WT and CD44KO 
cells. 
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Figure 4.54: Osteoactivin mediated inhibition of ERK signaling is abrogated in 
CD44 deficient cells. BMM from WT and CD44KO cells were treated with M-CSF 
(20ng/mL) and RANKL (40ng/mL) along with rOA (100 ng/mL) for 48 hours in order to 
generate pre-osteoclasts. After the 48 hour period, cells were serum starved for 4 hours 
prior to the addition of RANKL (50 ng/mL) for the indicated time periods. Total protein 
cell lysates were collected and analyzed by Western blot (A). Blots were probed for 
antibodies anti-CD44, anti-phospho ERK, anti-ERK, and anti-GAPDH. (B) Densitometric 
analysis reveals a significant increase in ERK signaling upon rOA treatment in CD44 
deficent cells compared to WT.  The experiment was repeated 3 times with similar 
results.  Data presented in all graphs represent Mean ± SEM. *=p<0.05 comparing 
untreated and treated samples from WT and CD44KO.  
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4.21 The Effect of Recombinant Osteoactivin in WT and CD44 Deficient Cells in 
vivo 
 Previous studies have shown that addition of certain anti-inflammatory cytokines 
can inhibit osteoclast differentiation and migration in a calvaria osteolysis model [477-
480]. Therefore, we wanted to examine the effects of recombinant Osteoactivin on 
osteoclast differentiation and recruitment in vivo. In WT cells, addition of RANKL 
significantly increased the number of TRAP positive osteoclasts as expected; however, 
addition of RANKL in combination with recombinant Osteoactivin abrogated the RANKL 
stimulation of osteoclast differentiation and recruitment by TRAP staining (Figure 4.55) 
and microCT (Figure 4.56). To further elucidate the mechanism involved in the 
Osteoactivin mediated inhibition of osteoclasts in vivo, we tested recombinant 
Osteoactivin using the same model in CD44 deficient mice.  As expected, RANKL alone 
stimulated osteoclast differentiation and recruitment. Interestingly, RANKL treatment, in 
combination with Osteoactivin, also stimulated osteoclast differentiation and recruitment 
in the CD44 deficient mice. This indicates that Osteoactivin inhibits RANKL mediated 
osteoclast differentiation through the CD44 pathway in vivo. 
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Figure 4.55: Recombinant Osteoactivin inhibits the differentiation and recruitment 
of TRAP positive osteoclasts in vivo. A collagen sponge coated with 30 µL of either 
PBS, RANKL (5 µg) alone, or RANKL and rOA (100 µg/mL) was placed on WT or 
CD44KO calvaria (n=5) for seven days. A week later calvaria were removed and TRAP 
stained as described in Materials and Methods. (A) Stereoscope images were taken of 
TRAP stained calvaria for each condition. Notice the increased number of osteoclasts in 
RANKL alone treatments which is inhibited in the rOA and RANKL combined treatment 
in WT cells. (B) TRAP stained area analysis reveals an increase in the overall TRAP 
stained area in RANKL treated WT calvaria which is reduced in rOA and RANKL 
combined treatments in WT. This effect seems to be abrogated in CD44KO calvaria as 
a reduction in the TRAP stained area is not observed in rOA and RANKL treatment 
compared to RANKL alone. Data presented in all graphs represent Mean ± SEM. 
**=p<0.01. 
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Figure 4.56: Recombinant Osteoactivin inhibits the resorption of osteoclasts 
through inhibition of osteoclast differentiation and recruitment in vivo. A collagen 
sponge coated with 30 µL of either PBS, RANKL (5 µg) alone, or RANKL and rOA (100 
µg/mL) was placed on WT or CD44KO calvaria (n=5) for seven days. Calvaria were 
collected and scanned by microCT. Notice the increase in the number of pores (yellow 
arrows) in RANKL alone treated WT calvaria which are inhibited upon rOA treatment. In 
the CD44KO calvaria notice that upon rOA treatment, the number of pores do not seem 
to decrease. 
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4.22 Recombinant Osteoactivin Stimulation of Osteoclast Resorption in vitro is 
Independent of CD44 
 Osteoactivin has been shown to stimulate osteoclast resorption both in vitro and 
in vivo [7-9]. We wanted to determine if CD44 is involved in the osteoactivin-mediated 
stimulation of osteoclast resorption. The addition of Osteoactivin to WT osteoclasts 
significantly enhanced osteoclast resorption when cultured on Corning® discs (Figure 
4.57). Interestingly, when Osteoactivin was added to CD44 deficient osteoclasts, a 
similar response as the wild type was observed. These results indicate that CD44 has 
no involvement in the Osteoactivin-mediated stimulation of osteoclast resorption on 
Corning® discs. To further elaborate, we cultured WT and CD44 deficient osteoclasts on 
cortical bovine slices and left them untreated (control) or treated with recombinant 
Osteoactivin. Wild type cells treated with Osteoactivin had smaller actin rings by 
immunoflourescent staining compared to untreated; however, there seemed to be no 
difference in actin ring size in CD44 deficient osteoclasts when treated with Osteoactivin 
(Figure 4.58). This indicates that Osteoactivin may be involved in regulating osteoclast 
sized potentially through CD44 mediated.  
 In order to determine the role of Osteoactivin in osteoclast resorption in WT and 
CD44 deficient osteoclasts, we treated osteoclasts with or without Osteoactivin for 48 
hours and removed the osteoclasts. After the removal of the osteoclasts, we stained for 
lectin-HRP to observe eroded areas on the cortical slices. Lectin-HRP staining revealed 
WT osteoclasts treated with Osteoactivin had significantly high number of pits and 
increased total resorbed area (Figure 4.59). Interestingly, recombinant Osteoactivin 
treatment in CD44 deficient cells showed a similar pattern as WT, as Osteoactivin 
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increased pit number and total resorbed area. This indicates that Osteoactivin 
stimulates osteoclast resorption independent of CD44.  
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Figure 4.57: Recombinant Osteoactivin stimulates osteoclast resorption in vitro 
independent of CD44. BMM from WT and CD44KO cells were differentiated with M-
CSF (20ng/mL) and RANKL (40ng/mL) alone (Control) or treated with recombinant 
osteoactivin (100 ng/mL) for 7 days to generate mature osteoclasts. (A) Microscopic 
images of Corning Discs revealing the resorption pits from the osteoclasts. (B) Analysis 
of the total area resorbed in WT and CD44KO cells untreated and treated with 
recombinant osteoactivin. Notice the increase in osteoclast resorption in WT rOA 
treated osteoclasts compared to control. The same trend is seen in the CD44KO cells 
indicating that CD44 does not play a role in osteoactivin mediated osteoclast resorption. 
The experiment was run in triplicates and repeated 3 times with similar results.  Data 
presented in all graphs represent Mean ± SEM comparing untreated controls and rOA 
treated samples in WT and CD44KO. *=p<0.05. Scale bars: 250 µm (Panel A). 
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Figure 4.58: Osteoactivin treatment inhibits actin ring and osteoclast size on                  
cells coated on cortical bovine slices. BMM from WT and CD44KO cells were 
differentiated with M-CSF and RANKL on collagen coated matrices for 5 days. After the 
5th day, pre-osteoclasts were transferred onto bovine cortical slices for 48 hours along 
with a second dose of M-CSF and RANKL alone (Control) or in combination with 
recombinant osteoactivin. Notice that upon rOA treatment in WT cells the osteoclast 
actin ring and size are smaller compared to untreated control. This effect seems to be 
abrogated in CD44KO cells as there seems to be no change in osteoclast size or actin 
ring formation. Scale bars: 10 µm. 
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Figure 4.59: Recombinant Osteoactivin stimulates osteoclast resorption on 
cortical slices independent of CD44. BMM from WT and CD44KO cells were 
differentiated with M-CSF (20ng/mL) and RANKL (100ng/mL) on collagen coated 
matrices for 5 days. After the 5th day, pre-osteoclasts were transferred onto bovine 
cortical slices for 48 hours along with a second dose of M-CSF and RANKL alone 
(Control) or in combination with recombinant osteoactivin. Osteoclasts were removed 
and osteoclast pits were determined by Lectin HRP staining. (A) Microscopic images of 
Lectin HRP stained pits. (B-C) Analysis of Lectin HRP stained pits shows an increase in 
the number of pits (B) and total resorbed area (C) in rOA treated WT cells compared to 
control. A similar trend is seen in CD44KO osteoclasts. The experiment was run in 
triplicates.  Data presented in all graphs represent Mean ± SEM. *=p<0.05 comparing 
untreated controls and rOA treated samples in WT and CD44KO . Scale bars: 100 µm 
(Panel A). 
 198 
 
 
Figure 4.60: Schematic diagram indicating the role of Osteoactivin and its 
receptors during each specific stage of osteoclast differentiation. Our results 
indicate that Osteoactivin has dual roles during osteoclast differentiation. At an earlier 
stage, the Osteoactivin-mediated inhibition of osteoclast differentiation and size is CD44 
dependent. At the mature stage, Osteoactivin-CD44 interaction had no effect on 
osteoclast resorption. The Osteoactivin-mediated increase in osteoclast resorption is 
most likely regulated through αvβ3 as previously described.   
 199 
 
Chapter 5 
Discussion 
Summary 
 The main objective of this study was to determine the role of recombinant 
Osteoactivin in both osteoblasts and osteoclasts, and identify a novel signaling 
mechanism that related to its function in both cell types. We determined that 
Osteoactivin binds to CD44 in both osteoblasts and osteoclasts and regulates 
differentiation. For osteoblasts, Osteoactivin stimulated osteoblast differentiation and 
function in a CD44-ERK dependent mechanism. Interestingly Osteoactivin and CD44 
were found to exist in the caveolin lipid raft and may also potentially regulate osteoblast 
differentiation through autophagy pathway. For osteoclasts, recombinant Osteoactivin 
inhibited osteoclast differentiation in a dose dependent manner. Similarly this 
Osteoactivin-mediated effect also seemed to be CD44 dependent; however, 
Osteoactivin-CD44 interaction had no effect on Osteoactivin-mediated upregulation of 
osteoclast resorption. Furthermore, in vivo results from a mouse osteolysis model 
revealed that Osteoactivin may inhibit osteoclasts differentiation in vivo. Overall these 
results support our hypothesis that Osteoactivin stimulates osteoblast differentiation 
while inhibiting osteoclast differentiation through a CD44 dependent mechanism.
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5.1 Aim 1 The role of Osteoactivin and CD44 interaction during osteoblast 
differentiation 
 In this study, we determined the signaling pathway of Osteoactivin in osteoblasts. 
Previous literature has shown that Osteoactivin is important for osteoblast differentiation 
[4-6]. In this study, we showed that recombinant Osteoactivin was able to stimulate 
osteoblast matrix deposition and mineralization. Several other recombinant ligands and 
growth factors have shown to increase osteoblast differentiation in culture including 
BMP-2 [481], FGF-2 [482], Wnt3a [483], NOTCH [484], CCN-1 [485, 486], CCN-2 [487, 
488] and BSP [489]. A previous report from our lab showed that overexpression of 
Osteoactivin increased osteoblast differentiation and function in vitro and in vivo [3, 5]. 
Our data supports this aspect that addition of Osteoactivin in culture enhances 
osteoblast differentiation and function. 
 Our data also indicates that CD44 may act as a novel receptor for Osteoactivin. 
CD44 has been shown to be expressed in both osteoblast and osteocytes and its 
expression increases during osteoblast differentiation [386, 394].  CD44 has been 
shown to have several ligands important for bone cell function which include 
hyaluronan, osteopontin, fibronectin, galectins, and serglycin. 
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 Furthermore our data shows that CD44 deficient mice have significantly less 
bone both in vivo and ex vivo, indicating that CD44 may act as a positive regulator of 
osteoblast differentiation and function. Previous studies have shown that CD44 
expression is very high in MSCs [490-492] and areas of fracture healing where 
expression was high in osteoprogenitor cells, osteoclasts, and osteocytes [407]. 
Furthermore, previous literature has found that knockdown of CD44 in dental pulp cells 
resulted in a reduction in ALP activity and mineralization in vitro [493]. This evidence 
supports our study that reduction or absence of CD44 results in an inhibition of 
osteoblast differentiation in vitro. Another study found that downregulation of CD44 in 
periodontal ligament cells resulted in reduced mineralized nodule formation and a 
reduction in osteoblast related gene expression of Intracellular adhesion molecule 
(ICAM), BMP-2, and FGF-1 [494]. This study supports our hypothesis that reduction of 
CD44 in osteoblasts results in a reduction of genes important for osteoblast 
differentiation and function. Furthermore, this study supports our hypothesis that upon 
addition of recombinant Osteoactivin to CD44 deficient osteoblasts, the Osteoactivin-
mediated upregulation of Osterix and Col1α1 is abrogated. In addition, CD44 has been 
shown to downregulate Runx2 expression and activity in the ATDC5 chondrocyte cell 
line [495]. Taken together, our data clearly show that CD44 is a receptor of Osteoactivin 
function in osteoblasts. This is the first report to identify a novel receptor for 
Osteoactivin signaling in osteoblasts. 
 We showed that recombinant Osteoactivin treatment stimulated the 
phosphorylation of ERK and P38. The ERK pathway has been found to be critical for 
osteoblast differentiation and proper skeletal development as osteoblast-specific 
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dominant-negative (DN) transgenic ERK mice have significantly delayed skeletal 
development [496]. The authors speculate that ERK regulates Runx2 activity through an 
integrin-mediated mechanism indicating the importance of the ERK signaling pathway 
during osteoblast differentiation. P38 has also been shown to be an important regulator 
of osteoblast differentiation as inhibition of P38 through the use of inhibitors and DN 
transfection resulted in an impairment in ALP activity and mineralization [497].                                                                                                           
 Next, we sought to determine the signaling pathway downstream of 
Osteoactivin/CD44 interaction. We found that knockdown of CD44 and treatment with 
recombinant Osteoactivin in osteoblasts resulted in a decrease in ERK and P38 
phosphorylation compared to scramble and recombinant Osteoactivin treated cells. 
CD44 has been shown to act as an important signal transduction molecule in several 
different cell types. A previous report has shown that ERK activation in cementifying 
fibroma cells of the jaw led to cell proliferation which was largely dependent on CD44 
[498]. Furthermore, this report showed that Raf and MEK were activated upon 
stimulation of CD44 [498]. Raf and MEK have been shown to act upstream of ERK 
signaling. It will be interesting to determine if recombinant Osteoactivin stimulates Raf 
and MEK upstream of ERK signaling in osteoblasts. CD44 has also shown to be 
involved in P38 signaling. A previous study has shown that CD44 activation stimulates 
downstream P38 signaling resulting in the progression of cervical cancer [499]. 
Furthermore, hyaluronan was shown to inhibit IL-1β-induced MMP-13 expression 
through CD44-P38 dependent signaling in human arthritic chondrocytes [500]. This 
indicates that CD44 activation of P38 may serve as a protective function. It will be 
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interesting to determine if Osteoactivin-CD44 mediated activation of ERK or P38 has 
any protective function in bone.  
 Currently, there is little literature describing the signaling pathway of Osteoactivin 
mediated enhancement of osteoblast differentiation. Here, we show that CD44 binds to 
recombinant Osteoactivin in osteoblasts. CD44 has several different methods in which it 
can act as a signal transduction molecule. CD44 has shown to act as a co-receptor for 
other intrinsic kinase receptors including EGFR [501, 502], FGFR [503, 504], CXCR4 
[505] and LRP6/Wnt signaling [506]. Each of these kinase receptors have been shown 
to play an important role in osteoblast differentiation and function. Interestingly, a 
previous study has shown that Osteoactivin may induce signaling through FGFR1 and 
ERK in MSCs [360]. It is possible that CD44 may act as a co-receptor and upon addition 
of Osteoactivin, CD44 may tether to FGFR1 and stimulate downstream ERK signaling. 
Future studies should focus on determining if Osteoactivin-CD44 binding stimulates 
downstream signaling directly, or requires another receptor.  
 Previous literature has shown that CD44 can also stimulate downstream 
signaling through its interaction with the cytoskeleton at its Ezrin-Radixin-Moesin (ERM) 
intracellular domain causing cytoskeletal rearrangement [507-509]. Actin cytoskeletal 
rearrangement has been shown to enhance osteoblast differentiation [510-512]. CD44 
has also been shown to interact with integrin receptors within a large complex and 
stimulate downstream signaling [452, 513]. It may be possible that upon binding of 
Osteoactivin to CD44, CD44 may induce signaling through its interactions with the 
cytoskeleton and other integrin receptors. Furthermore a previous study has shown that 
Osteoactivin interacts with αvβ1 and stimulates osteoblast adhesion [367]. Furthermore, 
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another study revealed that Osteopontin, a ligand for CD44, stimulated MSC 
differentiation into osteoblasts and inhibitied adipocyte differentiation [514]. Therefore, it 
may be possible that CD44 may interact with αvβ1 and stimulate Osteoactivin-mediated 
downstream signaling and osteoblast differentiation (Figure 4.35). Future studies should 
focus on the role of Osteoactivin/CD44 interaction on actin cytoskeletal rearrangement.  
 Our data suggests that CD44 is important for Osteoactivin-mediated osteoblast 
differentiation in vitro. A previous report has shown that CD44 is necessary for Galectin-
9-induced osteoblast differentiation through the Smad pathway [395]. This suggests that 
CD44 may be an important factor for stimulating osteoblast differentiation and function. 
Furthermore, another study revealed that CD44 stimulation along with αvβ3 stimulates 
Runx2 activation [515]. Previous literature has shown that Osteoactivin interacts with 
αvβ3 [8, 10]. In our study, recombinant Osteoactivin treatment to CD44 deficient 
osteoblasts resulted in an inhibition of osteoblast differentiation compared to WT treated 
cells. It will be interesting to determine if CD44 and αvβ3 interaction is the source behind 
Osteoactivin-mediated enhancement of osteoblast differentiation.  
 In our study, we have shown that upregulates Osterix, Col1α1, and Runx2 mRNA 
in WT osteoblasts. Interestingly, when recombinant Osteoactivin is added to CD44 
deficient osteoblasts the upregulation of Osterix and Col1α1induced by Osteoactivin is 
unaffected; however, Runx2 remains upregulated. This indicates that the upregulation 
of Osterix and Col1α1 by Osteoactivin is CD44 dependent, but the upregulation of 
Runx2 by Osteoactivin is CD44 independent. Previous literature from our lab has shown 
that both overexpression of Osteoactivin or addition of recombinant Osteoactivin induce 
focal adhesion kinase (FAK) activation in C2C12 and MC3T3-E1 cells respectively [4, 
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367]. Furthermore, our lab has shown that overexpression of Osteoactivin in C2C12 
cells stimulates osteoblast differentiation through the upregulation FAK activation of 
Runx2 and upon transfection of dominant-negative FAK (DN-FAK), this effect is 
abrogated [4]. Previous literature has shown that integrin activation stimulates 
downstream FAK-ERK-Runx2 signaling in osteoblasts [158]. Therefore, it may be 
possible that Osteoactivin stimulation of Runx2 may be mediated at least in part through 
integrin and FAK activation.    
 There is much attention being drawn to CD44 and Osteoactivin as repair factors. 
CD44 has been hypothesized to act as an important repair factor in a variety of tissues 
including skin [516], kidney [517-519], liver [520], and heart [521, 522]. CD44 has also 
been shown to play a large role in musculoskeletal repair. CD44 has been shown to 
play a large role in cartilage homeostasis [448, 523, 524]. Previous studies have shown 
that CD44 plays a role in chondrocyte matrix assembly [525, 526].  The role of CD44 in 
tissue injury repair may best be explained by the ability of CD44 to interact with certain 
growth factors and extracellular matrix proteins to stimulate MSC migration. A previous 
study has shown that CD44 and its interactions with hyaluronic acid and PDGF are 
necessary for stem cell migration [527]. Furthermore, MSCs have been shown to be 
recruited and migrate to areas of liver injury in a β1 and CD44 dependent manner [528]. 
Preliminary data from our lab has shown that Osteoactivin stimulates MSC migration in 
vitro through a CD44 dependent mechanism (unpublished data). Furthermore, previous 
literature has shown that CD44 and Osteoactivin are both upregulated in fracture 
calluses [362, 407, 529]. Previous data from our lab and others have shown that 
Osteoactivin stimulates bone formation and angiogenesis in vivo in a mouse and rat 
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calvaria defect model [360, 363]. It will be interesting to determine if the interaction 
between CD44 and Osteoactivin can be translated in vivo. The use of fracture models in 
CD44 and Osteoactivin knockout models may help to identify the role of CD44 and 
Osteoactivin in bone repair.  
5.2 Aim 2: The role of Osteoactivin in the osteoblast lipid raft 
 In this study, we sought to determine the relationship between Osteoactivin and 
the lipid raft in osteoblasts. Lipid rafts and caveolin proteins (Caveolin-1) have been 
shown to play an important role in osteoblasts. Caveolin-1 knockout mice were shown 
to have increased bone mass and stiffness [86]; however, another study revealed that 
knockdown or overexpression of Caveolin-1 inhibited or enhanced osteoblast 
mineralization, respectively [422]. Several other growth factors and extracellular matrix 
proteins important for osteoblast differentiation and function have been shown to be 
associated with lipid rafts. BMP receptors have been shown to co-localize within lipid 
rafts [530, 531]. Interestingly, BMP-2 treatment in osteoblasts has shown to enhance 
the incorporation of β1 integrin into lipid rafts resulting in the promotion of cell migration 
[430]. Furthermore, FGFR2 activation has been shown to act as a pro-survival factor in 
osteoblasts [429]. Another study has shown that interaction between the lipid raft and 
Galectin-9 stimulates osteoblast proliferation through a Src/ERK mediated mechanism 
[431]. It will be interesting to determine whether Osteoactivin function is mediated 
through lipid rafts in osteoblasts. 
 Our lab has shown that Osteoactivin binds to and interacts with CD44 in 
osteoblasts. CD44 has been shown to co-localize with other kinase receptors and 
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stimulate downstream signaling. A previous study has shown that transdifferentiation of 
fibroblast to myofibroblast is dependent upon Epidermal Growth Factor Receptor 
(EGFR) and CD44 co-localization into lipid rafts [450]. Furthermore, knockdown of 
CD44 and disruption of the lipid rafts by nystatin resulted in an inhibition in ERK and 
CaMKII signaling in fibroblasts [450]. Another study revealed that upon CD44 
engagement with another ligand, CD44 and Caveolin-1 co-localize within the lipid raft 
and recruit β1 integrin and Src to facilitate signaling resulting in increased cell survival 
[452]. It will be interesting to determine the role of CD44-Osteoactivin-lipid raft signaling 
complex in osteoblasts and how it relates to osteoblast differentiation and function. 
 Currently, there exists the idea that cross-talk among signaling complex exists to 
facilitate downstream signaling and function. Our data indicates that disruption of the 
lipid raft inhibits downstream ERK signaling in osteoblasts. Furthermore, CD44 
engagement with Osteoactivin results in co-localization into lipid rafts. Previous data 
from our lab has shown that Osteoactivin interacts with β1 integrin and facilitates 
downstream ERK and FAK signaling [367]. Therefore, it may be plausible to assume 
that Osteoactivin along with CD44 form a complex within the lipid raft that stimulates 
downstream signaling. Since Osteoactivin has been shown to stimulate multiple 
signaling pathways, it may also be possible that cross-talk exists among signaling 
complexes. A previous study has shown that cross-talk between Caveolin-1/ERK and 
Wnt/β-catenin is important for osteocyte viability under mechanical stress [532]. Further 
investigation is needed to determine if cross-talk among signaling pathways exists upon 
Osteoactivin stimulation.  
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 Our results indicate that recombinant Osteoactivin interacts with both CD44 and 
Caveolin-1 in the lipid raft complex. Previous literature has shown that lipid rafts can be 
endocytosed into the cell resulting in the stimulation of cell signaling [533-536]. 
Furthermore, CD44 has been extensively shown to be involved in caveolin-mediated 
endocytosis of hyaluronan resulting in intracellular signaling [537-540]. Currently, there 
is an accumulation of evidence that indicates that endocytosis may play a role in 
osteoblast signaling and differentiation. A previous study has shown that inhibition of 
endocytic processes during BMP-2 stimulation resulted in impaired Smad 1/5/8 
signaling and inhibited osteoblast differentiation [541]. Furthermore, endocytosis has 
been shown to be important for extracellular matrix remodeling, degradation, and 
receptor recycling in osteoblasts [542-544]. During endocytosis, the actin cytoskeleton 
undergoes rearrangement in order to bring the complex into the cell [545]. Since CD44 
has been shown to associate with and transduce signaling through the lipid raft and 
actin cytoskeleton [451, 546, 547] it may be plausible that Osteoactivin,CD44, and the 
lipid raft complex may undergo endocytosis and internalization into the osteoblast 
resulting in the stimulation of cell signaling. It will be interesting to determine if 
Osteoactivin undergoes endocytosis upon CD44 binding and whether disruption of this 
process regulates Osteoactivin mediated osteoblast differentiation.  
 One of the downstream processes of the caveolin-lipid raft complex (caveosome) 
after internalization, is to undergo endosome formation. Once the complex undergoes 
endosome formation, the complex is either recycled to the cell membrane, or undergoes 
degradation in the autophagosome [459, 548, 549]. The autophagosome will eventually 
fuse with an intracellular lysosome resulting in an autophagolysosome in a process 
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known as autophagy [550]. Our results show that Osteoactivin may undergo autophagy 
in osteoblasts through the conversion of LC3B-I to LC3B-II. Autophagy has become an 
emerging field in musculoskeletal biology. Previous studies have shown that 
suppression of autophagy results in osteopenia, decreased bone mineral density, and 
inhibition of terminal osteoblast differentiation, [463, 464]. Furthermore, a previous study 
has shown that bioactive silica nanoparticles promote osteoblast differentiation through 
stimulation of autophagy [461]. Interestingly the authors of this study showed that these 
nanoparticles enter the cell through a caveolae-mediated endocytosis process through 
ERK stimulation. This may explain what might be occurring in the Osteoactivin mediated 
process involving CD44, the lipid raft, and endocytosis. Future studies should focus on 
the role of Osteoactvin and autophagy during osteoblast differentiation and function.  
 The role of caveolins in the disease process, in particular musculoskeletal 
diseases, is only recently becoming understood. Caveolin-1 is differentially expressed in 
certain tissues during injury repair. For example, Caveolin-1 has a positive role in 
cutaneous skin wound healing as Caveolin-1 knockout mice have slower wound healing 
compared to controls [551, 552]. During muscle regeneration, Caveolin-1 has been 
shown to be downregulated during injury repair both in vitro and in vivo [435, 553]. In 
chondrocytes, lipid rafts have been shown to be important for chondrogenesis through 
neogenin and BMP receptor interaction [554]. Interestingly, patients with bone fracture 
have increase Caveolin-1 levels in peripheral blood mononuclear cells (PBMCs) [436]. 
Furthermore, overexpression of Caveolin-1 in human MSCs resulted in an inhibition of 
adipogenic differentiation. This data indicates that Caveolin-1 may be an important 
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regulator of skeletal injury. Future directions should focus on the role of Osteoactivin 
and Caveolin-1 during fracture repair.  
5.3 Aim3: The role of Osteoactivin-CD44 interaction during osteoclastogenesis 
 In this study, we showed that recombinant Osteoactivin inhibits osteoclast 
differentiation and size by downregulating osteoclast specific genes. Our lab was the 
first to show that mutation in Osteoactivin results in increased osteoclast differentiation 
but inhibits resorption [7]. Controversially, other groups have published that Osteoactivin 
stimulates both osteoclast differentiation and function [8, 9]. This may be explained by 
the fact that Osteoactivin may regulate osteoclasts in a stage specific manner. Previous 
results generated from our lab have shown that addition of recombinant Osteoactivin 
has different effects on osteoclast differentiation and function (unpublished results). This 
may explain the discrepancy observed between our group and others.  
  In this study, we demonstrated that recombinant Osteoactivin inhibits osteoclast 
differentiation in vitro and in vivo through a CD44-ERK dependent mechanism. Previous 
data from our lab has shown that mutation in Osteoactivin results in enhanced 
osteoclast differentiation and inhibits bone resorption [7]. Furthermore, mutation in 
Osteoactivin resulted in an increase in the MAPK pathway. The MAPK pathway has 
extensively been shown to be important for osteoclast differentiation [555-557]. In this 
study, RANKL was used to stimulate members of the MAPK, NFКB, and AKT pathway in 
osteoclasts. Our data indicates that recombinant Osteoactivin inhibits AKT and ERK 
activation during RANKL mediated osteoclast signaling. Previous literature has shown 
that TNF-α and IL-1α stimulate osteoclast survival through AKT and ERK signaling [558, 
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559]. Furthermore, PI3K was shown to coordinate the activity of both MEK/ERK and 
AKT to maintain osteoclast survival [560]. It will be interesting to determine if 
recombinant Osteoactivin plays any role in either MEK or PI3K signaling and if 
recombinant Osteoactivin regulates osteoclast survival through the MEK/ERK or AKT 
pathways in osteoclasts.  
 In the current study, we have shown that Osteoactivin interacts with CD44 in 
osteoclasts. Previous studies have shown that absence of CD44 has no effect on 
osteoclastogenesis [393]; however, when challenged with an inflammatory cytokine 
such as TNF-α, develop inflammatory bone loss [391]. Furthermore, engagement of 
CD44 with hyaluronan was found to inhibit MMP-9 mRNA expression and result in the 
inhibition of osteoclast motility [405]. Similarly, our results show that Osteoactivin binds 
to CD44 in osteoclasts and that Osteoactivin mediated inhibition of osteoclasts is CD44 
dependent. CD44 has also been shown to be an important fusion marker [561], and 
upon engagement with another ligand, inhibits multinucleation [406]. Similarly, our data 
shows that recombinant Osteoactivin inhibits osteoclast size which seems to be CD44 
dependent. CD44 has been shown to play a role in osteoclast migration and adhesion 
[562].  We did not study the role of Osteoactivin on osteoclast motility. It will be 
interesting to determine if Osteoactivin plays a role in osteoclast motility.  
 CD44 has shown to play a role in osteoclast resorption. Several sources of 
literature have shown that CD44 along with αvβ3 integrin regulate osteoclast motility and 
bone resorption [398, 400, 563]. Osteoactivin has shown to bind to αvβ3 and is believed 
to be responsible for osteoclast mediated resorption [8, 10]. In our study, we reveal that 
Osteoactivin binds to CD44; however, our data suggests that CD44 does not play a role 
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in osteoclast mediated resorption in vitro. This may be explained by the fact that 
previous literature has shown that CD44 and αvβ3 integrin organize two functionally 
distinct domains in osteoclasts [564]. In this study, the authors reveal that CD44 
occupies the osteoclast podosome core, structures important for differentiation, 
adhesion and migration, while αvβ3 integrin occupies the outer F-actin cloud, important 
for matrix degradation. Therefore it may be possible that Osteoactivin binds to CD44 
and inhibits osteoclast differentiation and fusion, but also binds to αvβ3 integrin and 
stimulates osteoclast resorption in vitro (Figure 4.60). Future studies should focus on 
particular interactions and binding specificities between Osteoactivin, CD44, and αvβ3 in 
modulating osteoclast function.   
 Our data suggests that recombinant Osteoactivin inhibits osteoclast 
differentiation, but stimulates resorption in vitro. Several other extracellular matrix 
proteins have shown to have this similar effect on osteoclasts. Fibrillin-1 has been 
shown to have dual roles in regulating osteoclast differentiation and function [565]. In 
this study, recombinant N-terminal Fibrillin-1 was shown to inhibit osteoclast formation 
but stimulate its function in vitro. Previous literature has also shown that fibronectin 
inhibits osteoclast differentiation activity, but stimulates function through IL-1β and nitric 
oxide [69]. Interestingly, fibronectin has been found to bind CD44 through its heparin 
binding domain [566]. It will be interesting to determine if CD44, Osteoactivin, and 
fibronectin have any interaction or involvement in osteoclast differentiation and function.  
 Our data suggests that recombinant Osteoactivin inhibits osteoclast 
differentiation and recruitment in an inflammatory in vivo osteolysis model. Previous 
literature has shown several different anti-inflammatory components that suppress 
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osteoclast formation in vivo [477-479]. It is interesting to note that recombinant 
Osteoactivin has a negative response on osteoclast resorption in vivo, yet stimulated its 
function in vitro. There may be two separate explanations seen in this phenomenon. 
First, Osteoactivin may be inhibiting the recruitment and differentiation of osteoclasts 
directly resulting in a reduced number of osteoclasts and less resorption. Secondly, the 
results seen in vivo may be indirectly due to the effect of Osteoactivin on osteoblasts. 
Previous data from our lab has shown that addition of recombinant Osteoactivin in 
osteoblasts results in the reduction of RANKL and other inflammatory cytokines 
(unpublished data). This is also supported by the fact that mutation in Osteoactivin 
results in an increase in RANKL expression [7]. Therefore, it may be possible that 
Osteoactivin may be indirectly affecting the osteoclasts by reducing the production of 
RANKL and other inflammatory cytokines secreted by the osteoblasts. Future studies 
should focus on the dual roles of Osteoactivin in osteoblasts and osteoclasts using 
tissue specific transgenic or knockout animals to define the role of Osteoactivin in these 
cell types.  
 Interestingly, deficiency of CD44 resulted in the abrogation of Osteoactivin 
mediated inhibition of osteoclast differentiation and recruitment in vivo. Previous studies 
have shown that CD44 has a potential role as an anti-inflammatory component in 
different tissue types [567-569]. A previous study has shown that CD44 can act as a 
critical inhibitor for joint destruction and inflammatory bone loss [391]. Furthermore, the 
anti-inflammatory response through CD44 has been linked to TGF-β [570-572]. 
Interestingly, Osteoactivin has been shown to regulate TGF-β levels as transgenic mice 
overexpressing Osteoactivin have increased levels of TGF-β [5]. It will be interesting to 
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determine if there is a link between Osteoactivin, CD44, and TGF-β in reducing the 
inflammatory response in vivo.  
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Figure 5.1: Schematic diagram depicting our overall hypothesis of the role of 
Osteoactivin-mediated regulation of both osteoblast and osteoclast. (1.) 
Osteoactivin has a direct effect on osteoblast differentiation and function. Osteoactivin is 
shed from the membrane and effects other MSCs and osteoblasts within the bone 
microenvironment. (2.) Osteoactivin has a direct effect on osteoclast differentiation. 
Osteoactivin shed from the osteoblasts binds to CD44 in the osteoclasts and inhibits 
osteoclast differentiation and size. (3.) Osteoactivin has an indirect effect on osteoclast 
differentiation through osteoblast regulation. Preliminary results indicate that 
Osteoactivin downregulates RANKL expression in osteoblasts. This results in a lower 
concentration of available RANKL in the matrix resulting in an inhibition of osteoclast 
differentiation. All of these mechanisms support our overall hypothesis that Osteoactivin 
increases bone formation by increasing osteoblast and inhibiting osteoclast 
differentiation.  
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Overall Summary and Conclusions 
 In this study, we have shown that recombinant Osteoactivin stimulates MSC and 
osteoblast differentiation in vitro. This was shown by the increase observed in ALP 
staining and activity as well as mineralization. Furthermore, recombinant Osteoactivin 
was shown to upregulate several osteoblast specific genes by qPCR and luciferase 
analyses. We identified CD44 as a potential receptor responsible for the Osteoactivin- 
mediated increase in osteoblast differentiation and function. 
 In order to understand the role of Osteoactivin-CD44 in osteoblast differentiation, 
we wanted to determine the role of CD44 in skeletal homeostasis. CD44 deficient mice 
had significantly less bone in vivo shown by microCT, histomorphometry, and serum 
analysis. Ex-vivo analysis revealed a reduction in osteoblast-related genes in the CD44 
deficient mice compared to controls. We concluded that the bone phenotype observed 
in the CD44 deficient mice was osteoblast, not osteoclast mediated.  
 Next we sought to determine the role of Osteoactivin and CD44 in osteoblast cell 
signaling. We demonstrated that addition of recombinant Osteoactivin resulted in an 
increase in pERK and pP38 levels in a dose and time dependent manner. This increase 
was abrogated when cells were transfected with CD44 siRNA. To demonstrate the role 
of Osteoactivin and CD44 during osteoblast differentiation, we treated recombinant 
Osteoactivin to WT and CD44 deficient MSCs. Recombinant Osteoactivin enhanced 
ALP staining and activity in the WT MSCs, however, this effect was abrogated in CD44 
deficient MSCs. Similarly, recombinant Osteoactivin addition upregulated osteoblast 
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related genes Col1α1 and Osterix; however, this was also abrogated in CD44 deficient 
cells.  
 Next, we sought to determine if Osteoactivin has any role in the lipid raft in 
osteoblasts. Our data suggests that Osteoactivin interacts with the lipid raft. 
Furthermore, recombinant Osteoactivin treatment results in the accumulation of CD44 
into lipid rafts. Lastly, disruption of lipid rafts results in the inhibition of ERK 
phosphorylation.  
 In conclusion, we sought to determine the role of recombinant Osteoactivin on 
osteoclast differentiation and signaling. Our data suggests the Osteoactivin inhibits 
osteoclast differentiation shown by TRAP staining and activity and gene expression. 
Osteoactivin treatment resulted in the inhibition of RANKL-mediated ERK signaling 
which seems in part to be mediated in part through CD44. Furthermore, recombinant 
Osteoactivin inhibited RANKL-induced osteoclast differentiation and recruitment in vivo 
using an osteolysis model. Interestingly, this effect was abrogated in CD44 deficient 
animals indicating that Osteoactivin and CD44 may play a role in inhibiting 
inflammatory-induced bone loss.  
 Overall, this project has shown that Osteoactivin acts as a positive regulator for 
bone formation. This concept may introduce the idea for the use of Osteoactivin as a 
novel therapeutic to help treat bone disease. Potential therapies may include systemic 
and local delivery of Osteoactivin, spinal fusion, and/or combined therapy with 
Osteoactivin and stem cells/bone graft. Future research should focus on specific 
applications of treatment for Osteoactivin in treating specific skeletal pathologies.  
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